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Liver disease represents a major cause of mortality and morbidity. 
Despite the regenerative capacity of the liver, maintained injury or 
acute injury can lead to loss of liver function and disease. The most 
common cause of acute liver damage is drug-induced liver injury (DILI). 
This can lead to organ failure and possible death. Therefore, new 
therapies to reduce the severity of the injury are required. Stimulation 
of anti-inflammatory and anti-oxidative stress pathways during the 
resolution of the injury have been proposed as powerful approaches to 
reduce organ injury and to enhance regeneration.  
A main transcription factor which regulates anti-inflammatory and 
anti-oxidative stress is ‘nuclear factor erythroid-derived 2-like 2’ (Nrf2). 
Therefore, pharmacological activation of the Nrf2 pathway offers the 
potential to exert a cytoprotective effect promoting tissue regeneration. 
Dimethyl fumarate (DMF) is a drug approved for some forms of multiple 
sclerosis.  
DMF’s protection is due in part by activation of the Nrf2 pathway. We 
hypothesize that DMF could be used to reduce the severity of DILI via 
Nrf2 activation. This thesis explores the protective effects of DMF and 
Nrf2 signalling during paracetamol-induced hepatotoxicity using in 
vitro and in vivo models.  
For the in vitro studies, a semi-automated platform to produce 
hepatocytes-like cells (HLCs) from human pluripotent stem cells was 
employed. Single-cell high content image analysis was performed to 
understand Nrf2 nuclear translocation dynamics following DMF 
administration. The protective properties of DMF were tested in three 
different combinations: pre-treatment prior to paracetamol incubation, 
co-treatment or post-treatment following paracetamol injury. In all 
cases, DMF protected HLCs from paracetamol exposure. These 




zebrafish liver GFP reporter line was employed to detect fluorescence 
changes upon paracetamol exposure. Pre-treatment with DMF prior to 
paracetamol injury reduced the level of GFP loss.  
RNA sequencing from both models identified that DMF protection was 
mediated via Nrf2 pathway stimulation. This was mainly by an increase 
in cell metabolism and oxidative stress management as well as 
reducing pro-inflammatory pathways activation. In summary, the 
findings of this work provide new understanding on the effects of DMF 
in the modulation of the Nrf2 pathway during paracetamol-induced 
liver injury. These studies may provide a platform to develop new 



















Liver disease represents a major cause of mortality and morbidity. 
Despite the regenerative capacity of the liver, maintained injury or 
acute injury can lead to loss of liver function and disease. The most 
common cause of acute liver damage is drug-induced liver injury (DILI). 
This can lead into hepatocyte death (the main cell type of the liver) and 
organ failure.  
Therefore, new therapies to reduce the severity of the injury are 
required. Inflammation and stress are responsible for cell death and 
injury development. Stimulation of anti-inflammatory and anti-cell 
stress pathways during the resolution of the injury have been proposed 
as powerful approaches to reduce organ injury and to enhance 
regeneration.  
Our body has a mechanism that can manage and reduce inflammation 
and cell stress called ‘nuclear factor erythroid-derived 2-like 2’ (NRF2). 
Therefore, pharmacological activation of the NRF2 pathway offers the 
potential to promote organ regeneration. Dimethyl fumarate (DMF) is 
a drug approved for some forms of multiple sclerosis. DMF’s protection 
is based in part by activation of the NRF2 pathway.  
We hypothesize that DMF could be used to reduce the severity of DILI 
via NRF2 activation. This thesis explores the protective effects of DMF 
and Nrf2 signalling during DILI. First, we tested the effects of DMF in 
a human stem cell derived hepatocytes (HLCs) model of DILI. DMF 
protected HLCs from injury via NRF2 activation. A zebrafish model of 
DILI was used to validate the findings on HLCs in a whole organism. 
In both models DMF protected hepatocytes from injury.  
This was mediated by NRF2 activation boosting the capacity of cells to 
resist injury and by stopping the development of the inflammation 




understanding on the effects of DMF in the modulation of the Nrf2 
pathway in liver injury. These studies may provide a platform for 

















































Table of contents 
Declaration .............................................................................. III 
Abstract .................................................................................... IV 
Lay abstract .............................................................................. VI 
Table of contents ..................................................................... IX 
List of figures and tables ........................................................ XIV 
Abbreviations ....................................................................... XVIII 
Acknowledgments ................................................................ XXIII 
Publications .......................................................................... XXV 
CHAPTER ONE ......................................................................... 29 
INTRODUCTION ....................................................................... 29 
1.1 The Liver ........................................................................... 30 
1.1.1 Liver function and architecture ....................................... 31 
1.1.2 Liver development overview ............................................. 33 
1.1.3 Liver diseases ................................................................. 39 
1.1.4 Liver biology and disease modelling ................................ 43 
1.1.5 Stem cells as a renewable model for liver research .......... 44 
1.2 The Nrf2 pathway .............................................................. 46 
1.2.1 Regulation of Nrf2 ........................................................... 47 
1.2.2 The role of Nrf2 in DILI modulation ................................. 48 
1.2.3 Therapeutic activation of Nrf2 ......................................... 51 
1.3 The objective of the thesis .................................................. 53 
1.4 Hypothesis of the thesis ..................................................... 53 
CHAPTER TWO ........................................................................ 55 
MATERIALS AND METHODS ..................................................... 55 
X 
 
2.1 Materials and reagents ....................................................... 56 
2.1.1 Cell culture medium ....................................................... 57 
2.1.2 Antibodies ...................................................................... 58 
2.1.3 Cell Painting assay ......................................................... 60 
2.1.4 Oligonucleotides ............................................................. 60 
2.2 Stem cell culture and differentiation .................................. 61 
2.2.1 Stem cell culture ............................................................ 61 
2.2.2 Stem cell passaging ........................................................ 61 
2.2.3 Stem cell freezing and thawing ........................................ 62 
2.2.4 Embryoid body formation ............................................... 62 
2.2.5 Hepatocyte-like cell differentiation .................................. 63 
2.2.6 High throughput culture of HLCs .................................... 63 
2.3 Cell characterisation .......................................................... 63 
2.3.1 Fluorescence activated cell sorting (FACS) ....................... 63 
2.3.2 CYP P450 activity ........................................................... 64 
2.3.3 Protein content quantification ......................................... 64 
2.3.4 High-content imaging and analysis ................................. 65 
2.3.5 Cell viability assay .......................................................... 65 
2.3.6 Cell Paint assay and morphological profiling ................... 65 
2.3.7 ELISA assay ................................................................... 66 
2.4 Molecular techniques ......................................................... 67 
2.4.1 Immunofluorescence ....................................................... 67 
2.4.2 Western blotting ............................................................. 67 
2.4.3 RNA extraction ............................................................... 69 
2.4.4 Reverse transcription ...................................................... 70 




2.4.6 RT2 PCR array ................................................................ 71 
2.4.7 RNA sequencing ............................................................. 72 
2.5 Reagent preparation .......................................................... 77 
2.5.1 Dimethyl fumarate .......................................................... 77 
2.5.2 H2O2 preparation ............................................................ 77 
2.5.3 Paracetamol preparation ................................................. 77 
2.6 Zebrafish work ................................................................... 77 
2.6.1 Zebrafish lines and husbandry ....................................... 77 
2.6.2 Zebrafish chemical exposure ........................................... 77 
2.6.3 Zebrafish high throughput live imaging ........................... 78 
2.6.4 Orientation tool for zebrafish imaging 3D printing ........... 78 
2.6.5 Zebrafish plate reader fluorescence quantification .......... 79 
2.7 Bioinformatic analysis ....................................................... 80 
2.8 Statistical analysis ............................................................. 80 
CHAPTER THREE ..................................................................... 83 
SEMI-AUTOMATED DIFFERENTIATION OF HUMAN STEM CELL-
DERIVED HEPATOCYTES ......................................................... 83 
3.1 Introduction ...................................................................... 85 
3.1.1 Current cell-based methods to study liver biology ........... 85 
3.1.2 Semi-Automation of the HLCs differentiation protocol ..... 88 
3.1.3 Cell segmentation and high content analysis .................. 89 
3.1.4 Multiparametric dataset analysis .................................... 91 
3.2 Results .............................................................................. 93 
3.2.1 Characterisation of human embryonic stem cells ............ 93 
3.2.2 Differentiation of hPSC-derived hepatocyte like cells ....... 96 
3.2.3 Semi-automated differentiation of HLCs from hPSC ...... 104 
XII 
 
3.2.4 Validation of the platform ............................................. 107 
3.2.5 Disease modelling in 96-well plate format ..................... 131 
3.3 Discussion ....................................................................... 133 
CHAPTER FOUR ..................................................................... 139 
INVESTIGATING THE PROTECTIVE PROPERTIES OF DIMETHYL 
FUMARATE AND Nrf2 SIGNALLING DURING DRUG-INDUCED 
HEPATOTOXICITY .................................................................. 139 
4.1 Introduction .................................................................... 141 
4.1.1 Liver disease ................................................................. 141 
4.1.2 Nrf2 stimulation as a tissue repair therapy ................... 142 
4.1.3 Pharmacological activation of Nrf2 by dimethyl fumarate
 143 
4.1.4 Cytoprotective effects of DMF in in vitro and in vivo models
 144 
4.2 Results ............................................................................ 145 
4.2.1 Dimethyl fumarate in HLCs .......................................... 145 
4.2.2 Assessment of DMF effects in an Zebrafish paracetamol 
injury in vivo model ................................................................ 171 
4.3 Discussion ....................................................................... 176 
CHAPTER FIVE ....................................................................... 185 
TRANSCRIPTOMIC ANALYSIS OF DRUG-INDUCED 
HEPATOTOXICITY WITH AND WITHOUT DIMETHYL FUMARATE 
TREATMENT .......................................................................... 185 
5.1 Introduction .................................................................... 187 
5.1.1 Transcriptomic analysis of DMF cytoprotection ............. 187 
5.1.2 Dimethyl fumarate in the context of liver disease .......... 188 




5.2.1 RNA extraction & Library preparation ........................... 190 
5.2.2 Differential expression analysis ..................................... 192 
5.3 Discussion ....................................................................... 219 
5.3.1 HLCs pre-treatment gene expression ............................. 219 
5.3.2 HLCs co-treatment gene expression .............................. 222 
5.3.3 HLCs post-treatment gene expression ........................... 226 
5.3.4 Zebrafish cytoprotective gene regulation. ...................... 229 
5.3.5 Conclusion ................................................................... 231 
CHAPTER SIX ........................................................................ 233 
CONCLUSIONS AND FUTURE PERSPECTIVES ......................... 233 
6.1 Conclusions ..................................................................... 235 
6.2 Future perspectives ......................................................... 236 
6.2.1 Improved HLCs disease modelling ................................. 236 
6.2.2 Nf-kb and TGF-b regulation by DMF treatment ............. 237 
6.2.3 Three-dimensional (3D) cellular aggregates ................... 238 
6.2.4 In vivo translational work .............................................. 239 
Bibliography .......................................................................... 242 










List of figures and tables 
FIGURE 1. LIVER STRUCTURE ................................................................................................................ 31 
FIGURE 2. LIVER ZONATION AND CELL ORGANISATION...................................................................... 33 
FIGURE 3. ENDODERM SPECIFICATION ................................................................................................ 35 
FIGURE 4. MOUSE LIVER BUD DEVELOPMENT .................................................................................... 36 
FIGURE 5. HEPATOBLAST BIPOTENTIAL DIFFERENTIATION ................................................................ 38 
FIGURE 6. ETHICOLOGY OF CHRONIC LIVER DISEASE. ......................................................................... 40 
FIGURE 7. HLCS MARKERS DURING THE DIFFERENTIATION PROCESS. ............................................... 46 
FIGURE 8. OVERVIEW OF THE NRF2-KEAP1 PATHWAY REGULATION ................................................. 48 
FIGURE 9. ROLE OF NRF2 IN PARACETAMOL METABOLISM. .............................................................. 49 
FIGURE 10. 3D DESIGNS OF THE ORIENTATION TOOL FOR ZEBRAFISH POSITIONING ....................... 79 
FIGURE 11. CELL SEGMENTATION OVERVIEW ..................................................................................... 90 
FIGURE 12. TEXTURE FEATURES ........................................................................................................... 91 
FIGURE 13. HPSC MORPHOLOGY IN CULTURE ..................................................................................... 94 
FIGURE 14. PLURIPOTENT MARKER EXPRESSION IN PSC .................................................................... 94 
FIGURE 15. H9 EXPRESS CELL SURFACE MARKERS OF PLURIPOTENCY DETECTED BY FLOW 
CYTOMETRY ................................................................................................................................ 95 
FIGURE 16. CHARACTERISATION OF EMBRYOID BODY PLURIPOTENCY BY IMMUNOSTAINING ....... 95 
FIGURE 17. DIAGRAM OF THE HEPATOCYTE-LIKE CELL DIFFERENTIATION PROTOCOL...................... 97 
FIGURE 18. REPRESENTATIVE CONFLUENCY FOR HLCS DIFFERENTIATION ........................................ 97 
FIGURE 19. DEFINITIVE ENDODERM MORPHOLOGICAL CHARACTERISATION ................................... 98 
FIGURE 20. DEFINITIVE ENDODERM IMMUNOFLUORESCENCE CHARACTERISATION ........................ 99 
FIGURE 21. HEPATOBLAST MORPHOLOGICAL CHARACTERISATION ................................................100 
FIGURE 22. HEPATOBLAST MARKERS CHARACTERISATION ..............................................................100 
FIGURE 23. MORPHOLOGICAL CHARACTERISATION OF HLCS. ..........................................................102 
FIGURE 24. H9 DERIVED HEPATOCYTE-LIKE CELLS MARKER EXPRESSION AT DAY 18 ......................102 
FIGURE 25. METABOLIC ACTIVITY CHARACTERISATION OF HLCS. ....................................................103 
FIGURE 26. HLCS ATP DEPLETION AFTER BMS COMPOUNDS EXPOSURE. ........................................103 
FIGURE 27. SCHEMATIC REPRESENTATION OF THE SEMI-AUTOMATED HIGH THROUGHPUT 
PLATFORM. ...............................................................................................................................104 
FIGURE 28. ASSESSMENT OF HLCS WELL-TO-WELL VARIABILITY IN 96-WELL FORMAT ...................106 
FIGURE 29. ASSESSMENT OF HLCS WELL-TO-WELL VARIABILITY IN 384-WELL FORMAT. ................107 
FIGURE 30. CELL PAINTING STAINING IN HLCS. .................................................................................111 
FIGURE 31. SUPERVISED MACHINE LEARNING FOR CELL SEGMENTATION ......................................112 
FIGURE 32. REPRESENTATION OF THE SCREEN DATA IN A HEATMAP. .............................................114 




FIGURE 34. DATA TRANSFORMATION .............................................................................................. 117 
FIGURE 35. DATA STANDARDISATION .............................................................................................. 118 
FIGURE 36. PARAMETER CORRELATION MATRIX AND DATA REDUCTION FROM THE 96-WELL PLATE 
DATASET ................................................................................................................................... 119 
FIGURE 37. POLAR PLOTS FROM THE 96-WELL PLATE DATASET ...................................................... 120 
FIGURE 38. DATA REDUCTION COMPARISON FROM THE 96-WELL PLATE DATASET ...................... 121 
FIGURE 39. HIT PICKING PARAMETER FROM THE 96-WELL PLATE DATASET .................................. 122 
FIGURE 40. PARAMETER CORRELATION MATRIX AND DATA REDUCTION FROM THE 384-WELL 
PLATE SCREEN .......................................................................................................................... 126 
FIGURE 41. POLAR PLOTS FROM THE 38-WELL PLATE DATASET ...................................................... 127 
FIGURE 42. DATA REDUCTION COMPARISON FROM THE 384-WELL PLATE DATASET. ................... 128 
FIGURE 43. HIT PICKING PARAMETER FROM THE 384-WELL PLATE DATASET ................................ 129 
FIGURE 44. INCUBATION OF HLCS WITH LPO AT LOW OR HIGH DOSE FOR 48 OR 96 H INDUCES 
STEATOSIS ................................................................................................................................ 132 
FIGURE 45. SCHEMATIC REPRESENTATION OF THE MECHANISM OF ACTION OF DIMETHYL 
FUMARATE ............................................................................................................................... 144 
FIGURE 46. ASSESSMENT OF DMF TOXICITY IN HLCS. ...................................................................... 146 
FIGURE 47. CASPASE 3/7 INDUCTION FOLLOWING DMF INCUBATION ........................................... 146 
FIGURE 48. NRF2 ANTIBODY OPTIMISATION.................................................................................... 147 
FIGURE 49. EXAMPLE OF THE THRESHOLDING FOR NRF2+ SELECTION ........................................... 149 
FIGURE 50. NRF2 NUCLEAR TRANSLOCATION FOLLOWING DMF ADMINISTRATION ..................... 151 
FIGURE 51. TIME COURSE QUANTIFICATION OF NRF2+ CELLS ......................................................... 151 
FIGURE 52. SINGLE CELL ANALYSIS OF NRF2 DYNAMICS UPON DMF 50 ΜM ADMINISTRATION ... 154 
FIGURE 53. MEDIUM INDUCED NRF2 STIMULATION. ...................................................................... 156 
FIGURE 54. ASSAY OPTIMISATION LEADS TO A SPECIFIC NRF2 NUCLEAR TRANSLOCATION 
QUANTIFICATION ..................................................................................................................... 157 
FIGURE 55. NRF2 TARGET GENES EXPRESSION FOLLOWING DMF 50 ΜM OR H2O2 1MM 
TREATMENT FOR 3H ................................................................................................................ 159 
FIGURE 56. HUMAN OXIDATIVE STRESS PLUS RT² PROFILER PCR ARRAY WAS USED TO INVESTIGATE 
DIFFERENTIAL EXPRESSION OF AN INJURY STIMULUS (H2O2) OR A CYTOPROTECTIVE 
STIMULUS (DMF).. .................................................................................................................... 160 
FIGURE 57. PARACETAMOL DOSE RESPONSE TOXICITY FOLLOWING 24 H TREATMENT ................ 161 
FIGURE 58. DMF EXHIBITS PROTECTIVE EFFECTS UPON PARACETAMOL EXPOSURE IN 
CONCENTRATION DEPENDENT MANNER. ............................................................................... 162 
FIGURE 59. BRUSATOL SHOWED NO DEPLETION OF ATP SYNTHESIS IN HLCS AFTER 24H 
INCUBATION ............................................................................................................................. 163 
FIGURE 60. INHIBITION OF NRF2 UPON BRUSATOL TREATMENT .................................................... 164 
XVI 
 
FIGURE 61. NRF2 IS REQUIRED FOR DMF TO PROTECT HLCS FROM PARACETAMOL ......................165 
FIGURE 62. DMF 10 ΜM PROTECTS HLCS FROM PARACETAMOL-INDUCED HEPATOXICITY ...........167 
FIGURE 63. CORRELATION MAP OF THE DMF CYTOPROTECTION QUANTIFICATION BY CELL PAINT 
PROFILING .................................................................................................................................169 
FIGURE 64. DMF CYTOPROTECTION QUANTIFICATION BY CELL PAINT PROFILING .........................170 
FIGURE 65. PROTECTIVE EFFECTS OF DMF IN A ZEBRAFISH MODEL OF LIVER INJURY ....................172 
FIGURE 66. METHODS FOR LARVAE ORIENTATION FOR LIVE IMAGING. ..........................................174 
FIGURE 67. AUTOMATIC ZEBRAFISH SEGMENTATION FOR IMAGE ANALYSIS .................................174 
FIGURE 68. LOSS OF GFP UPON PARACETAMOL 10 MM TREATMENT FOR 48 H WAS DETECTED IN 
BOTH PLATFORMS ....................................................................................................................175 
FIGURE 69. PRE-TREATMENT WITH DMF 2.5 ΜM PROTECTS ZEBRAFISH FROM PARACETAMOL 10 
MM INDUCED INJURY ...............................................................................................................176 
FIGURE 70. EXAMPLE FROM RIN SCORE QUANTIFICATION ..............................................................191 
FIGURE 71. ASSESSMENT OF LIBRARY SIZE QUANTIFICATION AFTER MULTIPLEXING .....................192 
FIGURE 72. PCA PLOT OF HLCS PRE-TREATMENT CLUSTERS THE DIFFERENT TREATMENTS 
DIFFERENTLY .............................................................................................................................194 
FIGURE 73. REPLICATE VARIABILITY ASSESSMENT USING HEATMAP VISUALISATION. ...................195 
FIGURE 74. GSEA-MSIGDB ENRICHMENT ANALYSIS FROM HLCS PRE-TREATMENT RNA-SEQ 
DATASET. ...................................................................................................................................199 
FIGURE 75. PCA PLOT OF HLCS CO-TREATMENT CLUSTERS THE DIFFERENT TREATMENTS 
DIFFERENTLY .............................................................................................................................200 
FIGURE 76. REPLICATE VARIABILITY ASSESSMENT USING HEATMAP VISUALISATION ....................201 
FIGURE 77. GSEA-MSIGDB ENRICHMENT ANALYSIS FROM HLCS CO-TREATMENT RNA-SEQ 
DATASET. ...................................................................................................................................205 
FIGURE 78. PCA PLOT OF HLCS POST-TREATMENT CLUSTERS THE DIFFERENT TREATMENTS 
DIFFERENTLY. ............................................................................................................................207 
FIGURE 79. REPLICATE VARIABILITY ASSESSMENT USING HEATMAP VISUALISATION ....................209 
FIGURE 80. GSEA-MSIGDB ENRICHMENT ANALYSIS FROM HLCS POST-TREATMENT RNA-SEQ 
DATASET ....................................................................................................................................212 
FIGURE 81. PCA PLOT ZEBRAFISH CLUSTERS THE DIFFERENT TREATMENTS DIFFERENTLY. ............213 
FIGURE 82. REPLICATE VARIABILITY ASSESSMENT USING HEATMAP VISUALISATION. ...................214 
FIGURE 83. GSEA-MSIGDB ENRICHMENT ANALYSIS FROM THE ZEBRAFISH RNA-SEQ DATASET. ...218 
FIGURE 84. PROPOSED MECHANISM OF ACTION OF DMF CYTOPROTECTION IN THE PRE-
TREATMENT. .............................................................................................................................222 





FIGURE 86. PROPOSED MECHANISM OF ACTION OF DMF CYTOPROTECTION IN THE POST-
TREATMENT.............................................................................................................................. 228 
 
TABLE 1 CELL CULTURE MEDIUM USED FOR HESC MAINTENANCE AND DIFFERENTIATION ............ 57 
TABLE 2. PRIMARY ANTIBODIES USED FOR IMMUNOSTAINING ....................................................... 58 
TABLE 3. SECONDARY ANTIBODIES USED FOR IMMUNOSTAINING .................................................. 59 
TABLE 4. ANTIBODIES USED FOR FLOW CYTOMETRY ......................................................................... 59 
TABLE 5. ANTIBODIES USED FOR WESTERN BLOT .............................................................................. 59 
TABLE 6. FLUORESCENT STAINING USED FOR THE CELL PAINTING ASSAY. ....................................... 60 
TABLE 7. LIST OF TAQMAN PRIMERS USED ........................................................................................ 60 
TABLE 8. LIST OF REAGENTS USED ...................................................................................................... 60 
TABLE 9. ASTRAZENECA COMPOUND LIBRARY ................................................................................ 109 
TABLE 10. 96-WELL PLATE SCREEN HIT LIST ...................................................................................... 125 
TABLE 11. 384-WELL PLATE SCREEN HIT LIST .................................................................................... 130 
TABLE 12. DIFFERENTIAL EXPRESSED GENES IN DMF + PARACETAMOL VERSUS PARACETAMOL IN 
PRE-TREATMENT HLCS ............................................................................................................. 196 
TABLE 13. PRE-TREATMENT PATHWAY ENRICHMENT ANALYSIS USING WIKIPATHWAYS ............. 198 
TABLE 14. DIFFERENTIAL EXPRESSED GENES IN DMF + PARACETAMOL VERSUS PARACETAMOL IN 
CO-TREATMENT HLCS .............................................................................................................. 202 
TABLE 15. CO-TREATMENT PATHWAY ENRICHMENT ANALYSIS USING WIKIPATHWAYS............... 204 
TABLE 16. DIFFERENTIAL EXPRESSED GENES IN DMF + PARACETAMOL VERSUS PARACETAMOL IN 
POST-TREATMENT HLCS ........................................................................................................... 210 
TABLE 17. POST-TREATMENT PATHWAY ENRICHMENT ANALYSIS USING WIKIPATHWAYS ........... 211 
TABLE 18. DIFFERENTIAL EXPRESSED GENES IN DMF + PARACETAMOL VERSUS PARACETAMOL IN 
ZEBRAFISH. ............................................................................................................................... 216 











AALD Alcohol-associated liver diseases 
ABCA1 ATP Binding Cassette Subfamily A Member 1 
AFP Alpha-fetoprotein 
ALB Albumin 
ALF Acute liver failure 
ALP Alkaline phosphatase 
ALS Amyotrophic Lateral Sclerosis 
ALT Aminotransferase 
APOC3 Apolipoprotein C3 
APOD Apolipoprotein D 
apoda.1 Apolipoprotein Da, duplicate 1 
ARE Antioxidant response element 
aSMA Alpha-smooth muscle actin 
ATP Adenosine Triphosphate 
BMP Bone morphogenetic protein 
BMS Bristol-Myers Squibb 
bp Base pairs 
BSA Bovine Serum Albumin 
B2M Beta-2 Microglobulin 
CCL3L1 C-C Motif Chemokine Ligand 3 Like 1 
CFA Common factor analysis 
CLDN6 Claudin 6 
CNC Cap’n’collar 
crygm Crystallin family 
Cull3 Cullin 3 
CYP Cytochrome 
Cys Cysteine residues 
d.p.f Days post fertilisation 
DE Definitive Endoderm 
DEGs Differential expression genes 




DILI Drug-induced liver injury 
DMF Dimethyl fumarate 
DMSO Dimethylsulfoxide 
DPBS Dulbecco's phosphate-buffered saline 
DUOX2 Dual oxidase 2 
DUSP9 Dual specificity phosphatase 9 
EBs Embryoid bodies 
EMA European Medicines Agency 
EMPs Extracellular matrix proteins 
EMT Epithelial–mesenchymal transition 
ETFB Electron Transfer Flavoprotein Subunit Beta 
ETS1 ETS Proto-Oncogene 1 Factor 
FACS Fluorescence activated cell sorting 
fbxo32 F-Box Protein 32 
FDA Food and drug administration 
FGF Fibroblast growth factor ( 
GFP Green fluorescent protein 
GGT Gamma-glutamyl transferase 
GMP Good Manufacturing Practice 
GSEA Gene Set Enrichment Analysis 
GSH GLutathione 
GSR Glutathione reductase 
GST Glutathione S-transferase 
H2O2 Hydrogen peroxide 
haao 3-hydroxyanthranilate 3,4-dioxygenase 
HCA High content analysis 
HCA2 Hydroxycarboxylic acid receptor 2 
HCC Hepatocellular carcinoma 
HE Hepatic endoderm 
hESC Human embryonic stem cell 
HGD Homogentisate 1,2-dioxygenase  
HGF Hepatocyte growth factor 
HIF-1a Hypoxia‐inducible factor 1‐alpha 
HLCs Hepatocytes-like cells 
XX 
 
HMOX1  Heme oxygenase-1 
HNF4a Hepatocyte Nuclear Factor 4 Alpha 
HTRA2 HtrA serine peptidase 2 
ICC Immunocytochemistry 
IL Interleukine 
iPSC Induced pluripotent stem cell 
ITGA2 Integrin a2 
Keap1 Kelch-like ECH-associated protein 1 
KOSR Knock-Out Serum Replacement 
KRT/CK Keratin/cytokeratin 
LFABP Liver-type fatty acid-binding protein 




ml  Millilitre 
mM Millimolar 
MMF Monoethyl fumarate 
MPT Membrane permeability transition 
MRP Multidrug resistance-associated protein 
MSigDB Molecular signatures database  
NAC N-Acetylcysteine 
NAFLD Non-alcoholic fatty liver disease 
NAPQI N-acetyl-p-benzoquinone imine 
NASH Non-alcoholic steatohepatitis 
NEAT1 Nuclear Enriched Abundant Transcript 1 
Nf-kb Nuclear factor kappa-light-chain-enhancer of activated 
B cells 
NIDI1 Nidogen 1 
nM NanoMolar 
NPPB Natriuretic Peptide B 
NQO1 NAD(P)H quinone reductase 1 





Nup160 Nucleoporin 160 
NUPR1 Nuclear Protein 1 
OCT Octamer-binding transcription factor 
OSM Oncostatin M 
PBS Phosphate Buffered Saline 
PCA Principal Component Analysis 
PDFG Platelet-derived growth factor 
PHH Primary human hepatocytes 
PSC Pluripotent stem cells 
PTGR1 Prostaglandin reductase 1 
qPCR Quantitative polymerase chain reaction 
QUIN Quinolinic acid 
RAS Renin-angiotensin system 
Rbx1 RING box protein 1 
RIN RNA integrity number 
ROCK Rho-Associated Protein Kinase 
ROS Reactive oxygen species 
rpe65a Retinoid Isomerohydrolase 
RPMI Roswell Park Memorial Institute (Medium) 
SCNN1A Sodium Channel Epithelial 1 Alpha Subunit 
SD Standard Deviation 
SE Standard Error 
SEMA7A Semaphorin7A 
SERPINB8 Serpin Family B Member 8 
SGOT Serum glutamic oxaloacetic transaminase 
SGPT Serum glutamic pyruvic transaminase  
SLC2A3 Solute carrier family 2 member 3 
sMAF Small musculoaponeurotic fibrosarcoma oncogene 
homologue 
SMOX Spermine Oxidase 
SSEA Stage-specific embryonic antigen 
STM Septum transversum mesenchyme 
SULT Sulfotransferase 




TCA Tricarboxylic acid 
tcnba Transcobalamin beta a 
TFPI2 Tissue Factor Pathway Inhibitor 2 
TGF Transforming Growth Factor 
TGF-b Transforming growth factor b 
TNF-a Tumour necrosis factor aplha 
TPM1 Tropomyosin 1 
TRIM71 Tripartite Motif Containing 71 
TTC37 Tetratricopeptide Repeat Domain 37 
UBR Ubiquitin Protein Ligase E3 Component N-Recognin  
UGT UDP-glucuronosyltransferase 
VEGF Vascular endothelial growth factor 
WB Western Blot 


















I would like to thank everyone who has helped me over the last few 
years for making the completion of this thesis a more bearable task. I 
am also really grateful for the Tissue Repair PhD programme for 
funding me and for creating such a great group to share this journey.  
I am especially grateful to my supervisor Prof. Dave Hay for taking me 
into his lab and for his guidance and support during these years. It 
has been a pleasure to work under his supervision. In addition, I would 
like to thank my second supervisor Prof. Jeremy Hughes for his great 
ideas, supervision and feedback during my project.  
I would also like to thank the members of my PhD committee: Prof. 
Lesley Forrester for her supervision and training, Dr. David Ferenbach 
for his support and Dr. James Dear for his supervision and 
collaboration during this project.  
I am also thankful to my collaborators at Novo Nordisk, especially to 
Dr. Nicola Beer for giving me the chance to undertake an internship 
with her team. Thanks to her scientific vision, the level of depth on this 
project increased.  
Many thanks to all the people I had the pleasure to work with during 
my studies, especially Baltasar and Celine for their help and training 
and for making the lab a welcoming and entertaining place to work. 
Thanks also go to the many friends I had the pleasure to meet 
throughout my time in Edinburgh, in particular though the SCRM, the 
tissue repair programme and many others. And despite the distance I 
could never forget my friends back in Spain, whose friendship and 





Special thanks to my family, firstly to my parents for their support in 
all my decisions (albeit not always the smartest). I will always be 
thankful to them for making me who I am today. To my sister, for 
always being a support and inspiration and for laughing at the same 
silly things as me. Last but not least, I would like to thank my partner 
Sam, for bringing fun and new adventures to my life; her support and 























The following publications were published during my PhD studies 
1. Semi-automated Production of Hepatocyte Like Cells from 
Pluripotent Stem Cells. Jose Meseguer-Ripolles, Baltasar Lucendo-
Villarin, Yu Wang, David C. Hay. J. Vis. Exp. (137), e57995, 
doi:10.3791/57995 (2018). 
2. Pluripotent Stem Cell-Derived Human Tissue: Platforms to 
Evaluate Drug Metabolism and Safety. Jose Meseguer-Ripolles, 
Salman R. Khetani, Javier G. Blanco, Miari Iredale, David C. Hay. 
Review, AAPS J (2018) 20: 20. https://doi.org/10.1208/s12248-017-
0171-8 
3. Modelling non-alcoholic fatty liver disease in human hepatocyte-
like cells. Lyall Marcus J., Cartier Jessy, Thomson John P., Cameron 
Kate, Meseguer-Ripolles Jose, O'Duibhir Eoghan, Szkolnicka 
Dagmara, Villarin Baltasar Lucendo, Wang Yu, Blanco Giovanny 
Rodriguez, Dunn Warwick B., Meehan Richard R., Hay David C. ,and 
Drake Amanda J. Philosophical Transactions B DOI: 
10.1098/rstb.2017.0362 
4. A human iPSC line capable of differentiating into functional 
macrophages expressing ZsGreen: a tool to study and track 
therapeutic cells in vivo. Martha Lopez Yrigoyen*, Antonella Fidanza*, 
Luca Cassetta, Richard A. Axton, A. Helen Taylor, Jose Meseguer-
Ripolles, Anestis Tsakiridis, Val Wilson, David Hay, Jeff W. Pollard, 
Lesley M. Forrester. Philosophical Transactions B DOI: 
10.1098/rstb.2017-02195 
5. Modelling foetal exposure to maternal smoking using hepatoblasts 
from pluripotent stem cells. Baltasar Lucendo-Villarin, Panagiotis Filis, 
Madeleine J. Swortwood, Marilyn A. Huestis, Jose Meseguer-Ripolles, 
Kate Cameron, John P. Iredale, Peter J. O’Shaughnessy, Paul A. 
Fowler, David C. Hay. Arch Toxicol (2017) 91: 3633. 
https://doi.org/10.1007/s00204-017-1983-0 
6. Defined and Scalable Generation of Hepatocyte-like Cells from 
Human Pluripotent Stem Cells, Yu Wang, Sharmin Alhaque, Kate 
Cameron, Jose Meseguer-Ripolles, Baltasar Lucendo-Villarin, 




7. Serum Free Production of Three-Dimensional Human 
Hepatospheres from Pluripotent Stem Cells. Balta Lucendo-Villarin, 
Hassan Rashidi, Sharmin Alhaque, Lena Fischer, Jose Meseguer-
Ripolles, Yu Wang, Cliona O'Farrelly, Michael Themis, David C. Hay. 
J. Vis. Exp. In-press (2019) 
8. Genome editing in pluripotent stem cells provides new understand-
ding of protein SUMOylation during stem cell specification. Yu Wang, 
Michael H. Tatham, Wolfgang Schmidt-Heck, Carolyn Swann, Karamjit 
Singh-Dolt, Jose Meseguer-Ripolles, Baltasar Lucendo-Villarin, Tilo 
Kunath, Timothy R. Rudd, Andrew Smith, Jan G. Hengstler, Patricio 


























































Introduction  31 
 
 
1.1 The Liver  
1.1.1 Liver function and architecture 
The liver is the largest internal organ in the body exhibiting multiple 
functions. The main endocrine functions include the secretion of 
hormones such as thrombopoietin, angiotensinogen and insulin-like 
growth factor; with bile secretion as the main exocrine function. In 
addition, the liver is also essential for several functions including drug 
detoxification, metabolism regulation, urea metabolism, cholesterol 
synthesis and transport, glycogen storage and secretion of serum 
plasma proteins such as albumin or apolipoproteins (1). Organ 
structure is key to maintaining the multifunctional properties of the 
liver. The main structural unit of the liver is the liver lobule. The lobule 
is formed by single-cell layers of hepatocytes, the main cell type of the 
liver, lined by sinusoidal capillaries and connected to a network of 
blood vessels. The lobule displays a hexagon shape with a central vein 
in the centre of the lobule and the portal triad at each of the corners 
(Figure 1).  
 
Figure 1. Liver structure. Schematic illustration of part of a liver lobule. From Si-
Tayeb et al., 2010 (1) 
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The portal triad consists of the hepatic artery, hepatic portal vein and 
the bile duct (1). Blood enters the lobule through both the hepatic 
artery and hepatic portal vein flowing through the sinusoidal space to 
the central vein. During this flow, blood is exposed to the basal surface 
of the hepatocytes allowing the protein secretion and the absorption of 
components from the blood. Hepatocytes secrete bile acids into the 
canaliculi and then into the bile ducts. The blood flow creates distinct 
microenvironments within the liver, with gradients in oxygen and 
nutrient concentrations. These creates three zones with distinct 
metabolic functions (1,2) (Figure 2A). The first zone or periportal zone 
is responsible for gluconeogenesis, oxidative metabolism and 
ureagenesis. The third zone or pericentral zone is responsible for 
metabolism of xenobiotics, lipogenesis and glycolysis. Zone two or the 
intermediate zone displays a mixture of zone one and zone three 
function (3). 
Although the hepatocyte is the main cell type of the liver, their function 
is coordinated by other cell types that regulate blood and bile flow and 
maintain liver homeostasis (Figure 2B). Cholangiocytes represent the 
second major cell type. Cholangiocytes are the epithelial cells from the 
bile duct. In addition, endothelial cells from the sinusoid vasculature 
required for blood flow. Within the sinusoid, Kupffer cells, the resident 
macrophages of the liver. Stellate cells reside in between the 
hepatocytes and the sinusoid (4).  




Figure 2. Liver zonation and cell organisation. (A) Diagram of hepatocyte metabolic 
zonation. (B) In each lobule, several sinusoids carry blood from the portal triads to the 
central vein. Hepatocytes form single-cell sheet cords separated by sinusoids. 
Cholangiocytes are the epithelial cells forming the bile duct. Stellate cells reside in the 
space of Disse which integrates the space between the hepatocyte and the sinusoid. 
Kupffer cells reside in the sinusoid which it is form by endothelial cells. Adapted from 
Birchmeier 2016 (5). 
Understanding how the different cell types interact in health and 
disease is key to develop new cell-based models for regenerative 
medicine. Liver development studies provide knowledge of the origin 
and interaction of the different cell types or the liver.  
1.1.2 Liver development overview 
Liver development is a complex process requiring the precise 
coordination of many steps. Studies from animal models have 
identified several phases during liver development, including 
endoderm specification, liver bud specification and hepatic 
differentiation (4). These phases are controlled by multiple signalling 
pathways. Given their complexity, I will deal with those in turn. 
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1.1.2.1 Endoderm specification 
The Early embryo is composed of three primary germ layers: ectoderm, 
mesoderm and endoderm. During gastrulation, endoderm is specified 
from mesoderm and forms the primitive gut tube. This can be divided 
into foregut, midgut and hindgut (6). The foregut develops into the 
liver, biliary tree, stomach, pancreas, lungs, oesophagus and thyroids. 
Midgut development gives rise to the small intestine whereas hindgut 
develops into the large intestine (7).  
Definitive endoderm formation is controlled by multiple signalling 
pathways. Transforming growth factor b (TGF-b) has been reported to 
be critical for endoderm formation. Within TGF-b growth factors, Nodal 
has been shown to orchestrate endoderm and mesoderm development 
in a concentration dependent manner. Increased levels of Nodal induce 
endoderm where reduced levels are required for mesoderm induction 
(8). Endoderm specification is controlled by an autoregulatory loop 
where Nodal expression controls fibroblast growth factor (FGF) and 
bone morphogenetic protein (BMP) signalling. In addition, definitive 
endoderm separation is controlled by the Wnt/b-catenin signalling 
pathway (9). All these signalling gradients lead to the primitive gut tube 
formation which can be divided into foregut, midgut and hindgut. 
Foregut development requires low levels of Wnt and BMP, where FGF 
signalling keeps cells susceptible to Wnt and BMP proteins (Figure 3). 




Figure 3. Endoderm specification. Nodal signalling is required for mesendoderm 
(ME) formation from the embryonic epiblast (Ep). This is increased by a reinforcing 
loop of Nodal, Wnt and BMP signalling. High levels of Nodal signalling promote 
definitive endoderm (DE) formation, while increase in BMP and FGF and reduction 
of Nodal are required for mesoderm commitment. The BMP, FGF and Wnt gradient 
patterns the DE forming the gut tube. From Gordillo et al., 2015 (4) 
1.1.2.2 Liver bud specification  
The liver bud originates from a newly specified ventral endodermal cell 
called hepatoblast. By E9.0 in mice, the ventral area of the foregut 
thickens to form the liver bud. During the liver bud formation, the 
ventral endodermal cells transition into a multilayer of pseudostratified 
cells called hepatoblasts (10). Between E9.0 and E9.5, hepatoblasts 
expand and break down the basal layer surrounding the developing 
hepatic endoderm. The basal layer is composed mainly by laminin and 
collagen IV, the hepatoblasts delaminate this layer and migrate into 
the adjacent septum transversum mesenchyme (STM) to form the liver 
bud (10). At this stage, endothelial cells are required for liver bud 
formation. Studies in mice showed endothelial infiltration between 
E8.25 and E10 (4). Conversely, the removal of the endothelial cells 
prior to vascularisation impaired liver bud development (11). Due to 
endothelial cell integration the liver bud is vascularised, permitting a 
continuous growth (Figure 4). Vascularisation of the liver bud permits 
the colonisation of hematopoietic cells, making the liver bud a driver 
of foetal haematopoiesis (4).  
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Figure 4. Mouse liver bud development. (A) Sagittal section of the mouse hepatic 
endoderm at E8.25 (HE, green), resting adjacent to the convergence of the cardiac 
mesoderm (blue) and septum transversum (ST, purple). (B-D) Transverse sections of 
the mouse liver bud development from E8.75 until E10. Diverticulum progressing to 
the liver bud stage. At E8.75, the hepatic endoderm thickens and forms the liver 
diverticulum, endothelial cells (ECs, orange) are surrounding the hepatic endoderm. 
At E9, hepatoblast are originated from the hepatic endoderm. Hepatoblast then 
proliferate and migrate into the ST forming the liver bud. From Gordillo et al., 2015 
(4). 
 
Hepatic specification from the foregut is controlled mainly by FGF, 
BMP and Wnt signalling. FGF is produced by the cardiac mesoderm. 
Impaired liver bud development it has been observed by both inhibition 
of FGF signalling as well as removal of the cardiac mesoderm (12). FGF 
hepatic induction is regulated by the MAPK pathway (13). BMP 
signalling is originated from the mesoderm and STM and has hepatic 
induction properties. BMP2a is required to induce the expression of 
key genes involved in liver development (14). In addition, inhibition of 
BMP4 in mice stopped liver bud formation (15). Finally, the role of 
Wnt/b-catenin signalling in hepatic specification is not fully 
understood. In zebrafish, loss of Wnt2 and Wnt2b leads to liver 
organogenesis failure (16). On the contrary, in mice Wnt2 and Wnt2b 
loss caused lung agenesis but it did not impair liver development or 
other endoderm-derived organs (17). The role of canonical and non-
canonical Wnt signalling pathway in hepatic induction is still requires 
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further investigation. In addition, the interactions of BMP, FGF and 
Wnt pathways are still unclear. FGF signalling is not a target of BMP 
and Wnt signalling is not activated by BMP or FGF signalling (4).  
1.1.2.3 Hepatoblast expansion and maturation 
Hepatoblasts originate from the liver bud and its expansion is 
regulated by interactions with endothelial and mesenchymal cell in the 
septum transversum. Wnt signalling promotes liver expansion and 
hepatoblast proliferation. Chicken studies showed how overexpression 
of β-catenin activation increased liver size at E15, as well as inhibition 
of the Wnt pathway resulted in liver shrinkage (18). In addition, Wnt 
acts in collaboration with FGF signalling and hepatocyte growth factor 
(HGF) to promote hepatoblasts proliferation (19). Hepatoblasts are 
proliferative cells with the bipotential ability to differentiate into 
hepatocytes and cholangiocytes (Figure 5). Hepatoblasts expresses a 
combination of hepatocyte markers such as albumin, Hepatocyte 
Nuclear Factor 4 Alpha (HNF4a) and keratin 18 (KRT18) as well as the 
cholangiocyte marker keratin 19 (KRT19) (4).  
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Figure 5. Hepatoblast bipotential differentiation. The differentiation potential 
of the hepatoblast (Hb) into hepatocytes (H) and cholangiocytes (Ch) is regulated 
by multiple signalling pathways. 
The differentiation process is regulated by TGF-b, Wnt, BMP, Notch 
and FGF. TGF-b signalling is originated around the portal mesenchyme 
and promotes bile duct development (20). In addition to TGF-b, Notch 
signalling is essential for bile duct differentiation, while Notch 
inhibition results in reduced bile duct differentiation (21). Wnt 
signalling is required for both cholangiocytes and hepatocytes, and b-
catenin promotes biliary differentiation while its deletion impairs bile 
duct formation in mice (22). Hepatocyte differentiation is also regulated 
by Wnt signalling. B-catenin deletion from hepatoblasts led to a 
decrease in HNF4a reducing hepatocyte differentiation (23). Working 
with Wnt signalling, HGF, oncostatin M (OSM) and glucocorticoids 
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1.1.3 Liver diseases 
Liver disease is a major problem in society as it is responsible for 
approximately 2 million deaths worldwide per year (25). Common 
causes of liver injury include non-alcoholic fatty liver disease (NAFLD), 
alcohol-associated liver diseases (AALD), viral hepatitis and drug-
induced liver injury (DILI) and liver cancer such as hepatocellular 
carcinoma (HCC) and cholangiocarcinoma.  
The liver is a highly regenerative organ that can adapt to injury through 
tissue repair by hepatocyte proliferation. Maintained or acute injury 
can reduce the regeneration capacity of the liver leading to liver fibrosis 
by extracellular matrix proteins (EMPs) accumulation. Chronic liver 
disease develops if this process continues. Chronic liver disease is 
characterised by fibrosis accumulation, reduction of liver function and 
regenerative properties leading to liver cirrhosis. Once liver cirrhosis is 
established, the potential to reverse disease decreases (Figure 6). At 
the point of end-stage disease, the only effective therapy is liver 
transplant (26). Chronic injuries are commonly caused by viral 
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Most types of liver injury are caused by hepatocyte and/or choanocyte 
death. Cell death generates a pro-injury microenvironment caused by 
the release of reactive oxygen species (ROS) as well as pro-
inflammatory cytokines such as interleukin-6 (IL-6), Il-1b and tumour 
necrosis factor alpha (TNF-a) (27). These factors stimulate immune 
cells and stellate cells, the major effectors of disease progression. The 
activation of both stellate cells and macrophages results into the 
secretion of pro-fibrotic signals such as TGF-b, platelet-derived growth 
factor (PDGF) or angiotensin II. TGF-b is one of the major pro-fibrotic 
mediators by upregulating type I collagen and alpha-smooth muscle 
actin (aSMA) production in hepatic stellate-derived myofibroblasts (28). 
PDGF induces myofibroblasts proliferation via ERK and nuclear factor 
kappa-light-chain-enhancer of activated B cells (Nf-kb) (29). 
Angiotensin II is a vasoactive cytokine and induces fibrosis via renin-
angiotensin system (RAS) activation in stellate cells (30). If this process 
is not stopped, TGF-b, PDGF and angiotensin II activation can generate 
 
Figure 6. Ethicology of chronic liver disease. Fibrosis originates from an unbalanced 
wound-healing process. Injury can be caused by viral infection, alcohol consumption, 
NAFLD or metabolic disorders. Chronic disease originates from a maintained fibrosis 
over the years. Unless stopped, this process leads to cirrhosis and organ failure. From 
Pellicoro et al. 2014 (26). 
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a positive feedback loop which will maintain fibrosis leading into 
cirrhosis (26).  
In contrast to chronic liver disease, acute liver failure (ALF) is a life-
threating disease characterised by a rapid loss of hepatocytes. ALF can 
be caused by prolonged ischemia, DILI or metabolic disorders, amongst 
others (31). Within the different origins of injury, hepatocyte death 
typically occurs by either apoptosis or necrosis. Apoptosis is a 
controlled cell death process that occurs following DNA damage, 
metabolism alterations or by death receptor ligands (32,33). This 
process is regulated by caspases, a family of proteases that cleave 
proteins involved in cellular homeostasis. During this process 
mitochondria permeability is compromised, releasing proapoptotic 
proteins like cytochrome c or Smac/Diablo (34). Following 
mitochondrial leakage, the activation of the caspase cascade will 
activate apoptosis. Ultimately, apoptotic cells shrink and fragment into 
apoptotic bodies that are phagocytosed by macrophages and adjacent 
cells, minimising the development of a pro-inflammatory environment 
(35). Necrosis in contrast, is a non-controlled cell death mechanism in 
response to acute injury (36). Necrosis is characterised by ATP 
depletion as a consequence of mitochondrial permeabilization by the 
opening of the mitochondrial membrane permeability transition (MPT) 
pore. Mitochondrial leakage leads to release of intermembrane protein, 
DNA fragmentation and ROS generation. These changes generate 
cellular swelling, forming large cellular membrane protrusions called 
blebs. Finally, bleb rupture causes cell death and release of the cellular 
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1.1.3.1 Drug-induced liver injury 
Drug-induced liver injury (DILI) is one of the most common causes of 
ALF in most developed countries at an estimated annual rate of 10 - 
15 patients per 100,000 (38–40). Paracetamol (acetaminophen) 
induced hepatotoxicity is the most common cause of DILI, causing over 
50% of ALF cases in the United States in 2003 (38). Paracetamol 
toxicity is caused via a dose-dependent mechanism. Under non-toxic 
concentration, paracetamol exhibits analgesic properties. This process 
generates low levels of toxic metabolites that the liver can metabolise. 
On the contrary, paracetamol overdose induces major hepatocyte 
death causing life-threatening acute liver damage (41,42); hepatoxicity 
is characterised by the generation in excess of N-acetyl-p-
benzoquinone imine (NAPQI) by cytochrome (CYP) P450 proteins 
(43,44). NAPQI is a highly reactive toxic metabolite that will induce 
ROS generation and inflammation (42).  
Following administration, 90% of the paracetamol is metabolised by 
UDP-glucuronosyltransferase (UGT) and sulfotransferase (SULT) and 
excreted with urine. The remaining paracetamol is metabolised by CYP 
P450 proteins, mainly CYP 2E1 as well as CYP 2A6, CYP 2D6 AND CYP 
3A4, into NAPQI (44–48). NAPQI is conjugated with glutathione (GSH) 
forming paracetamol-GSH - a non-toxic conjugate that can be excreted 
with the urine (49).  
The common method of paracetamol toxicity is by overdose. 
Paracetamol-induced hepatotoxicity is developed through ingestion in 
single dose of more than 10 g in adults and 150 mg/kg in children, but 
lower doses or repeated administration of paracetamol can also lead to 
hepatotoxicity (38,50,51). During an overdose, NAPQI is produced in 
excess by CYP P450 proteins resulting in GSH depletion. After GSH 
depletion, NAPQI forms protein adducts by binding sulfhydryl groups 
of cellular proteins including mitochondrial proteins (52,53). This leads 
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to mitochondrial dysfunction and disruption, generation of ROS, lipid 
peroxidation, DNA fragmentation, ATP depletion and cell death by 
necrosis or apoptosis as explained previously (49). The depth of the 
injury can be further amplified by the immune response by the release 
of pro-inflammatory cytokines including TNF-a and Il-1b (54,55). 
Organ failure occurs when the remaining hepatocytes fail to proliferate 
and regenerate the liver (56). A recent study showed how injury-
induced senescence in hepatocytes following paracetamol injury 
inhibited liver regeneration (57). Necrotic cells induce the spread of 
senescence to the remaining hepatocytes, blocking regeneration. This 
process is regulated by a positive-feedback loop that spreads 
senescence from both necrotic cells and macrophage-dependent TGF-
b signalling. 
The only current treatment for paracetamol-induced hepatotoxicity is 
N-Acetylcysteine (NAC). The main effect of NAC is to increase the 
production and availability of hepatic glutathione which neutralises 
NAPQI and reduces hepatocyte death (58–60). NAC treatment is only 
effective if it is administrated within the first 8-10 hrs following 
paracetamol overdose consumption (58). Therefore, new treatments 
that increase the treatment window or block the spread of senescence 
could be potential approaches to reduce the level of injury and/or 
promote liver regeneration. 
1.1.4 Liver biology and disease modelling 
There is a need to develop models that recapitulate liver physiology 
during health and disease. Current approaches use in vitro and in vivo 
tools to study liver biology. To date, in vitro models rely heavily on 
immortalised cell lines, usually derived from human tumours. These 
models have advantages, such as cost-effective scale-up and well-to-
well reproducibility. Additionally, these cell lines can be easily 
genetically engineered, allowing the expression or suppression of key 
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genes of interest. While these models demonstrate advantages, they 
offer limited biological relevance when compared to the intact organ or 
the cancer they were derived from (61,62). Currently, primary human 
hepatocytes (PHH) are considered the gold standard for drug discovery 
and regenerative medicine. There are however drawbacks with PHH. 
The main disadvantages of using primary cell types are their labour-
intensive isolation from diseased organs, the scarcity of donor tissue, 
the rapid loss of cell phenotype, and significant batch-to-batch 
variation (63,64).  
1.1.5 Stem cells as a renewable model for liver research 
Stem cell technology has been proposed as a suitable alternative to 
overcome the limitations of primary and immortalised cell types. 
Current advances in human embryonic stem cell (hESC) and induced 
pluripotent stem cell (iPSC) differentiation protocols into hepatocyte-
like cells (HLCs) better mimic primary cells than the immortalised lines 
(65). Through model refinement and cost-effective scale-up it is now 
possible to prototype systems from defined genetic backgrounds to 
study and better understand the biology behind drug-induced liver 
injury and other forms of liver diseases (66–71).  
Human pluripotent stem cells (hPSC) exhibit self-renewal and 
pluripotency, the potential to differentiate into the three germ layers 
(72). hESC are derived from the inner cell mass of blastocytes 
unsuitable for implantation (73). iPSC were first produced by 
overexpressing key transcription factors: Oct 3/4, Sox2, Klf4 and c-
Myc (74). hPSC express the pluripotent transcription factors Oct4, 
Nanog and Sox2 (75–77) and the cell surface markers like tumour 
rejection antigens TRA-1-60 and TRA-1-81, stage-specific embryonic 
antigen 3 (SSEA3) and 4 (SSEA4). 
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Over the last two decades, several groups have established 
differentiation protocols that allow the efficient differentiation of hPSC 
HLCs. Hepatocyte differentiation attempts to recreate aspects of a 
human liver development in vitro by using growth factors and small 
molecules (for a review of the different protocols for HLCs production 
see (78)). To date, most of the work has focused on monolayer 
hepatocyte systems. 
Hepatocyte monolayer differentiation systems usually consist of a 
stagewise approach where the stem cell populations are driven to 
definitive endoderm using activin and Wnt signalling (79,80). This is 
followed by hepatic progenitor cell specification (81,82) and hepatocyte 
maturation (83–87). These protocols produce HLCs that express 
mature hepatocyte markers such as HNF4a, albumin, and cytochrome 
P450 proteins, exhibit metabolic activity and secrete serum proteins 
such as albumin (88,66). Successful differentiation of the different 
stages of the protocol can be assessed using a panel of protein markers 
(Figure 7).  
Advantages of the monolayer systems include the ease and cost of 
scale-up, and relatively reduced batch-to-batch variation, making 
them ideal for regenerative medicine research (89). However, current 
systems face some limitations such as a mixture of foetal and adult 
hepatocyte traits and limited organisation, and as a consequence 
cannot recapitulate all situations that occur in vivo (90). Recent 
advances in HLCs differentiation protocols have been proven to model 
liver diseases. HLCs have been used to model human metabolic liver 
disease (70,71), non-alcoholic fatty liver disease (67,69), drug-induced 
liver injury (68,91) and foetal hepatotoxicity (92). Another advantage is 
the ability to create HLCs from multiple libraries to capture genetic 
diversity offering new resources to study mechanism of action and to 
develop better models to study idiosyncratic reactions (93). 
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Figure 7. HLCs markers during the differentiation process. Pluripotent stem cells 
are differentiated to definitive endoderm, then primed to the hepatoblast stage. 
Following this, the progenitors are matured to hepatocyte-like cells. A panel of markers 
can be employed to assess successful differentiation at each stage of the process. OCT 
- octamer-binding transcription factor, SSEA - stage-specific embryonic, GATA - GATA 
binding protein, FOXA - forkhead box protein A, FGF17 - Fibroblast growth factor 17, 
hHex—hematopoietically-expressed homeobox, HNF - Hepatocyte nuclear factor, AFP - 
Alpha-fetoprotein, CK - cytokeratin, GSTA1 - glutathione S-transferase A1, APOA1-
apolipoprotein A1, MRP2 - Multidrug resistance-associated protein 2, CYP - Cytochrome 
P450. Adapted from Meseguer-Ripolles et al, 2018 (78). 
 
1.2 The Nrf2 pathway 
As described previously, therapies that increase the antioxidant and 
anti-inflammatory capacity of the hepatocytes or block the spread of 
senescence could reduce the severity of acute liver injury and enhance 
regeneration. The transcription factor ‘nuclear factor erythroid-derived 
2-like 2’ (Nrf2) is a major regulator of a large battery of cytoprotective 
genes involved in multiple processes such as oxidative stress 
management, glutathione synthesis, detoxification, drug excretion and 
NADPH synthesis (94). Therefore, pharmacological activation of Nrf2 
during acute liver injury may provide a successful therapy for patients.  
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1.2.1 Regulation of Nrf2 
Nrf2 is a member of the cap’n’collar (CNC) basic-region leucine zipper 
transcription factor family and it was discovered in 1994 (95). It 
regulates the expression of more than 200 genes that contain an 
enhancer region in their promotor named antioxidant response 
element (ARE) (96). Nrf2 is able to regulate the expression of the ARE 
depended genes in response to multiple forms of stress.  
The main regulation of Nrf2 is through its interaction with Kelch-like 
ECH-associated protein 1 (Keap1). Keap1 was firstly described in 1999 
as the main Nrf2 repressor (97). Keap1 is an E3 ubiquitin ligase that 
targets Nrf2 for proteasomal degradation via the cullin 3 (Cul3) and 
RING box protein 1 (Rbx1) complex (98,99). Therefore, under non-
stress conditions, Keap1 interacts with Nrf2 and undergoes a rapid 
proteasomal degradation, this mechanism limits the half-life of Nrf2 to 
15-40 minutes (96). However, oxidative stress and electrophilic 
molecules can limit the binding capacity of Keap1 by interacting and 
covalently modifying Keap1 cysteine residues (Cys) (100). Keap1 is a 
cysteine-rich protein, with Cys-151, Cys-226, Cys-273, Cys-288 and 
Cys-613 as the most common modified residues with Cys-151 the 
preferable residue for interaction with electrophile compounds (101). 
Following Keap1 inhibition, Nrf2 is rapidly accumulated into the 
cytoplasm. This is followed by a nuclear translocation of Nrf2 where it 
forms a heterodimer with small musculoaponeurotic fibrosarcoma 
oncogene homologue (sMAF) proteins inducing the ARE-dependent 
gene expression (96).  
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Figure 8. Overview of the Nrf2-Keap1 pathway regulation. Upon cell stress Keap1 
structure changes allowing the dissociation of the Nrf2–Keap1 complex allowing Nrf2 
to undergo nuclear translocation initiating the expression of the ARE mediated genes. 
ARE = antioxidant response element, Cys = cysteine groups, sMAF = small Maff 
protein, Ub = ubiquitin. Figure drawn by author. 
1.2.2 The role of Nrf2 in DILI modulation 
In hepatocytes, Nrf2 is highly expressed to maintain organ homeostasis 
(102). Nrf2 regulates the expression of several proteins involved in drug 
metabolism including phase I, phase II and phase III proteins. Nrf2 
regulates the expression of several processes involved in paracetamol 
metabolism (Figure 9). Nrf2 also controls the expression of proteins 
that control glutathione and NAPDH homeostasis. NAPDH is an 
essential cofactor for multiple drug metabolising enzymes and to the 
antioxidant machinery. Lipid metabolism and heme and iron 
metabolism is also regulated by Nrf2 (for a detailed review of the Nrf2 
regulatory network in drug metabolism see (94)).  





In addition, Nrf2 displays anti-inflammatory properties by a crosstalk 
with Nf-kb and direct inhibition of pro-inflammatory genes. Nrf2 can 
inhibit Nf-kb transcription. Treatment with lipopolysaccharide (LPS) in 
a Nrf2 knockout mice model of sepsis exhibited an increased 
expression of the Nf-kb signature when compared to control mice. In 
Nrf2 knockout mice, the inhibitor of Nf-kb (IκB) was highly 
phosphorylated and undergoing proteasomal degradation, reducing 
the inhibition of the Nf-kb pathway (107). Another mechanism where 
Nrf2 can suppress Nf-kb is by the competition to bind the 
transcriptional cofactor p300 (108). Finally, the activation of Nrf2 
suppresses the macrophage inflammatory response by blocking the 
 
Figure 9. Role of Nrf2 in paracetamol metabolism. In green are all the processes 
regulated in part by the Nrf2 pathway. Nrf2 can regulate the UGT and SULT enzymes 
responsible for the non-toxic paracetamol metabolism. In addition, Nrf2 also 
regulates glutathione (GSH) recycling by the induction of GSR as well as the 
glutathione-S-transferases responsible for NAPQI neutralisation. Finally, Nrf2 can 
also regulate the ABC transporters responsible for metabolite efflux (103–106).  
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transcription of pro inflammatory cytokines (Il-6, IL-1b, IL-1a and 
Nos2) via an ARE non-dependent mechanism (109).  
The protective role of Nrf2 in paracetamol-induced hepatoxicity was 
demonstrated in a study with Nrf2-knockout mice. Nrf2 knockout mice 
exhibited an increased paracetamol-induced injury due to a reduction 
in the detoxification enzymes expression (106,110,111). Opposite 
results were observed where Keap1-knockout mice were exposed to 
paracetamol (112). Moreover, a different study reported Nrf2 activation 
following paracetamol administration in a mouse model. Nrf2 nuclear 
translocation was observed in both toxic and non-toxic paracetamol 
concentrations (113). In this study, upregulation of Nrf2 target genes 
was not detected at the toxic concentrations despite the nuclear 
translocation of Nrf2. Recent work in mouse liver cells probed the 
direct interaction of NAPQI and Nrf2. In this study, NAPQI activated 
Nrf2 nuclear translocation by depleting cellular glutathione and by 
modifying the cysteine residues of Keap1 (114). Therefore, the 
cytoprotective potential of Nrf2 following paracetamol overdose might 
be dependent of the level of injury; where higher concentrations of 
NAPQI could activate Nrf2 nuclear translocation but fail to induce 
transcription (113). This could be due to a significant dysregulation of 
cellular processes involved in cellular homeostasis from paracetamol 
overdose. Following injury, Nrf2 has been shown to play an important 
role in liver regeneration; it is required to maintain hepatocyte identity 
during the regenerative process by regulating the expression of Notch1 
and HNF4a (115,116). 
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1.2.3 Therapeutic activation of Nrf2  
Pharmacological activation of Nrf2 following paracetamol-induced 
hepatotoxicity might represent a potential therapy to enhance 
hepatocyte health and liver regeneration. The majority of Nrf2 inducers 
are electrophile compounds that covalently modify the cysteine 
residues of Keap1 (117). Keap1 inhibition is mainly by changing the 
conformational structure of Keap1 or by blocking the interaction 
between Keap1 and the CUL3/RBX1 complex (118–120). Fumaric acid 
compounds are potential Nrf2 activators; Dimethyl fumarate (DMF) is 
a fumaric acid compound approved by the food and drug 
administration (FDA) and the European Medicines Agency (EMA) for 
relapsing multiple sclerosis and psoriasis (121,122). DMF is 
metabolised by hydrolysis to monoethyl fumarate (MMF) by esterases 
(123). Both DMF and MMF can interact directly with Keap1 cysteine 
residues activating Nrf2 (124). MMF is further metabolised through the 
tricarboxylic acid (TCA) cycle with no CYP P450 involvement. MMF is 
mainly eliminated by CO2 exhalation (60%) followed by renal (16%) and 
fecal (1%) elimination (125).  
Even though the mechanism of action of DMF is not fully understood, 
DMF presents some immunomodulatory and oxidative stress 
management properties (124). To date, most of the work has been 
focused in understanding the mechanism of action of DMF in multiple 
sclerosis and psoriasis. The main effects observed by DMF treatment 
are: activation of Nrf2 pathway, indirect inhibition of Nf-kb and 
hypoxia‐inducible factor 1‐alpha (HIF-1a), modulator of intracellular 
GSH and modulation of the immune system.  
DMF induces the expression of multiple Nrf2 target genes including 
Heme oxygenase-1 (HMOX1), NAD(P)H quinone reductase 1 (NQO1) or 
glutathione reductase (GSR) as well as by inhibiting the expression of 
pro-inflammatory signalling such as Il-1b, TNFa, nitric oxide and Il-6 
 
 52 Jose Meseguer Ripollés 
(126–129). DMF inhibits Nf-kb activation by a covalent modification of 
p65, a member of the Nf-kb transcription factor family. DMF inhibits 
the nuclear translocation and DNA biding activity of phosphorylated 
p65 (130,131). Inhibition of HIF-1a by DMF treatment has also been 
reported; DMF can interact with HIF-1a and promote its degradation 
reducing the expression of HIF-1a target genes such as vascular 
endothelial growth factor (VEGF) and Il-8 (132). In addition, there is 
complex interaction between DMF and GSH;  
In vitro work in astrocytes and peripheral blood monocytes reported 
GSH depletion followed by an upregulation of HMOX-1 following DMF 
treatment (133,134). Interestingly, the initial decrease of GSH was 
accompanied with an increase in total basal levels of GSH after 24 h of 
DMF treatment; this could be controlled by GSR upregulation after 
DMF treatment (134,135). In contrast, Kramer et al. showed how DMF 
prevented glutathione depletion and Nrf2 activation in a mouse model 
of traumatic brain injury (136). Finally, several immunomodulation 
properties of DMF have been reported. First, DMF can activate the 
hydroxycarboxylic acid receptor 2 (HCA2) expressed in neutrophils 
reducing their neutrophil adhesion, activity and recruitment capacity 
(137,138). In addition, work in multiple sclerosis patients showed that 
long term treatment of DMF induces reduction in peripheral memory 
T-cells, natural killer cells and B cells with a relative increase in Th2 
and naïve T-cells with a higher anti-inflammatory activity (139,140). 
Further research to fully understand the immunomodulatory 
properties of DMF is required. Therefore, pharmaceutical repurposing 
of the use of DMF could potentially lead to a successful treatment to 
reduce the severity of acute liver injury. 
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1.3 The objective of the thesis 
The focus of this study is to investigate the cytoprotective properties of 
dimethyl fumarate and Nrf2 signalling during drug-induced 
hepatotoxicity in both in vitro an in vivo models. For the in vitro studies, 
(HLCs) from human pluripotent stem cells were employed. The in vitro 
findings were validated in a zebrafish liver-GFP reporter line.  
 
1.4 Hypothesis of the thesis 
Short term stimulation of Nrf2 by dimethyl fumarate will protect 
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2.1 Materials and reagents 
2.1.1 Cell culture medium 
Table 1 Cell culture medium used for hESC maintenance and differentiation 
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2.1.2 Antibodies 
Table 2. Primary antibodies used for immunostaining 
Primary antibodies   
Antibody Host species Dilution Supplier 
Oct4 Rabbit Poly 1/200 Abcam 
NANOG Rabbit Poly 1/200 Abcam 
AFP Mouse Mono 1/400 Abcam 
a-SMA Mouse Mono 1/200 DAKO 
b-tubulin Mouse Mono 1/1000 Sigma Aldrich 
Sox17 Goat Poly 1/400 R & D Systems 
Foxa2 Mouse Mono 1/200 R & D Systems 
HNF4a Rabbit poly 1/200 Santa Cruz 
CK19 Mouse Mono 1/50 DAKO 
E-cadherin Mouse Mono 1/200 Abcam 
CYP2D6 Sheep Poly 1/200 University of Dundee 
CYP3A4 Sheep Poly 1/4200 University of Dundee 
MRP1 Mouse Mono 1/100 Abcam 
Nrf2 Rabbit poly 1/100 Abcam 
Nrf2 Mouse Mono 1/100 Santa Cruz 
IgG Rabbit Poly 1/400 DAKO 
IgG Mouse Mono 1/400 DAKO 
IgG Goat Poly 1/400 DAKO 
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Table 3. Secondary antibodies used for immunostaining 
Secondary antibodies   
Antibody Host species Dilution Supplier 
Anti-Rabbit 568 Donkey 1/400 Life Technologies 
Anti-Rabbit 488 Donkey 1/400 Life Technologies 
Anti-Mouse 488 Rabbit 1/400 Life Technologies 
Anti-Mouse 568 Goat 1/400 Life Technologies 
Anti-Sheep 488 Donkey 1/400 Life Technologies 
Anti-Goat 488 Rabbit 1/400 Life Technologies 
Anti-Goat 568 Rabbit 1/400 Life Technologies 
Anti-Rabbit 568 Donkey 1/400 Life Technologies 
Hoechst 350 nm 
(DNA staining)  1/1000 Invitrogen 
 
Table 4. Antibodies used for flow cytometry 
Antibody Fluorophore Host species Dilution Supplier 
SSEA-1 FITC Mouse 1/50 Biolegend 
SSEA-4 PE Mouse 1/50 Biolegend 
TRA-1-60 PE Mouse 1/50 Biolegend 
Mouse 
IgG 
FITC/PE Rabbit 1/50 Biolegend 
 
Table 5. Antibodies used for western blot 
Antibody Host species Dilution Supplier 
Nrf2 Mouse Mono 1/1000 R & D Systems 
b-actin Mouse Mono 1/10000 Sigma 
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2.1.3 Cell Painting assay 
Table 6. Fluorescent staining used for the cell painting assay. 
Compound Florescence (nm) Dilution Supplier 
HCS CellMask 488 1/50000 Invitrogen 
MitoTracker Deep 
Red 647 1/4000* Invitrogen 
Hoechst 33342 350 1/1000 Invitrogen 
2.1.4 Oligonucleotides 
Only TaqMan probes from applied biosystems were used for this study. 
Table 7. List of TaqMan primers used 
Gene Primer 
Glutathione reductase Hs00167317_m1 
NADPH quinone dehydrogenase 1 Hs01045993_g1 
Heme oxygenase 1 Hs01110250_m1 
Beta 2 microglobulin Hs00187842_m1 
2.1.4.1 Chemical reagents 
Table 8. List of reagents used 
Reagent Supplier Catalogue number  
Dimethyl fumarate Sigma Aldrich 242926 
H2O2 Sigma Aldrich H1009 
Paracetamol Sigma Aldrich P0300000 
Brusatol Sigma Aldrich SML1868 
N-Acetylcysteine Sigma Aldrich PHR1098 
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2.1.4.2 Semi-automated platform equipment 
Equipment Supplier 
Multidrop Thermo Fisher Scientific 
ViaFlo Integra 
Automatic plate washer Biotek 
Operetta high throughput microscope Perkin Elmer 
GloMax explorer multiplex plate reader Promega 
 
2.2 Stem cell culture and differentiation 
All cell culture reagents were GIBCO products supplied by Thermo 
Fisher Scientific unless stated otherwise. Corning (UK) supplied the 
plastic ware utilised throughout the cell culture. For high throughput 
imaging, specific µClear 96-well plates from Greiner Bio-one were used. 
Cell culture medium used in this study is described in Table 1. 
2.2.1 Stem cell culture 
H9 human embryonic stem cells were cultured on 5µg/cm2 of laminin 
521 (BioLamina) with mTser1 media (STEMCELL Technologies). 
Medium was changed daily. The cells were incubated at 37 °C in 5 % 
(v/v) CO2, 95 % (v/v) air, for optimal growth. 
2.2.2 Stem cell passaging 
hESC were passaged when they reached 80% of confluency. Medium 
was aspirated and the cells were washed with Dulbecco's phosphate-
buffered saline (DPBS) (Life Technologies) once. Gentle cell dissociation 
reagent (STEMCELL Technologies) was added to the cells. For regular 
passaging, cells were incubated for 5 minutes until the edges of the 
colonies were rounded up. The Gentle cell dissociation regent was 
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aspirated and fresh mTser1 medium was added. Using a cell scraper, 
a homogeneous suspension of cells was formed. Cell split ratio was 1:3 
for regular PSC colonies maintenance.  
2.2.3 Stem cell freezing and thawing  
Stem-cellbanker (Amsbio) was used as a freezing solution. hESC at 80-
90 % confluence were dissociated and collected, cells were centrifuged 
at 200xg for 3 minutes in a 15 ml tube. Supernatant was removed and 
the cell pellet was resuspended in 1 ml of the freezing solution and 
transferred to -80 °C freezer for one night and then to the liquid 
nitrogen tank. Cells were thawed by warming the cryotube in a 37 °C 
water bath. Once thawed, cell suspension was transferred into a 15 ml 
tube with 5 ml of fresh mTeSR1 medium to resuscitate the cells. The 
cells were then centrifuged at 200xg for 3 minutes. The supernatant 
was removed, and the cells were resuspended in 2 ml of mTeSR1 
medium supplemented with 10 μM ROCK inhibitor Y27632 and seeded 
onto a laminin 521 coated 6 well-plate well.  
2.2.4 Embryoid body formation 
Embryoid bodies (EBs) were generated from the hESCs. At 80-90 % 
confluence, hESCs were dissociated briefly for 2-3 minutes and 
collected with 4 ml of EB media. The whole 4 ml cell suspension was 
then plated in low attachment plates to promote cell self-aggregation. 
The media was changed every other day for 7 days until the EBs were 
defined and vacuolated. At day 7, EBs were transferred to 0.5 % gelatin 
coated 24-well plates. The EBs were allowed to differentiate 
spontaneously for 14 days and fed every other day with EB media. On 
day 14, the differentiated cells were fixed with 100% ice-cold methanol 
at -20 °C for 30 minutes. Cells were washed after fixation three times 
with DPBS at room temperature. Cells were then stained with specific 
antibodies of markers for the three germ layers.  
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2.2.5 Hepatocyte-like cell differentiation 
For HLCs differentiation, cells were incubated for 7-9 minutes with 
gentle cell dissociation regent until all cells were rounded up while still 
attached at the plate. Using a cell scraper, a homogeneous suspension 
of single cells was formed. Single cells at 50,000 cells/cm2 were plated 
on 5µg/cm2 of laminin 521, when they reached 30 – 40 % of confluency 
the differentiation protocol was initiated. Once the cells reach the 
correct confluence, mTseR media was replaced with the endoderm 
differentiation medium. On day 4, the second stage, hepatoblast 
differentiation medium was added for 5 days changing the media every 
two days. On day 9, the HLCs medium was added. The medium was 
changed every second day.  
2.2.6 High throughput culture of HLCs 
The semi-automated platform was used to differentiate and 
characterize the cells. An automatic liquid handling dispenser 
(multidrop) was used to coat matrix and seed single cells. Cellular 
differentiation was initiated when the cells reached 40% confluency 
(Day 0). Media changes were performed using an automatic hand-held 
electronic channel pipette (ViaFlo) system to remove medium and the 
liquid handling dispenser for medium addition. Cell fixation and 
staining were performed using the automatic liquid handling dispenser 
in combination with the automatic plate washer (Biotek).  
2.3 Cell characterisation 
2.3.1 Fluorescence activated cell sorting (FACS) 
Fluorescence activated cell sorting (FACS) was performed to 
characterise the expression of cell surface proteins in hESCs. hESCs 
were washed once with 2 ml DPBS and then dissociated with 1ml 
TrypLE. Cells were collected as single cells. Post centrifugation, cells 
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were resuspended in DPBS and filtered through a 0.22 μM filter. The 
single cell suspension was then incubated for 30 minutes at 4 °C with 
the fluorochrome conjugated antibodies (for antibody details, see Table 
4). IgG controls were used for antibody specificity. After incubation, 
cells were then washed twice with DPBS, and spun down at 200xg for 
5 minutes. Cells were then resuspended in 300 μl of DPBS. Only single 
live cells were used for quantification: dead cells were excluded by 
labelling them using DNA staining prior to acquisition. The analysis 
was carried out by using a live gate on forward scatter and side scatter 
parameters. Data for 20,000-50,000 ‘live’ events were acquired for each 
sample using a BD LSR Fortessa (4 laser) analyser. The data was 
analysed using FlowJo software.  
2.3.2 CYP P450 activity 
CYP 3A and CYP 1A2 activity were measured on HLCs at day 18 by 
using the P450-Glo™ assay (Promega). CYP 3A (1:20) and CYP 1A2 
(1:50) substrates were diluted in hepatocyte maturation medium and 
added to the HLCs for 5 37 °C in 5 % (v/v) CO2, plain medium with 
substrate was incubated in parallel to subtract background. After 
incubation, 50 μl of supernatant was collected and mixed with 50 μl 
of luciferin detection reagent in a white 96-well plate at room 
temperature in the dark for 20 minutes. Luminescence was measured 
using a multiplex plate reader (GloMax Explorer, Promega) and 
normalised per mg of protein (RLU/ml/mg). 
2.3.3 Protein content quantification 
The Pierce bicinchoninic acid (BCA) assay kit (Thermo Fisher Scientific) 
was used to quantify the protein content in HLCs. Protein supernatant 
was obtained by adding 50 μl of RIPA buffer (Thermo Fisher Scientific) 
per well of a 96-well plate. 10 μl per sample were analysed in duplicates 
added into a 96-well plate. A standard curve was generated using 
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bovine serum albumin standards at concentrations ranging from 0-
2000 μg/ml. Reagents A and B from the kit were mixed at a 1:50 ratio 
for a final volume of 200 μl per well. Samples were incubated at room 
temperature in the dark for 30 minutes and absorbance was read at 
562 nm using a multiplex plate reader (GloMax Explorer, Promega). 
Concentrations were calculated using standard curve.  
2.3.4 High-content imaging and analysis 
Image acquisition was performed using the automated Operetta 
fluorescent microscope. In brief, plates were placed in the Operetta and 
several random fields of view were imaged per well. Cell segmentation 
for image analysis was performed using the Columbus image analysis 
software. Cell segmentation is a process were the different organelles 
of the cells are identified for feature identification. Cell segmentation 
was performed by a first identification of the nuclei followed by 
cytoplasm identification. Details in Chapter 3. 
2.3.5 Cell viability assay 
Cell viability was determined by the amount of ATP in HLCs 
differentiated in 96-well plate format measured using CellTiter-Glo® 
Luminescent Cell Viability assay (Promega). 100 μl of CellTiter-Glo 
luciferase substrate were mixed with 100 μl of culture medium in the 
plate containing the HLCs. After incubation 100 μl of the mixture was 
transferred into a white 96-well plate and luminescence was measured 
using a multiplex plate reader (GloMax Explorer, Promega). 
2.3.6 Cell Paint assay and morphological profiling 
Cell Paint was developed by Bray et all, 2016 (141), The idea of this 
assay is to create an imaged cell-based profiling using specific dyes to 
stain cellular organelles. After a 4% paraformaldehyde fixation, cells 
were stained for cytoplasm (CellMask 488nm, ThermoFisher), 
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mitochondria (Mitotracker 665nm, ThermoFisher) and nuclei (NucBlue 
460 nm, ThermoFisher) according to manufacturers' instructions.  
Morphological profiling was performed by image cell segmentation. 
First cell nuclei are defined using Dapi channel. Next, cytoplasm was 
identified using CellMask staining from the nuclei identified 
previously. After cells have been identify automatically, a quality 
control step is performed to remove incorrect object segmentations. 
Then, by measuring the cell number, intensities, morphologies and 
pixel texture from the different channels a morphological profile was 
created using 86 different features. This was used to define changes in 
cells upon different stimuli.  
2.3.7 ELISA assay  
HLCs supernatant was collected after 24 h of culture at day 18. 
Albumin or AFP protein secretion was determined using commercially 
available micro-well plates pre-coated with immobilized human 
albumin or AFP antibodies (Alpha Diagnostic Intl. Inc, San Antonio, 
USA). The enzyme-linked immunosorbent assay (ELISA) was carried 
out according to the manufacturer’s instructions. The supernatant was 
diluted 1:3 or 1:10 using the working sample diluent and pipetted into 
the wells in duplicate. Samples for the standard curve were pipetted in 
parallel. After one-hour incubation at room temperature, the micro-
wells were washed four times with working wash solution. Anti-human 
albumin or AFP HRP-conjugated secondary antibody was then diluted 
in working sample diluent and added to the micro-wells followed by 30 
minutes incubation at room temperature. After incubation, the micro-
wells were washed five times using working wash solution. The 
substrate for the HRP enzyme TMB was then added and incubated for 
15 minutes in the dark at room temperature. Stop solution was added 
directly to the wells in order to stop the enzymatic reaction. The plates 
were then read at 450 nm with a reference wavelength of 630nm with 
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the multiplex plate reader. The data was then normalised to per ml per 
mg protein as determined by BCA assay (Pierce, UK).  
2.4 Molecular techniques 
2.4.1 Immunofluorescence 
Cell cultures in 96-well plates were fixed in 4% paraformaldehyde in 
H2O for 15 minutes at room temperature. Subsequently, fixed cells 
were washed twice with PBS at room temperature. Cell were blocked 
with 0.1% PBS-Tween containing 10% BSA for one hour, followed by 
an incubation with primary antibodies diluted in PBS-0.1% Tween/1% 
BSA at 4°C overnight. Then the cells were washed three times with 
PBS-0.1% Tween/1% BSA. Secondary antibody was diluted in 
PBS/0.1% Tween/1% BSA and incubated for 1 hr at room temperature 
in the dark. Finally, the cells were washed three times with PBS and 
the nuclei was stained using Hoechst for 5 minutes.  
2.4.2 Western blotting 
Proteins for Western blotting were collected after one cell wash with 
DPBS, cell lysis was performed using RIPA buffer (Sigma Aldrich) 
supplemented with proteinase and phosphatase inhibitors (Sigma-
Aldrich) at 1 %. After cell lysis, protein suspension was spun down for 
15 min at 12,000 rpm at 4 °C and supernatant was transferred into a 
new 1.5 ml tube. Protein concentration was quantified by BCA.  
2.4.2.1 SDS-NuPAGE polyacrylamide gel electrophoresis  
The SDS-NuPAGE polyacrylamide gel electrophoresis (SDS-PAGE) was 
used to separate proteins based on their sizes. 50 μg protein 
supernatant was denatured at 100 °C for 10min in 1 x NuPAGE LDS 
(Thermo Fisher Scientific) sample buffer supplemented with 10 mM 
DTT before being used for electrophoresis. 4-12 % Bis-Tris precast 
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polyacrylamide gels (Thermo Fisher Scientific) were used with the XCell 
SureLock Mini-Cell System (Thermo Fisher Scientific) for the 
electrophoresis. After placing the gel in the chamber, the tank was 
filled with 1x NuPAGE MES-SDS running buffer with 0.5 ml of NuPAGE 
Antioxidant (Thermo Fisher Scientific) added into the inner chamber. 
The samples were loaded along with a SeeBlue Plus 2 Pre-Stained 
Standard (Invitrogen). A current of 200 V was applied and the samples 
were run for 1.5 hours. The gels containing proteins were carefully 
removed from the cassette for further use in western blotting 
2.4.2.2 Protein transfer  
Following the protein separation using SDS-PAGE gels, the proteins 
were then transferred from the gels to the Polyvinylidene fluoride 
(PVDF) membrane. The transfer sack was assembled from cathode to 
anode as follows: 3x sponge; 2x filter paper soaked in 1x NuPAGE 
Transfer Buffer; SDS-PAGE gel; PVDF membrane activated in 100 % 
ice-cold methanol; 2x filter paper soaked in 1x NuPAGE Transfer 
Buffer; 3x sponge. No bubbles between the gel and the membrane were 
created. After stack assembly, it was placed into the XCell Blot II 
module, the module was tightly sealed and placed into the transfer 
SureLock tank and 1x transfer buffer in the inner chamber and ice-
cold water in the outer chamber was added. The tank was then placed 
on ice for the entire protein transfer process. A constant current of 
160mA was applied for 90-120 min.  
2.4.2.3 Immunoblotting 
Following protein transfer into the PVDF membrane, the membrane 
was blocked in 10 % skimmed milk at room temperature with gentle 
agitation for at least one hour to reduce non-specific antibody binding. 
After blocking, the membrane was probed with desired primary 
antibody diluted in 5 ml 10 % skimmed milk/PBST at 4 °C overnight 
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with gentle rolling. The dilution ratios were optimised specifically for 
each primary antibody as listed in Table 5. Unbound antibody was 
removed by three washes with 0.1 % PBST at room temperature with 
agitation for 5 minutes. After primary antibody incubation, the 
membrane was then incubated with corresponding horseradish 
peroxidase (HRP)-conjugated secondary antibody diluted in 5 ml 10 % 
skimmed milk at room temperature for at least one hour with gentle 
rolling. Unbound secondary antibody was then removed by three 
washes with 0.1 % PBST at room temperature with agitation for 5 
minutes. Β-actin was used for loading control (142). 
2.4.2.4 Enhanced Chemiluminescence (ECL) 
Finally, protein content was quantified using enhanced chemilumi-
nescence (ECL). Proteins bands were visualised using the Pierce 
Enhanced Chemiluminescence Kit (Pierce, UK). Peroxidase buffer and 
the Luminol/Enhancer solution were mixed at a 1:1 ratio and spread 
evenly onto the membrane (2 ml for each membrane), followed by a 5-
minute incubation at room temperature. The HRP substrate reacts 
with the conjugated HRP group presented on the secondary antibody, 
specifying the target protein. The membrane was developed in the dark 
room using a film developer. Protein quantification was performed 
using FIJI software.  
2.4.3 RNA extraction 
RNA was extracted using RNeasy kit (Qiagen), accordingly to 
manufacturer’s instructions. The cells were washed with PBS and 350 
µl of lysis buffer was added into the cells (buffer RTL, RNEasy MiniKit, 
Qiagen) containing β-mercaptoethanol (Gibco, UK). The suspension 
was collected and placed in a 1.5 ml. Cell lysis was ensured by 
vortexing the samples for 30 seconds before addition of an equal 
volume of 70 % Ethanol. The suspension was transferred into a RNeasy 
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Spin Column placed with a collection tube. Column was centrifuged at 
10,000 rpm for 20 seconds, flow through was discarded and 700 μl 
Buffer RW1 was added. Next, centrifugation at 10,000 rpm for 20 
seconds was performed and the flow-through was discarded. Following 
this, 500 μl of Buffer RPE was added. After centrifugation at 10,000 
rpm for 30 seconds, 500 μl buffer RPE was added followed by 
centrifugation at 10,000 rpm for 2 minutes. Then the RNeasy Spin 
Column was transferred to a new collection tube and centrifuged at 
16,000 rpm for 1 minute. The spin column was placed into an RNAse 
free 1.5 mL tube and 30 μl RNAse free H2O was added to the 
membrane. After 3 minutes incubation at room temperature, the tube 
was centrifuged at 10,000 rpm for 1 minute and stored at -80 °C for 
later use. RNA concentration and integrity were quantified using the 
Nanodrop. Both 260/280 and 260/230 rations were quantified and 
only samples with ratios > 1.8 – 2 were used for downstream analysis. 
260/280 ratio measures the purity of RNA from proteins, phenol or 
other contaminants that absorb at 280 nm. 260/230 ratio measures 
RNA purity from contaminants such as TRIzol, EDTA or carbohydrates 
that absorb at 230 nm.  
2.4.4 Reverse transcription 
400 ug of RNA was converted into cDNA using the QuantiTect Reverse 
Transcription Kit (Qiagen) accordingly to manufacturer’s instructions. 
Genomic DNA contamination removal was performed by adding 7 µl of 
gDNA Wipeout Buffer to the purified RNA and RNase-free water up to 
14 µl. The reaction was incubated at 42 °C for 5 minutes and then 
placed on ice. Next, 1 µl Quantiscript Reverse Transcriptase, 4 µl 5x 
Quantiscript RT Buffer and 1 µl RT Primer Mix were added to the 
reaction. Mix was incubated at 42 °C for 30 minutes, followed by a 95 
°C heat treatment for 5 minutes, finishing with a final cool down to 4 
°C for 5 minutes.  
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2.4.5 Quantitative polymerase chain reaction (qPCR) 
qPCR was performed by using Taqman Fast Advance Mastermix and 
Taqman compatible primers (Table 7). Reaction mix was prepared by 
using 0.5 µl of primers, 5.5 µl of Taqman Fast Advance Mastermix and 
5.5 µl of nuclease-free water containing 12 ng of cDNA per reaction. 
Reactions were prepared in triplicate. qPCR reaction consisted of: an 
initial denaturation step at 95 °C for 10 minutes, then 40 cycles of 
denaturation at 95 °C with an annealing/extension at 60 °C for 1 
minute in accordance with the manufacturer’s instructions. qPCR was 
performed using Roche LightCycler 480 Real-Time PCR System and 
data analysis was performed using Roche LightCycler 480 Software 
(version 1.5) in the form of cycle threshold (Ct) values. This value 
represents the point at which fluorescence intensity generated in the 
PCR reaction reaches a set threshold above the background signal. 
Relative expression was calculated by the ΔΔCt method and normalised 
to the housekeeping gene Beta-2 Microglobulin (B2M) (143).  
2.4.6 RT2 PCR array 
For the RT2 PCR array, 500 ug of RNA were converted into cDNA using 
T2 First Strand Kit (Qiagen) and the real time PCR was performed using 
the PAHS-065ZG-4 – RT2 Profiler PCR Array Human Oxidative Stress.  
cDNA was synthesized using the RT2 First Strand Kit (Quiagen) 
according to the manufacturer’s instructions. Genomic DNA 
contamination removal was performed by adding to the RNA 84µl of 
Buffer GE and RNase-free water up to 20 µl. The reaction was 
incubated at 42 °C for 5 minutes and then place on ice. 16 µl of 5x 
Buffer BC3, 4 µl of Control P2, 8 µl of RE3 Reverse Transcriptase Mix 
and 12 µl of RNase-free water were added to the reaction and incubated 
at 42 °C for 15 minutes, followed by a 95 °C heat treatment for 5 
minutes. Finally, 182 µl of RNase-free water was added to each 
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reaction. The mix was placed on ice until PCR array immediately was 
performed.  
Per sample, a qPCR reaction mix containing 1,300 µl of 2x RT2 SYBR 
Green Mastermix, 1,096 µl of RNase-free water and 204 µl of cDNA was 
prepared. Following this 10 µl of the master mix reaction was added to 
each well of the RT2 Profile PCR Array. Real-time reactions were 
performed Roche LightCycler 480 Real-Time PCR System. The qPCR 
reaction consisted of: an initial denaturation step at 95 oC for 5 
minutes, 40 cycles of denaturation at 95 °C with annealing/extension 
at 60 °C for 1 minute. Four biological replicates per condition were 
used. The gene expression was analysed by RT2 Profiler PCR array 
Data Analysis using the cycle threshold (Ct) values.  
2.4.7 RNA sequencing 
RNA sequencing was performed during a 3-week internship at the Novo 
Nordisk Research Centre Oxford (NNRCO) 
2.4.7.1 RNA isolation 
RNA used for sequencing was isolated using the Dynabeads mRNA 
DIRECT Purification Kit (Thermo Fisher Scientific) according to 
manufacturer’s instructions. This protocol is designed for a simple and 
rapid isolation of intact polyadenylated (polyA) mRNA by using 
Oligo(dT)25 magnetic beads. Following treatment, cells were washed 
once with DPBS. Cells were frozen without medium at – 80 °C prior to 
RNA extraction. 50 μl of Lysis /Binding Buffer was added to each well 
of a 96-well plate. Pipetting of the solution was performed to obtain 
a complete lysis. Replicates from different treatments were 
combined in 1.5 ml tubes. DNA-shear was performed by passing the 
solution through a 21 gauge needle 3–5. In parallel, 50 μl of the 
Dynabeads solution were placed in a 1.5 ml tube and placed on a 
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magnet. After 30 seconds the supernatant was removed and 100 μl 
of Washing buffer A was added. Beads were placed on the magnet and 
supernatant was removed. The tube was separated from the magnet 
and the RNA suspension was pipetted and mixed with the beads. 
Lysate mix was incubated with continuous mixing for 5 minutes for 
hybridation. Next, tubes were placed on the magnet for 5 minutes. 
Beads with the RNA were washed two times with 600 μl of Washing 
buffer A and one time with 300 μl of Washing buffer B. Finally, the tube 
was placed on the magnet and supernatant was removed. 10 μl of Elution 
buffer was added and incubated at 70 °C for 2 minutes. Immediately 
after, the tube was placed on the magnet and the supernatant 
containing the mRNA transferred to a new RNase-free tube. Samples 
were stored at – 80 °C until downstream applications.  
2.4.7.2 RNA integrity and quantification 
RNA was quantified using the Qubit RNA HS Assay Kit (Thermo Fisher 
Scientific) according to manufacturer’s instructions. Qubit working 
solution was prepared by diluting the Qubit RNA HS Reagent 1:200 in 
Qubit RNA HS Buffer. The final volume per reaction was 200 μl per 
sample. For samples, 1 μl of RNA and 199 μl of Qubit Mix were added 
in a 0.5 ml tube. For standards 10 μl of standard and 190 μl of Qubit 
Mix were added in a 0.5 ml tube. Samples and standards were mixed 
by vortexing for 2–3 seconds. The Qubit 3.0 Fluorometer was calibrated 
with the standards and samples were acquired next. The RNA 
concentration was calculated automatically by the Qubit 3.0 
Fluorometer. RNA integrity was determined by RNA ScreenTape Assay 
(Agilent) according to manufacturer’s instructions. 1 μl of RNA sample 
or RNA ladder were mixed with 5 μl of sample buffer in a 0.2 ml tube 
strip (Agilent). The samples were mixed using the IKA vortex at 2000 
rpm for 1 min. Samples and ladder were spun and denaturalised by 
incubating the samples and ladder at 72 °C for 3 minutes and placing 
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the tubes on ice immediately for 2 minutes. Following denaturalisation, 
samples and ladder were placed in the Agilent 4200 TapeStation 
instrument. The RNA ScreenTape and tips were loaded into the 
TapeStation instrument and the electrophoresis was run. Only 
samples that have a RIN > 7 were used for subsequent analysis.  
2.4.7.3 Library preparation and sequencing 
Following RNA quality control, library preparation was performed 
using the QUANT SEQ 3’ mRNA-seq Library Prep Kit FWD HT for 
Illumina (Lexogen) according to manufacturer’s instructions. 15 ng of 
RNA was used to prepare the libraries.  
Library generation 
5 μl containing 15 ng of RNA was mixed with 5 μl of FS1 and incubated 
for 3 minutes at 85 °C and then cooled to 42 °C. In the meantime a 
master mix with 9.5 μl of FS2 and 0.5 μl of E1 per reaction was 
prepared, mixed and pre-warmed at 42 °C for 2-3 minutes. 10 μl of 
mix per reaction was added. The mix was incubated for at 42 °C for 15 
minutes to generate the first cDNA strand. Remaining RNA was 
removed by adding 5 μl of RS and incubated at 95 °C for 10 minutes 
and then cooled to 25 °C. Synthesis of the second cDNA strand was 
performed by adding 10 μl to the mix with an incubation at 98 °C for 
1 minute. After the incubation, slowly ramp down to 25 °C (0.5 °C / 
sec) and the mix was incubated 30 min at 25 °C. In the meantime, the 
master mix with 4 μl of SS2 and 1 μl of E2 per reaction was prepared. 
Following incubation 5 μl of the SS2/E2 mix was added into each 
sample and incubated at 25 °C for 15 minutes. Next step of the protocol 
was to purify the double stranded cDNA. To do so, 16 μl of purification 
beads (PB) were added, mixed well and incubated for 5 min. Samples 
were placed on a magnet for 2 – 5 minutes and the supernatant was 
discarded. 40 μl of EB was added and the mixture was removed from 
the magnet. Samples were mixed and incubated for 2 min at room 
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temperature (RT). Beads were washed twice for 30 seconds with 20 μl 
80 % EtOH and air dried for 5 - 10 min. Next 20 μl EB was added into 
the tubes, samples were removed from the magnet, mixed well and 
incubated for 2 min at RT. Samples were placed on a magnet for 2 - 5 
min. Finally, 17 μl of the supernatant was transferred into a fresh PCR 
plate. 
Library amplification  
Following library purification, amplification of the library was 
performed. A master mix was prepared by adding with 7 μl PCR and μl 
E3 per reaction. 8 μl of the master mix was added to the 17 μl of each 
purified library. 5 μl of i7 primer was added for sample identification 
and PCR was performed by a first incubation at 98 °C for 30 seconds 
followed by 20 cycles of incubation at 98 °C for 10 seconds then 65 °C 
for 20 and 72 °C for 30 seconds with a final step of 72 °C for 1 minute 
followed by a maintenance step of 10 °C. Following library 
amplification, a final purification step was performed to prepare 
samples for sequencing. For this, 30 μl of PB was added, mixed well 
and incubated for 5 minutes. Samples were placed on a magnet for 2 - 
5 minutes, supernatant was removed and discarded. Next, 30 μl EB 
was added to the samples and removed from the magnet, mixed well 
and incubated 2 min at RT. Then, 30 μl PS was added, mixed well and 
incubated 5 min at RT. Mix was placed on a magnet for 2 - 5 min, and 
supernatant was removed and discarded. Beads were washed twice for 
30 seconds with 120 μl 80 % EtOH. Beads were air dried for 5 - 10 min 
and 20 μl EB were added. Samples were removed from the magnet, 
mixed well and incubated for 2 min at RT. Finally, samples were placed 
on magnet for 2 - 5 min and 15 - 17 μl was transferred into a fresh 
PCR plate 
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Sequencing 
Following library preparation, library size and concertation were 
calculated using the Qubit dsDNA HS Assay Kit (Thermo Fisher 
scientific) and DNA ScreenTape (Aligent) as described before. Samples 
were pooled in a 10 mM library for long-term storage. Library 
sequencing was performed using the NextSeq 500/550 High Output 
Kit (Illumina) on the NextSeq 500 (Illumina) according to the 
manufacturer’s instructions. Reagents for sequencing were thawed at 
least 1 hour before running the sequencing, including the reagent 
cartridge, HT1 and the flow cell. Sample and PhiX (internal control 
library) libraries need to be denatured before sequencing. A 0.5 mM 
starting library was prepared by diluting the 10 mM stock library. Next, 
40 μl of the library was mixed with 40 μl of 0.2N NaOH, vortexed the 
mixed and spun down. The mix was incubated at RT for 5 minutes, 
immediately after 40 μl of 200 mM Tris-HCL (pH 7) was added to the 
mix. Libraries were vortexed, spun and 880 μl of prechilled HT1 was 
added generating a 20 pM library. The PhiX was denatured by adding 
2 μl of PhiX 10 nM, 3 μl of elution buffer and 10 μl of NaOH 0.2N. After 
mixing, PhiX was vortexed, spun and incubated for 5 minutes. Next, 5 
μl of 200 mM Tris-HCL (pH 7) was added. Following vortex and spin, 
985 μl of 200 mM Tris-HCL (pH 7) was added to generate a denatured 
library at 20 pM. Libraries were placed on ice until next step. The 
library loading concentration was prepared by adding 117 μl of the 
denatured library 20 pM, 1181 μl of HT1 and 2 μl of PhiX to generate 
a library between 2 and 2.5 pM. Library is then prepared for 
sequencing. The NextSeq cartridge and flow cell were placed into the 
NextSeq 500 sequencer and the run was stated. Cluster generation and 
sequencing were performed on the instrument. The instrument will use 
the required reagents provided in the cartridge. Following sequencing, 
data transfer and sequence alignment were performed by our 
collaborators at NNRCO.  
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2.5 Reagent preparation 
2.5.1 Dimethyl fumarate  
Dimethyl fumarate (Sigma) stock solutions of 50mM were prepared 
freshly for each experiment in DMSO (Sigma).  
2.5.2 H2O2 preparation 
H2O2 (Sigma) 30 % (w/w) (molar concentration of 9.79 mol/l) was 
diluted in HepatoZYME medium to obtain a final concentration of 1 
mM, concentration used to induce ROS damage (144,145). A fresh 
solution was prepared for every experiment. 
2.5.3 Paracetamol preparation 
Paracetamol 2 M (Sigma) was prepared freshly for each experiment in 
DMSO.  
2.6 Zebrafish work  
2.6.1 Zebrafish lines and husbandry 
Experiments were conducted in accordance with the United Kingdom 
Animals (Scientific Procedures) Act 1986 in a United Kingdom Home 
Office-approved establishment. Zebrafish (Danio rerio) were 
maintained at 28.5 °C, as previously described by Westerfield 
(Westerfield, 2007). Established lines used were WIK and Tg(-2.8 
lfabp:GFP)), where GFP is green fluorescent protein (146,147). All 
experiments were terminated at day 5 days post-fertilization (d.p.f.). 
2.6.2 Zebrafish chemical exposure 
The wild-type WIK line was used for paracetamol-induced toxicity and 
dimethyl fumarate dosage. Unless otherwise stated, larvae were 
maintained at 28.5 °C in 50 ml conditioned water (CW), treatments 
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were carried out for 48 h (3–5 d.p.f.). Single Tg(-2.8lfabp:GFP)) 
Zebrafish larvae per well were positioned into a black V-shape 96-well 
plate for 48 h (3–5 days postfertilization (dpf)). At day 5, total 
fluorescence was measured using a fluorescence plate reader (ex/em 
485 /520). 
2.6.3 Zebrafish high throughput live imaging  
Single larvae were oriented into a 96-well plate with 150 µl agar (0.75%, 
wt/vol) containing 84 mg/l MS-222. An orientation tool was 3D 
printed. Briefly, 0.75%, wt/vol agar was added into the 96-well plate 
following the positioning of the orientation tool. Once the agar was set, 
removal of the orientation tool creating an agar V shape where the 
larvae could be positioned. Imaging was performed using the operetta 
microscope, and image analysis was performed using Colomus 
software where supervised machine learning was used for automatic 
fish and liver recognition and analysis.  
2.6.4 Orientation tool for zebrafish imaging 3D printing 
3D printing of the orientation tool was done following the available files 
from Wittbrodt et al (148). Base plate and columns pins were printed 
by ‘CNCvac 3D Printing’ in generic Standard ABS using 100 μM layers 
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Figure 10. 3D designs of the orientation tool for zebrafish positioning. (A) 3D 
printed orientation tool to facilitate the zebrafish orientation. Pins are inserted in a 
96-well-plate embedded with agarose 0.75% wt/vol. (B) Pin shape creates a ‘V’ 
shape that allows the zebrafish positioning. (C) Schematic representation of the 
agarose mold. First, 150 µl of agarose 0.75% wt/vol was added into a well of a 96-
well plate. The orientation tool was positioned inside the 96-well plate while the 
agarose was not solidified. Upon solidification, the orientiation tool was removed 
creating a ‘V’ shaped incision where Zebrafish were positioned.  
 
2.6.5 Zebrafish plate reader fluorescence quantification 
Total fluorescence was detected using a fluorescence plate reader was 
used to detect changes in GFP signal. Paracetamol 10mM for 48 hours 
was used to quantify fluorescence decrease upon liver damage. Single 
larvae were introduced into a well of a black 96-well plate after 
treatment for fluorescence quantification. Wild type larvae were used 
to subtract larvae autofluorescence. 
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2.7 Bioinformatic analysis 
Data formatting from the screening was performed using Python 
programming language. Following data organisation, analysis was 
performed by a combination of Spotfire and HC StratomineR software. 
Single cell imaging analysis for the Nrf2 nuclear translocation 
quantification was performed using Spotfire software. Data analysis 
from the Cell Pain assay was performed using Python. RNA-seq 
analysis was performed in R using with the DEseq2 packages. Details 
of each analysis are described throughout the thesis.  
2.8 Statistical analysis  
One-way ANOVA test and post-hoc Tukey multiple-comparison test 
was used for experiments that contained more than two groups. All 
data is represented as means with SEM. Statistical analysis was 
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3.1.1 Current cell-based methods to study liver biology 
Current cell-based models to study liver biology rely heavily on 
immortalized cell lines or primary cells. Despite their advantages, 
immortalized cell lines offer limited biological relevance when 
compared to the intact organ. Primary human hepatocytes (PHHs) are 
currently viewed as the gold standard to study liver biology (149). The 
disadvantages of their use include: their labour-intensive isolation 
from diseased organs, the scarcity of donor tissue, the rapid loss of cell 
phenotype in culture and significant batch-to-batch variation. 
Therefore, more stable, reproducible and cost-effective models that 
recapitulate liver physiology are required. Human pluripotent stem cell 
(hPSC) have been proposed as an alternative cell source to study liver 
biology. Advances in pluripotent stem cell differentiation protocols 
better mimic primary cells than the immortalised lines (65). In 
addition, hPSC-derived models exhibit drug sensitivity patterns similar 
to primary cells (150). 
3.1.1.1 Human pluripotent stem cells 
Human pluripotent stem cells are capable of self-renewal and retain 
pluripotency. Their ability to differentiate into any cell in the body 
render them a powerful tool to study human biology, model disease, 
high reproducibility and on defined genetic background.  
hPSCs can be derived from early-stage embryos called human 
embryonic stem cells (hESC) (73) or induced pluripotent stem cells 
(iPSC), produced from somatic cells by overexpressing key 
transcription factors: Oct 3/4, Sox2, Klf4 and c-Myc (74). iPSCs have 
been produced in many different ways (for a review, see (151)). 
 
 86 Jose Meseguer Ripollés 
hESC cell lines are derived from the inner cell mass (ICM) of grade B 
blastocysts not suitable for implantation (73). Current protocols allow 
the generation of hESC from blastomeres without affecting the 
development of the embryo. This process can be performed under the 
current good manufacturing practice (cGMP) conditions providing 
translational promise for the clinic (152). iPSC technology created a 
new tool for personalised medicine for both research and clinical 
applications. However, detailed analysis of the reprogramming process 
for iPSC generation showed an epigenetic memory in iPSCs when 
compared to ESCs (153) rising some issues about the quality of iPSCs. 
On the whole, both systems are powerful tools for research and 
medicine. 
In the last decade, hPSCs have been successfully used for disease 
modelling, drug screening and cell therapy studies. Current clinical 
trials using hPSC as a treatment include: dry age-related macular 
degeneration (154), Parkinson’s disease (155), Amyotrophic Lateral 
Sclerosis (ALS) (156) and ischemic heart disease (157) among others 
(158).  
Under culture, hPSC colonies display packed cell colonies with marked 
edges, cells have a distinct nucleoli and high nuclei to cytoplasm ratio. 
In addition, hPSCs express a range of proteins markers, which include 
transcription factors such as OCT4 (75), NANOG (76) and SOX2 (77); 
Cell surface markers like tumour rejection antigens TRA-1-60 and 
TRA-1-81 and stage-specific embryonic antigen 3 (SSEA3) and 4 
(SSEA4). SSEA1 can be used as a negative marker. in humans SSEA1 
is expressed in some myeloid cells and tumours but not in 
undifferentiated hPSC (159,160). To assess the pluripotency capacity 
of hPSC, hPSC can be differentiated into the three germ layers in vivo 
by teratoma formation or in vitro embryoid bodies. Teratoma formation 
is considered the gold standard for demonstrating pluripotency on 
hPSC. Transplanting hPSC to immunodeficient mice leads into tumour 
Semi-automated differentiation of human stem cell-derived  87   
hepatocytes               
 
 
development of all three germ layers (72). Teratoma formation varies 
from 4 to 15 weeks and methods to assess are not fully standardised 
(161). Teratoma formation is a great tool to test pluripotency in newly 
produced hPSC lines but not a technique suitable for regular 
pluripotency confirmation of established hPSC lines. In vitro generation 
of embryoid bodies allows the spontaneous differentiation into the 
three germ layers. This process takes under 4 weeks (162). EBs 
formation can be used routinely as a tool for pluripotency confirmation 
of well-characterised hPSC lines.  
3.1.1.2 Hepatocyte differentiation from hPSC  
The self-renewal and pluripotency properties of hPSC creates a 
potentially unlimited source of hepatocytes to study liver biology. 
Several groups have established differentiation protocols that allow the 
efficient differentiation of human pluripotent stem cells (ES and iPSC) 
into hepatocyte-like cells (HLCs) (78). Hepatocyte differentiation 
attempts to recreate aspects of human liver development using growth 
factors and small molecules. Our approach has three key stages. First, 
hPSC are driven to definitive endoderm by using several growth factors 
such as activin A and Wnt3A. At definitive endoderm, cells display 
triangular morphology and by the expression of SOX17 and FOXA2. 
Definitive endoderm is followed by hepatic progenitors specification or 
hepatoblasts. Hepatoblasts are characterised by a distinct 
cobblestone-like morphology and expression of several markers which 
include hepatocyte nuclear factor 4 α (HNF4α), alpha fetoprotein (AFP) 
and cytokeratin 19 (CK19). Finally, hepatoblasts are matured into 
HLCs. They express hepatocyte markers such as HNF4a, albumin and 
cytochrome P450 proteins and exhibit metabolic function, protein 
secretion, glycogen storage and urea synthesis. However, current HLCs 
protocol do face some limitations, such as the mixture of foetal and 
adult hepatocyte traits and limited tissue structure (90). Work in the 
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last decade has been focused on improving phenotype, standardisation 
and large-scale production.  
3.1.2 Semi-Automation of the HLCs differentiation protocol 
Standardisation of somatic cell differentiation protocols are required to 
develop robust tools that accurately model human biology in the dish. 
Traditional cell culture techniques rely heavily on manual pipetting, 
which is both time consuming and error prone. This limits the 
throughput of the assay and the plate format one can work with. To 
date, most studies describing the generation of HLCs are labour 
intensive in nature and therefore small scale in size. Recent advances 
in liquid handling and pipetting systems have made possible the high 
throughput production of HLCs in multi-well plates (96- or 384- well 
plates) with reduced well-to-well and plate-to-plate variation (89). In 
combination with automated microscopy and high throughput 
analysis, it is possible to develop automated procedures which 
minimize the requirement for human intervention. This allows the user 
to create multi-parametric profile data sets to profile changes in 
human liver biology and model disease (67).  
Platform assessment was performed in collaboration with AstraZeneca; 
a training compound library was employed to validate platform 
sensitivity and specificity to detect hepatotoxic compounds. First, a 96-
well plate screen was performed and high throughput analysis was 
performed. After data analysis, results were validated in collaboration 
with AstraZeneca. Finally, a 384-well plate screen was performed for 
platform comparison.  
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3.1.3 Cell segmentation and high content analysis 
Automated microscopy and high content analysis are powerful tools 
when combined with high throughput culture of HLCs. Automated 
microscopy allows an unbiased and reproducible image acquisition 
and analysis. Image-based cell profiling, uses these image-datasets to 
extract several morphological features per image creating a 
morphological profile, these profiles can be used to distinguish 
different cell traits (163). The image analysis begins with cell 
segmentation, which consists of set algorithms that will automatically 
identify the cells in the image. This is done by grouping pixels from one 
channel to distinguish cells from the background. A common 
procedure for cell segmentation is to first identify the nuclei, followed 
by cytoplasm identification. Next, a quality control of the segmentation 
based to discard incorrectly segmented cells can be performed (Figure 
11). 
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Figure 11. Cell Segmentation overview. (A) Raw image used for cell segmentation, the 
DAPI channel is used to automatically detect nuclei (B). Next, nuclei previously identified 
are used for cytoplasm detection (C). Finally, different features are used to perform a 
quality control to discard incorrectly segmented cells (D). Image consists of three channels: 
DAPI (Blue): stains nuclei; Cell Mask (Green): unspecific cytoplasmic stain, used for 
cytoplasmic recognition and protein of interest (orange) to quantify.  
 
Following cell segmentation, images are prepared for feature 
extraction. Several morphological features per channel and cell are 
extracted, which can be divided into the following:  
Shape features - features such as roundness and area can be 
quantified for the whole cell, nuclei, cytoplasm and any other different 
segmented parts.  
Intensity- Intensity from each channel at the different regions of the 
cells is quantified.  
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Texture- texture features are quantified by mathematical functions 
measuring changes in pixel distribution and intensity structure of a 
region (e.g. nuclei or cytoplasm) to find patters e.g. spots, holes or 
edges (Figure 12).  
 
Figure 12. Texture features. Example of the ‘SER Features’ (Saddles, Edges, Ridges) 
generated on the Harmony software. Image obtained from PerkinElmer.  
 
3.1.4 Multiparametric dataset analysis 
High content analysis generates large multiparametric datasets. 
Without the correct pre-processing or tools for analysis, large 
multiparametric data sets can be underutilised. However, by using 
suitable data mining tools, it is possible to combine multiparametric 
data sets and distil the valuable information for downstream 
applications. A recent review summarises some of the best strategies 
for image acquisition, data processing and analysis to create high-
quality image-based profiles (163). These pipelines have been 
successfully applied to drug screening (164) and morphological 
profiling of gene function (165). Multiple tools have been developed in 
recent years for standardised and unbiased analysis. Those include 
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CellProfiler (166), Ilastik (167) or Columbus (PerkinElmer) for image 
analysis and feature extraction and HC StratomineR (168), Spotfire 
(TIBCO), CellHTS2 (169) for data mining.  
For my studies I used a combination of Python programming codes and 
commercially available software. Python was used for data preparation 
prior to analysis; software used was TIBCO Spotfire Data Visualisation 
and Analytics Software and HC StratoMineR (168). TIBCO Spotfire was 
used for data visualisation and annotation; HC StratoMineR is an easy-
to-use data mining tool which follows the best practices as described 
in (163) for large multiparametric datasets analysis. I used Spotfire for 
quick visualisations of large data sets to assess plate-to-plate 
variations as well as for data annotation. HC StratoMineR allowed an 
in-depth data mining analysis. Thanks to a web-based tool it can be 
used with non-workstation computers. In addition, it is easy-to-use 
and its interactivity makes this a perfect tool for non-specialised users 
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3.2.1 Characterisation of human embryonic stem cells 
Current cell culture technologies allow standardised and reproducible 
hPSC culture. This is achieved by using defined matrices and media. 
Examination of hPSC culture includes morphological validation, 
expression of pluripotent markers and cell surface markers. 
Assessment of pluripotency was carried out by developing the PSC into 
the three germ layers (endoderm, mesoderm and ectoderm) and is 
determined by embryoid body (EB) formation into the three germ 
layers.  
For my studies, a female human ESC line H9 was used. Cell culture 
was performed using a commercial matrix (laminin 521) and 
commercial maintenance medium (cGMP-mTeSR1). Spontaneous 
differentiation was minimised by regular passaging. Cell colonies were 
formed by packed colonies with marked edges. Cells displayed a 
distinct nucleoli and high nuclei to cytoplasm ratio (Figure 13). H9 
expressed pluripotent markers Nanog and Oct4 as shown by 
immunocytochemistry (Figure 14). Pluripotent markers were also 
checked by cell surface protein expression using flow cytometry. H9 
expressed SSEA-4 and TRA-1-60 and displayed a negative expression 
for SSEA1(Figure 15). Finally, embryonic body formation was 
performed to test the pluripotent capacity of the hESC. Results show 
that H9 can differentiate into the three germ layers (Figure 16). 
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Figure 13. hPSC morphology in culture. Representative images of Human PSC, hPSC 
were cultured using mTseR1 medium and laminin 521. (A) hESC line H9 passage 42 and 
a hiPSC line, P106 passage 36 (B), Scale bar 100 μm. 
 
 
Figure 14. Pluripotent marker expression in PSC. Pluripotent markers were detected by 
immunofluorescence in both hESC (H9) and hiPSC (P106). Nanog (green) and Octamer 4 
(Oct4) (red) were expressed at 96% (A) and 98% (B) in H9 and 97% (D – E) in P106, 
Immunoglobulin G was used as a negative control (E, F). The percentage is the average of 
three experiments. Images were taken at 10x magnification. Nuclei were stained with DAPI 
(blue) for cell detection. Scale bar = 100μm. The data represents six biological replicates 
+/- SEM.  
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Figure 16. Characterisation of embryoid body pluripotency by immunostaining. 
Pluripotency markers were detected by immunostaining, (A) mesoderm cell lineage 
was detected by a-SMA (green), (B) ectoderm lineage by β-Tubulin (green) expression 
and (C) endoderm lineage by AFP staining (green). (D) IgG control was used for 
staining specificity. Nuclei were stained with DAPI (blue) for cell detection. Scale bar 
= 100 μm. 
Figure 15. H9 express cell surface markers of pluripotency detected by flow cytometry. 
Flow cytometry analysis was performed to assess pluripotent marker expression in H9. H9 
expressed the pluripotent markers (A) SSEA-4 and (B) TRA-1-60, H9 were negative for a 
marker of cell differentiation (C) SSEA1. (D-F) IgG controls were used for antibody specificity. 
Figure shows a representative sample distribution. n=3 biological replicates.  
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3.2.2 Differentiation of hPSC-derived hepatocyte like cells 
For hepatic differentiation, I used a defined and serum-free protocol 
that drives human hepatocyte differentiation in the dish (Figure 17) 
(87,89). Single hPSCs seeded into laminin-521 coated plates at 50,000 
cells/cm2 and cultured with mTseR1. 24 h after seeding and once the 
right confluency was reached differentiation was started (Figure 18). 
H9 were primed into definitive endoderm using Wnt3a and Activin A 
for three days with daily media change. Following this, hepatoblast 
specification was achieved by culturing the definitive endoderm with 
media supplemented with DMSO and Knock-Out Serum Replacement 
(KOSR) for an extra five days with media change every other day. 
Finally, hepatocyte-like cells maturation was obtained by culturing 
hepatoblast with medium containing oncostatin M (OSM) and 
hepatocyte growth factor (HGF) for ten days with medium change every 
other day. Assessment of cell differentiation was examined by change 
in morphology, protein expression and cell function at the different 
stages of the differentiation process.  
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Figure 18. Representative confluency for HLCs differentiation. PSC cell confluency 
after 24h single cell seeding, cell confluency should be around 30 – 40% prior to 






Figure 17. Diagram of the hepatocyte-like cell differentiation protocol. Three 
stage differentiation protocol from single cell seeding hPSC (Day 0) to definitive 
endoderm (Day 3), hepatoblast specification (Day 8) and hepatocyte maturation (Day 
18). Abbreviations: hPSCs = human pluripotent stem cells; RPMI = Roswell Park 
Memorial Institute (RPMI) 1640 medium; B27 = B27 medium supplement: DMSO = 
dimethyl sulfoxide; KOSR = knockout serum replacement; KO-DMEM = knockout 
Dulbecco’s Modified Eagle’s Medium; HGF = hepatocyte growth factor; OSM = 
oncostatin M; HCC = hydrocortisone. 
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3.2.2.1 hPSC differentiation to definitive endoderm 
24 h after seeding and when hPSC cell confluency reached 30-40% 
differentiation was started. This was deemed optimal for H9 (66). 
Differentiation was started by replacing the medium with definitive 
endoderm differentiation medium supplemented with Wnt3a and 
Activin A. After 72 h hPSC lines acquired triangular shape (Figure 19), 
induction of definitive endoderm markers Sox17 and FoxA2 was 
confirmed by immunofluorescence (Figure 20). H9 hESCs expressed 




Figure 19. Definitive endoderm morphological characterisation. After 72 
hours of definitive endoderm induction, a monolayer is formed and cells display a 
distinct triangular shape as marked by the arrows. Images were taken at 10x (A) 
and 20X (B) magnification. Scale bar = 100μm.  
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Figure 20. Definitive endoderm immunofluorescence characterisation. Cells at 
after 72 hours of definitive endoderm induction were fixed and stained for definitive 
endoderm markers (A) Sox17 in green and (B) FoxA2 in red. (C) IgG controls for 
antibody specificity staining. Nuclei were stained with DAPI for cell detection. Scale 
bar = 50μm. The data represents three biological replicates +/- SEM. 
 
3.2.2.2 Hepatic progenitor specification from hPSC 
Following definitive endoderm, hepatic progenitors were induced by 
culturing the cells with KO-DMEM supplemented with 1% DMSO and 
20% KOSR for 5 days. Cells acquired hepatoblast morphology by the 
formation of cobblestone-like cells with well-defined cell-to-cell edges 
(Figure 20). A panel of protein markers was used to assess hepatoblast 
differentiation efficiency by immunofluorescence. AFP, HNF4α and 
CK19 expression were expressed ubiquitously (Figure 22).  
 
 






Figure 21. Hepatoblast morphological characterisation. After five days of hepatoblast 
differentiation, day nine of differentiation. hepatoblast display cobblestone-like 
morphology with marked cell-to-cell edges. Phase contrast Images were taken at 10x (A) 
and 20X (B) magnification. Scale bar = 100μm. 
Figure 22. Hepatoblast markers characterisation. Hepatoblast markers were detected by 
immunofluorescence. HNF4α in red (A), AFP in green (B) and CK19 in red (C). IgG was used as 
negative control (D). Nuclear staining was used for cell identification (Blue). Abbreviations: 
HNF4α: Hepatocyte nuclear factor 4 α, AFP: Alpha fetoprotein and CK19: Cytokeratin 19. Scale 
bar = 50μm. The data represents three biological replicates +/- SEM, >300 cells counted per 
replicate. 
Semi-automated differentiation of human stem cell-derived  101   
hepatocytes               
 
 
3.2.2.3 Hepatocyte-like cells maturation 
Finally, hepatoblasts were matured into hepatocyte-like cells, this 
process requires an extra ten days in culture. Hepatoblast were 
cultured with HepatoZYME medium supplemented with hepatocyte 
growth factor (HGF) and oncostatin M (OSM). At day 18, HLCs resemble 
some of the key features of hepatocytes. HLCs derived from H9 exhibit 
polygonal-shape and defined cell-to-cell contact. At day 18, HLCs were 
fixed and stained for typical hepatocyte markers (Figure 24 A-G) and 
tested for CYP P450 activity. HLCs expressed hepatocyte markers such 
as HNF4α (89.2% ±2 positive cells), ALB (92.8% ±6 positive cells), AFP 
(61.8% ±2 positive cells). HLCs also expressed CYP P450 proteins, CYP 
2D6 and CYP 3A4 as well as MRP1, a drug transporters protein (Figure 
24). 
HLCs also displayed a distinct polygonal appearance as shown by E-
Cadherin protein expression and phase contrast. CYP 1A2 and CYP 
3A4 basal activity for H9 was measured at day 18. H9 exhibited CYP 
1A2 activity at 295,906 ±45,828 RLU/mL/mg of protein and CYP 3A 
at 1,066,112 ±177,416 RLU/mL/mg of protein (Figure 25).  
In addition, specific CYP P450 metabolic activity was determined by 
Bristol-Myers Squibb (BMS) compound incubation. Each of the BMS 
compounds are metabolised into toxic metabolites by a specific CYP 
P450 protein. Toxic metabolite generation can be correlated into CYP 
P450 activity (170). Therefore, ATP depletion is an indirect measure of 
CYP P450 activity. Hepato-sensitivity was detected on BMS compounds 
1, 4 and 5 which relate to CYP 2C19, CYP 2C9 and CYP 2D6 activity 
respectively (Figure 26).  
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Figure 24. H9 derived hepatocyte-like cells marker expression at day 18. (A) The percentage of 
hepatocyte nuclear factor 4 alpha (HNF4α) expression ± SEM is based on thirty wells with ten fields of view 
per well. (B) The percentage of albumin (ALB) expression +/- SEM, is based on 3 separate wells with ten 
fields of view per well. (C) The percentage of alpha fetoprotein (AFP) +/- SEM is based on 3 separate wells 
with ten fields of view per well. (D) E-cadherin staining. (E) CYP2D6 staining. (F) CYP3A4 staining. (G). 
Multidrug resistance-associated protein 1 (MRP1) (H) Immunoglobulin G (IgG) staining control. Scale bar = 




Figure 23. Morphological characterisation of HLCs. Images of HLCs at day 18, 
cells displayed a distinct polygonal appearance with marked cell-to-cell contact. 
Images were taken at 10X (A) and 20X (B). Scale bar 50μm. 
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Figure 25. Metabolic activity characterisation of HLCs. (A) Basal CYP P450 activity of 
HLCs at day 18, CYP 3A and CYP 1A2 activity were measured. Activity is quoted as relative 
light units (RLUs)/mL per 1 mg of protein. (B) Albumin and AFP protein secretion was 
quantified by ELISA. Protein secretion produced during 24 h was quantified by μg of 




Figure 26. HLCs ATP depletion after BMS compounds exposure. HLCs differentiated 
from H9 (A) and P106 (B) at day 18 were incubated with BMS compounds for 48 hours. 
Following incubation, ATP was quantified. ATP levels are represented as relative light units 
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3.2.3 Semi-automated differentiation of HLCs from hPSC 
The ability to generate large quantities of multi-well plates for 
screening or for basic research has been limited by labour intensive 
procedures and batch-to-batch variation. To tackle this issue, I have 
developed a semi-automated high throughput platform to differentiate 
pluripotent stem cells into HLCs (Figure 27). Stem cell seeding and 
HLCs differentiation were performed using liquid handling and 
automatic pipetting systems in 96-well and 384-well plate format. 
Following the differentiation, a high throughput pipeline was developed 
for sample processing and analysis. For sample processing, liquid 
handling systems and automatic plate washer were used. Cell 








Figure 27. Schematic representation of the semi-automated high throughput 
platform. For tissue culture, a combination of a liquid handling system (Multidrop 
– ThermoFisher) and an automatic hand held pipette (ViaFlo - Integra) were used. 
For sample processing, the multidrop and an automatic plate washer (BioTek405) 
were used. Sample analysis was performed using a high content imaging system 
(Operetta - Perkinelmer) and a multi well plate reader (GloMax Explorer – Promega).  
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3.2.3.1 Tissue culture of HLCs using liquid handling systems 
hPSC single cell suspension was dispensed using the Multidrop liquid 
handling system. Cell number per well was 50,000 cells/cm2. Once cell 
confluency reached 30-40% differentiation was started. Medium 
changes were performed using automatic handheld pipette (ViaFlo). On 
day 18, the variability in HLCs number between wells was examined 
following DAPI staining, seven fields of view were captured per well and 
the number of nuclei quantified with no statistical differences between 
wells. Cell number was 41,662 ±3,366 cells per well for the 96-well 
plate format (Figure 28) and 16,290 ± 236 cells per well for 384-well 
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Figure 28. Assessment of HLCs well-to-well variability in 96-well format. (A) 
Representation of a 96-well plate view of HLCs stained with DAPI. Scale bar = 1 mm. (B) 
Quantification of cell number per well. Average of cell number per wells in columns (top) 
and rows (bottom), from seven fields of viewsper well and quantified using Columbus 
software. Average cell number across the plate is 41,662 ± 3,366 SEM cells per well. No 
statistically significant differences were observed between wells. A One-way ANOVA with 
Tukey's post-hoc statistical tests was employed.  
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3.2.4 Validation of the platform 
In collaboration with AstraZeneca, a training compound library was 
employed to validate the drug sensitivity and specificity of the semi-
automated differentiation system (Table 9). Screens were performed in 
both 96 and 384-well plate format using H9-derived HLCs. For the 96-
well format, a total of 88 compounds were tested in the range of 
0.002µM, 0.02µM, 0.2µM, 2µM, 20 µM, 200 µM in triplicate plates. 48h 
following compound incubation, assay performance was assessed. 200 
µM as the highest concentration was selected to keep DMSO 
concentration below 1%. Higher DMSO concentration would increase 
the effect of the toxic compounds as it can induce cell toxicity (171).  
Sensitivity of the screen was determined by the efficiency of the HLCs 
produced from this platform to detect correctly hepatotoxic compounds 
from the training library. In addition, sensitivity was determined by the 




Figure 29. Assessment of HLCs well-to-well variability in 384-well format. 
Quantification of cell number per well. Average of cell number per wells in (A) 
columns and (B) rows from seven fields of views per well and quantified using 
Columbus software. Average cell number across the plate is 16,290 ± 236 cells per 
well. No statistically significant differences were observed between wells. A One-way 
ANOVA with Tukey's post-hoc statistical tests was employed.  
 
A v e r a g e  o f  w e l ls  p e r  r o w
A B C D E F G H I J K L M N O P
0
5 0 0 0
1 0 0 0 0
1 5 0 0 0
2 0 0 0 0
2 5 0 0 0











































5 0 0 0
1 0 0 0 0
1 5 0 0 0
2 0 0 0 0
2 5 0 0 0











A v e r a g e  o f w e lls  p e r  c o lu m n
A B
 
 108 Jose Meseguer Ripollés 
To quantify the effect of the compounds into the cells, a combination 
of commercial assays were used to measure cell viability: ATP depletion 
(CellTiter-Glo®, Promega) and CYP3A metabolic activity (CellTiter-
Glo®, Promega) were used. Parallel plates were used for high content 
imaging. Cells were stained for mitochondria, cytoplasm and nuclei 
following a modified version of the cell painting assay (141). After 
staining, plates for Cell Paint were imaged using the Operetta high-
throughput microscope and ~90 features were extracted using 
Columbus image analysis software. Combination of the three different 
assays created a multiparametric data set. Data mining was performed 
to detect hits. Following this, sensitivity and sensitivity of the platform 
was determined in collaboration with AstraZeneca.  
In the 384-well plate screen a concentration range of 17.5 µM, 25 µM, 
35 µM, 50 µM, 70 µM, 100 µM, 140 µM, 180 µM, 200 µM was used with 
four replicates per plate. 72h following compound high content imaging 
assay was performed. Changes in the design of the screen were made 







Table 9. Astrazeneca compound library. Library of known hepatotoxic compounds to assess specificity and 
sensitivity of the semi-automated HLCs culture. Clinical and experimental concern to develop DILI was used for 
compound classification as shown on the FDA toxicity comlumn. N/A = no data available. APAP = 
Acetaminophen. DMSO= Dimethyl sulfoxide. 
 
3.2.4.1 High content analysis 
High content analysis was performed using the cell painting assay. 
HLCs were stained with NucBlue for the nuclei, Cell Mask green for 
the cytoplasm and Mitotracker for the mitochondrial activity (Figure 
30A). After imaging, image analysis was performed using the 
Colombus image analysis software. Prior to cell segmentation, an 
extra quality control step was implemented to only analyse in-focused 
areas. The cell segmentation algorithm is not trained to distinguish 
from in-focused to out-focused areas (Figure 31A). This can lead to 
incorrect segmentation and feature extractions from out-of-focus 
regions which can lead to inaccurate results. To reduce this, a 
supervised machine learning package from Colombus image analysis 
software was used. This package can train an algorithm to 
distinguish in-focused from out-of-focused cells by using the texture 
features from these regions (Figure 12, Figure 31B). This creates a 
region of interest which only contains in-focus cells which are used 
for cell segmentation (Figure 31C-D). Following the quality control, 
cell segmentation was performed. ~90 morphological features such as 
fluorescence intensity, size, morphology or pixel texture were 
extracted.  
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These features were combined to create a cell profile, which can be 
used to distinguish between toxic and non-toxic compounds. Effects 
of compounds can be visualised on Figure 30B, a representation of a 
96-well of the screen, where a rectangle represents a well with Cell 
Paint staining. It is possible to visualise intensity variation between 
wells which can be quantified by high throughput analysis. A 
correlation matrix of all the features was created to visualise the 




Figure 30. Cell Painting staining in HLCs. (A) HLCs were stained for nuclei (NucBlue), 
cytoplasm (Cell Mask green) and mitochondria (Mitotracker deep red). (B) Representation of 
a 96-well plate from the AstraZeneca compound screen at the higher concentration (200 
μM). C. Correlation matrix of the 89 different features extracted from each image. 
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3.2.4.2 Multiparametric data analysis 
Data annotation and visualisation 
Following data acquisition from the 96-well plate screen the different 
data sets (ATP quantification data, CYP 3A metabolic activity and the 
Cell Paint data) were combined creating a multiparametric data set for 
each drug at the different concentrations. Each data set was obtained 
from multiple sources with different file formatting and spatial data 
distribution. Data conversion was required to standardise the different 
file formats in order to combine them into one unique file. To solve this, 
 
Figure 31. Supervised machine learning for cell segmentation. Following 
imaging, some areas of the well can be out of focus (A) leading to incorrect feature 
extraction. (B) A supervised machine learning algorithm was trained to distinguish 
between in-focused and out-of-focus cells based on image texture properties. (C) 
Areas with cells correctly focused are selected for subsequent (D) quality control and 
cell segmentation analysis.  
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I developed a Python programming code which allowed me to 
standardise formats and combine the different data sets into one 
unique file; as well as adding important metadata required for data 
mining such as well location or plate number.  
Following data combination, TIBCO Spotfire software was used for data 
visualisation and compound annotation. Spotfire allows a rapid and 
interactive visualisation of the combined data. Plate-to-plate 
visualisation using heatmaps allows the annotation of compounds, 
plate triplicates and compound concentrations (Figure 32). Spotfire 
can be used for data normalisation and analysis. This is be done by 
manually coding the functions for normalisation for each feature. Due 
to the large quantity of features, this software does not allow an 
efficient and interactive analysis.  
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Figure 32. Representation of the screen data in a heatmap. Heat map 
representing the number of nuclei per well in triplicates in an increasing 
concentration. Each square of the heatmap represents a well of a 96-well plate. 
Triplicate plates are represented on the X-axis. The different concentrations were 
plotted on the Y-axis at increasing concentrations. 
 
Data normalisation 
Data analysis was performed using HC StratoMineR. This software 
provides a web-based easy-to-use pipeline for data mining. Per plate, 
each parameter was normalised by the median value of the negative 
control (Figure 33). Performing consistent normalisation using the 
median of the negative control in a plate-to-plate basis, plate effects 
can be normalised, allowing plates to be compared for analysis.  
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For subsequent analysis of multiparametric data sets, each parameter 
should approximate a normal distribution to reduce 
underrepresentation of the data (29,33). Mathematical functions can 
be applied to transform features with non-normal distribution to 
approximate them into a normal distribution. For this reason, HC 
StratoMineR has a step for data transformation. In this step, the 
distribution of each feature is automatically checked. If the software 
detects a feature which does not have normal distribution, it will 
suggest several mathematical functions to transform and approximate 
the data into normal distribution (Figure 34).  
Data standardisation  
Following data transformation, data standardisation is recommended 
to avoid a bias toward a parameter that has a larger range. Min-Max 
scalation was performed for each parameter at a screen level 
distribution (Figure 35).  
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Figure 33. Data normalisation. Dapi nuclei intensity data plotted per plate in a box 
plot, each column represents a plate, dots represent the wells, shape of the dots 
represents the replicate and the colour the reagent classes. (A) Dapi nuclei intensity raw 
data. (B) Box plot of Dapi nuclei intensity where data has been normalised by the mean 
value of the negative controls in a plate-to-plate basis.  
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Following data normalisation, transformation and standardisation, the 
data set is prepared for analysis. Data reduction is performed to reduce 
the complexity of the multiparametric data set. Common factor 
analysis (CFA) is performed based in a correlation matrix (Figure 36A). 
Number of factors was determined automatically by the Kaiser’s 
method to avoid bias in number of factors (Figure 36B). Eight factors 
were created and each factor was visualised in a polar plot, which 
indicates the loadings for each parameter in the generation of the 
factors for data reduction. In each plot, the angles display the different 
parameters, and the radius represents the factor loading of the 
parameter (Figure 37). The effect of the data reduction can be 
visualised when comparing the signature from plotting all the 
parameters across the wells (Figure 38A) versus the factors from the 
data reduction across the wells (Figure 38B). The sample variability is 
maintained after the data reduction from the eight factors generated 
during the data reduction.  
 
Figure 34. Data transformation. Data distribution was automatically checked using HC 
StratoMineR, in this example, the untransformed histogram plots data of CYP 450 activity 
(A) shows a non-normal distribution. HC StratoMineR suggests a log2 transformation (B) 
approximating the data into a normal distribution facilitating any further analysis.  
 






Figure 35. Data standardisation. (A) Non-standardised plot, on the x-axis, each 
column represents a parameter. The y-axis represents the value parameter, whic 
shows the range difference. (B) Standardised data plot, all the data set is in a similar 
range with a mean close to 0 reducing the bias based on range differences. 
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Figure 36. Parameter correlation matrix and data reduction from the 96-well 
plate dataset. (A) Hierarchical correlation matrix. The x-axis and y-axis represent the 
parameters. Each square represents a parameter compared to another parameter, the 
colour represents a Pearson’s correlation between 1 and -1. Number of factors are 
determined automatically by the Kasier’s method (B). (C) Loading plot representing 
which parameter contribute to each factors and how strong its contribution is. Values 
represent a Pearson’s correlation between 1 and -1.  
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Figure 37. Polar plots from the 96-well plate dataset. The polar angles of each factor 
generated from the data reduction display the parameters from the data set, the radius 
represents the factor loading of the parameter. A significant contribution is considered if 
>0.4 or <-0.4 and is indicated with a red line. Every factor is visualized in this manner. (A) 
Factor 1, (B) Factor 2, (C) Factor 3, (D) Factor 4, (E) Factor 5, (F) Factor 6, (G) Factor 7 and 
(H) Factor 8. Values represent a Pearson’s correlation between 1 and -1. 
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Finally, hit selection was performed. HC StratoMineR calculates a 
distance score from the eight factors generated by the data reduction. 
The result is one final distance factor where distance from controls will 
be close to 0 and distance from compounds will increase depending on 
their feature profile (Figure 39A). This is performed in a plate-to-plate 
basis for each replicate (Figure 39C). HC StratoMineR transforms the 
 
Figure 38. Data reduction comparison from the 96-well plate dataset. (A) 
Multiparametric plot from the pre-processed data, X-axis show all the wells of the 
plate where y-axis shows the values of the different parameters each represented in a 
different colour. (B) Multiparametric plot from the factors generated from the CFS on 
the y-axis instead of the parameter values. Comparison of (A) and (B) displays the 
effect of the data reduction step.  
 
 122 Jose Meseguer Ripollés 
distance factor into p-value and statistically significant hits can be 
identified. Compound was called a hit when p < 0.05 when compared 
to the negative control (Figure 39B).  
 
 
Figure 39. Hit picking parameter from the 96-well plate dataset. (A) 
Distribution of the screen to detect possible outliers. Each box in the box plot 
represents a condition (negative in blue or sample in red), the three replicates are 
combined to see the variation between plates and to detect outliers in the data set. 
On the x-axis are plotted all the wells and on the y-axis the distance from the 
negative control. (B) Scatter plot showing the hits detected from the screen. On the 
x-axis are plotted all the wells and on the y-axis the log10 p-value value, the red 
dotted line marks the value when a compound is marked as a hit. (C) Hit selection 
plot, x-axis represents replicate 1 and y-axis represent replicate 2. The plots shows 
the distance score from the negative controls in the replicates.  
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From the 96-well plate screen, 26 compounds were called as hits, see 
Table 10 for details. Results were sent to AstraZeneca for results 
validation. The training compound library was composed of 64 
hepatotoxic compounds and 19 non-hepatotoxic compounds. From the 
26 compounds detected as hits, 23 compounds were related to DILI. 
Three compounds (Clotrimazole, Oxybutynin, Colchicine) were 
annotated as negative in AstraZeneca’s data. After validating the 
results, the sensitivity and specificity of the assay were determined, 
giving a sensitivity of 35.9% and specificity of 84.2%. Sensitivity was 
determined as the ability of the system to detect compounds annotated 
as toxic by AstraZeneca’s as hits or true positives. The specificity was 
determined as the ability of the system to not detect compounds 
annotated as non-toxic by AstraZeneca’s as hits or true negatives. 
Similar analysis was performed for the 384-well plate dataset. 
Common factor analysis (CFA) (Figure 40A) generated twelve factors. 
Number of factors was determined automatically by the Kaiser’s 
method to avoid bias in number of factors (Figure 40B). Each factor is 
visualised in a polar plot, which indicates the loadings for each 
parameter in the generation of the factors for data reduction. In each 
plot, the angles display the different parameters, and the radius 
represents the factor loading of the parameter (Figure 41). The effect 
of the data reduction can be visualised when comparing the signature 
from plotting all the parameters across the wells (Figure 42A) versus 
the factors from the data reduction across the wells (Figure 42B). The 
sample variability is maintained after the data reduction from the 
twelve factors generated during the data reduction. Following this, hit 
selection was performed as explained before (Figure 43). Compound 
was called a hit when p < 0.05 when compared to the negative control. 
From the 384-well plate screen, 66 compounds were called as hits, see 
Table 11 for details. From the 66 hits; 51 compounds belonged to the 
hepatotoxic group and 15 to the non-hepatotoxic. After validating the 
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results, the sensitivity and specificity of the assay were determined, 
giving a sensitivity of 79.7% and specificity of 21.1%. Due to its 
specificity, I selected the 96-well plate format for my studies.  
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Table 10. 96-well plate screen hit list. Compound hits obtained from the 
screening. To detect specificity and sensitivity our hits were compared with 
AstraZeneca’s results as shown on the Pos/Neg column. The results of this screen 
were a sensitivity of 35.9% and a specificity of 84.2%. Pos = positive, Neg = Negative.  
 
 126 Jose Meseguer Ripollés 
 
Figure 40. Parameter correlation matrix and data reduction from the 384-well 
plate screen. (A) Hierarchical correlation matrix. The x-axis and y-axis represent the 
parameters. Each square represents a parameter compared to another parameter, 
the colour represents a Pearson’s correlation between 1 and -1. Number of factors 
are determined automatically by the Kasier’s method (B). (C) Loading plot 
representing which parameter contribute to each factor and how strong its 
contribution is. Values represents a Pearson’s correlation between 1 and -1. 
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Figure 41. Polar plots from the 38-well plate dataset. The polar angles of each 
factor generated from the data reduction display the parameters from the data set, the 
radius represents the factor loading of the parameter. A significant contribution is 
considered if >0.4 or <-0.4 and is indicated with a red line. Every factor is visualized 
in this manner. (A) Factor 1, (B) Factor 2, (C) Factor 3, (D) Factor 4, (E) Factor 5, (F) 
Factor 6, (G) Factor 7, (H) Factor 8, (I) Factor 9, (J) Factor 10, (K) Factor 11 and (L) 
Factor 12. Values represents a Pearson’s correlation between 1 and -1. 
 
 





Figure 42. Data reduction comparison from the 384-well plate dataset. (A) 
Multiparametric plot from the pre-processed data, X-axis show all the wells of the plate 
where y-axis shows the values of the different parameters each represented in a 
different colour. (B) Multiparametric plot from the factors generated from the CFS on 
the y-axis instead of the parameter values. Comparison of (A) and (B) displays the effect 
of the data reduction step. 
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Figure 43. Hit picking parameter from the 384-well plate dataset. (A) Distribution of 
the screen to detect possible outliers. Each box in the box plot represents a condition 
(negative in blue or sample in red), the three replicates are combined to see the variation 
between plates and to detect outliers in the data set. On the x-axis are plotted all the 
wells and on the y-axis the distance from the negative control. (B) Scatter plot showing 
the hits detected from the screen. On the x-axis are plotted all the wells and, on the y-
axis, the log10 p-value value, the red dotted line marks the value when a compound is 
marked as a hit. (C) Hit selection plot, x-axis represents replicate 1 and y-axis represent 






Drug Name AZ Copound Name FDA Pos/Neg Drug Name AZ Copound Name FDA Pos/Neg
Piroxicam AZ10133063 vLess-DILI-Concern NaN Glimepiride AZ13695398 vLess-DILI-Concern Pos
Ambrisentan AZ13616209 Ambiguous DILI-concern Neg haloperidol AZ10047978 vLess-DILI-Concern Pos
betaine AZ10003728 vNo-DILI-Concern Neg Ibuprofen AZ10005713 vLess-DILI-Concern Pos
Buspirone AZ10047343 Ambiguous DILI-concern Neg Imipramine AZ10120857 vLess-DILI-Concern Pos
cromoglicic acid (cromolyn) AZ10005214 #N/A Neg Indomethacin AZ10003646 vMost-DILI-Concern Pos
Dexamethasone AZ10168612 Ambiguous DILI-concern Neg Iproniazid AZ10013584 vMost-DILI-Concern Pos
Diphenhydramine AZ10009895 vNo-DILI-Concern Neg Labetalol AZ10337779 vMost-DILI-Concern Pos
Donepezil AZ10087366 vLess-DILI-Concern Neg Lapatinib AZ10402704 vMost-DILI-Concern Pos
Entacapone AZ13299485 vLess-DILI-Concern Neg leflunomide AZ10042615 vMost-DILI-Concern Pos
epinephrine AZ10453071 vNo-DILI-Concern Neg Lumiracoxib AZ13112694 vMost-DILI-Concern Pos
folic acid AZ10013790 vNo-DILI-Concern Neg Mercaptopurine AZ10184621 vMost-DILI-Concern Pos
isoproterenol AZ10064045 vNo-DILI-Concern Neg Metformin AZ10046538 vLess-DILI-Concern Pos
Oxybutynin AZ10491901 vNo-DILI-Concern Neg Methotrexate AZ10403554 vMost-DILI-Concern Pos
Pargyline AZ10065948 #N/A Neg Naproxen AZ10222853 vLess-DILI-Concern Pos
Procyclidine AZ10620821 vNo-DILI-Concern Neg Nefazodone AZ10150878 vMost-DILI-Concern Pos
streptomycin AZ12121615 vNo-DILI-Concern Neg Nevirapine AZ12307889 vMost-DILI-Concern Pos
Acetylsalicylic acid AZ10015436 #N/A Pos Nimesulide AZ10491890 vMost-DILI-Concern Pos
Alpidem AZ11636409 vMost-DILI-Concern Pos nomifensine AZ10154702 vMost-DILI-Concern Pos
Amiodarone AZ10131427 vMost-DILI-Concern Pos Perhexilene AZ10466355 vMost-DILI-Concern Pos
Benzbromarone AZ10132264 vMost-DILI-Concern Pos Phenytoin AZ10246255 vMost-DILI-Concern Pos
Bromfenac AZ13432419 vMost-DILI-Concern Pos Pioglitazone AZ10080838 vLess-DILI-Concern Pos
Busulfan AZ10072216 vMost-DILI-Concern Pos Pravastatin AZ10154396 vLess-DILI-Concern Pos
Clofibrate AZ10007325 vLess-DILI-Concern Pos Propylthiouracil AZ10006157 vMost-DILI-Concern Pos
Clozapine AZ10030042 vMost-DILI-Concern Pos Simvastatin AZ10410259 vLess-DILI-Concern Pos
Coumarin AZ10246257 #N/A Pos Stavudine AZ10129833 vMost-DILI-Concern Pos
Dacarbazine AZ10523577 vMost-DILI-Concern Pos Sulindac AZ10173856 vMost-DILI-Concern Pos
Dantrolene AZ11874538 vMost-DILI-Concern Pos sunitinib AZ11755299 vMost-DILI-Concern Pos
Diclofenac AZ10194317 vMost-DILI-Concern Pos Tacrine AZ10050561 #N/A Pos
Erythromycin AZ12201437 vMost-DILI-Concern Pos Tamoxifen AZ10009015 vMost-DILI-Concern Pos
Felbamate AZ10130800 vMost-DILI-Concern Pos Ticlopidine AZ10025601 vMost-DILI-Concern Pos
Fenofibrate AZ10116192 vLess-DILI-Concern Pos Tienilic acid/Ticrynafen AZ10256496 #N/A Pos
Fluconazole AZ10456348 vMost-DILI-Concern Pos Troglitazone AZ10308701 vMost-DILI-Concern Pos
Fluoxetine AZ10166761 vLess-DILI-Concern Pos Ximelagatran AZ11942255 vMost-DILI-Concern Pos
Furosemide AZ10130507 Ambiguous DILI-concern Pos
Table 11. 384-well plate screen hit list. Compound hits obtained from the screening. To detect specificity and sensitivity our hits where 
compared with AstraZeneca’s results as showed on the Pos/Neg column. The results of this screen were a sensitivity of 35.9% and a specificity 
of 84.2%. Pos = positive, Neg = Negative, NaN = No information available.  
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3.2.5 Disease modelling in 96-well plate format 
In addition to drug toxicity studies, the semi-automated platform can 
be applied for disease modelling. Non-alcoholic fatty liver disease 
(NAFLD) is the most common cause of liver disease in developed 
countries. In vitro modelling of NAFLD would permit mechanistic 
studies to find therapies. I contributed to the development of an in vitro 
model of NAFLD by implementing the model into the semi-automated 
differentiation platform (67). In this study, HLCs were exposed to 
lactate, pyruvate and octanoic acid (LPO) for 48h or 96h to induce lipid 
accumulation. Following incubation, HLCs were stained with NucBlue 
for the nuclei, BODIPY green for lipids and Mitotracker for the 
mitochondrial activity. Imaging and analysis were performed as 
described before. Lipid accumulation and mitochondrial stress was 
quantified. LPO treated cells displayed a dose- and time-dependent 











Figure 44. Incubation of HLCs with LPO at low or high dose for 48 or 96 h induces 
steatosis. (A) Fluorescence microscopy demonstrating BODIPY staining of neutral lipid 
vacuoles within HLC following exposure to LPO. (B) LPO induces a dose- and time-
dependent increase in lipid vacuoles in HLCs. (C) Exposure to LPO increases 
mitochondrial stress in a dose-dependent manner at 48 and 96 h. Data was analysed by 
one-way ANOVA with Bonferroni correction. The minimum number of biological replicates 
is shown for each experiment. **p < 0.01, ***p < 0.001, n.s. = non-significant. Figure 
adapted from Lyall et al, 2018 (67). 
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Biomedical research requires tools that better mimic and predict 
human liver biology. Traditionally, in vitro models relied heavily on 
immortalized cell lines. While these models demonstrate advantages, 
they offer limited biological relevance when compared to primary cells. 
Primary cells are considered the gold standard to study liver biology 
but due to batch-to-batch variations, rapid loss of phenotype and the 
scarcity of donor tissue more stable and reproducible models are 
required. Recent advances in stem cell technologies offer the possibility 
to develop more accurate models that better mimic hepatocyte 
physiology.  
Our hepatocyte differentiation protocol consists of a stagewise 
approach where the stem cell populations are driven to definitive 
endoderm using Activin A and Wnt3a. This is followed by hepatic 
progenitor cell specification and hepatocyte maturation. HLCs express 
a battery of hepatocyte markers such as HNF4a, albumin. In addition, 
HLCs displayed cytochrome P450 including CYP P450, CYP1A2, 
CYP2C9, CYP2C19, CYP2D6, and CYP3A4 (Figure 25, Figure 26). 
These CYPs are responsible for the metabolism of approximately 90% 
of marketed drugs (173). Despite as the mixture of foetal and adult 
hepatocyte traits (90), HLCs provides a reproducible system to study 
hepatocyte biology for basic and translational research. HLCs 
produced in this protocol exhibit comparable metabolic activity and 
response to paracetamol toxicity to primary hepatocytes (66,150).  
Over the last decade, researchers have demonstrated the potential of 
HLCs differentiation protocols as a tool to model human diseases or 
drug exposure. Several groups have applied HLCs for disease modelling 
or drug screening. Rashid et al. (70) and Cayo et al. (71) produced HLCs 
from patient-derived human iPSC cell lines which accurately modelled 
human metabolic liver disease. Similarly, Lyall et al. contributed to the 
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development of an in vitro model to study non-alcoholic fatty liver 
disease from human pluripotent stem cells, HLCs lipid accumulation, 
to recapitulate the transcriptional and metabolic dysregulation seen in 
NAFLD and additionally retain liver-like epigenome (67). Another 
model of non-alcoholic fatty liver disease was developed by Parafati et 
al. (174), in this study, induction of NAFLD was linked to an increase 
of endoplasmic reticulum stress. Following administration of both 
unsaturated and saturated fatty acids, there was an increase in 
endoplasmic reticulum stress, triglyceride accumulation as well as 
dysregulation of lipid metabolism without leading to cell apoptosis. 
Additionally, Lucendo-Villarin et al. (92) showed how HLCs can be used 
to study foetal hepatotoxicity when exposed to tobacco derivatives.  
Relative to other types of hepatocyte sources, HLCs were found to be 
more sensitive than the cancer cell line HepG2 (175) and exhibit a 
comparable response to primary hepatocytes when challenged with 
toxins (150,175). While continued research into the cell niche is 
required to further improve the HLC phenotype, the studies described 
above evidence the power of stem cell-derived HLCs to model human 
disease and improve drug discovery. 
The semi-automated procedure of HLCs differentiation is efficient, 
reliable and economical, allowing the production of HLCs at scale. As 
seen in the validation drug screen, the semi-automation workflow 
enables the user to produce large numbers of plates at once, for the 
96-well plate screen, 60 plates were differentiated at once. This was 
not possible using traditional cell culture. Importantly, the automation 
process did not impact on differentiation yields, with the majority of 
cells expressing HNF4α and ALB. HLCs also exhibited metabolic 
activity comparable to previous reported experiments (66,87). Despite 
the standardization of the protocol, cell confluency prior to the 
differentiation is critical for pure HLC differentiation. Cell number and 
confluency needs to be empirically optimised for different hPSC. 
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In its current form, this platform is not suitable to produce large 
quantities of HLCs for clinical applications, and this will most likely be 
achieved through the use of cell factories and bioreactors. However, 
the methodology developed does allow for the rapid generation of 
human liver cells for basic and translational research.  
An example of current limitations of in vitro models can be noticed 
during the different phases of drug development. Although high-
throughput screening platforms permit the testing of large compound 
libraries during drug development, the high attrition rates demonstrate 
the need for improved screening platforms and more reliable pre-
clinical models. The percentage of drug failure at phase II and phase 
III is high and the main reasons for failure are the lack of efficacy, 48% 
in phase II and 55% in phase III, and safety, 25% in phase II and 14% 
in phase III (176), with hepatotoxicity (18%) representing the first 
reason for drug withdrawal (177). Because of that, there is a need to 
improve current screening models to improve the early detection of 
hepatotoxic drugs. By combining the semi-automated production of 
stem cell-derived hepatocytes with high content analysis, alternative 
tools that better predict liver physiology could be developed delivering 
safer medicines for the patient.  
Drug metabolism and hepatotoxic compound detection was tested onto 
the HLCs produced with the semi-automated platform in collaboration 
with AstraZeneca. A combination of commercial assays were combined 
with the cell painting staining (141). The main advantages of using high 
content analysis are that it generates a multiparametric data set 
instead of a single readout. In addition, by using the cell paint assay, 
it is possible to determine effects in the different stained organelles. 
Both 96 and 384-well plate were tested with the compound library.  
Data analysis was performed using several data mining tools. First 
Python programming was used for data formatting and file merging. By 
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using Python, high quantities of files can be processed at once reducing 
time and minimising manual errors. Next, I used Spotfire for data 
visualisation. This software allows rapid data visualisation and 
analysis of large data sets. Similar visualisations can be achieved with 
Python but Spotfire allows a user-friendly interface allowing non-
specialised programmers to work with big data. Analysis could be 
performed using Spotfire. The main disadvantage of using Spotfire for 
data mining is that normalisations, transformations or hit picking have 
to be programmed one by one. Due to the large quantity of features 
extracted from the analysis analysis with Spotfire would be time 
consuming and its use requires advance programming skills. 
Therefore, HC Stratominer was used for data analysis. HC Stratominer, 
allows a rapid analysis of big data sets to users with no previous 
programming experience. Due to its intractability, different thresholds 
or methods can be applied at every step of the analysis facilitating data 
exploration.  
After analysis, 96-well plate assay detected 26 compounds as hits, see 
table Table 10 for details. Results produced from the screen was 
validated with AstraZeneca’s screen results. The sensitivity and 
specificity of the assay were 35.9% and 84.2% respectively. From the 
26 hits, three compounds: Clotrimazole, Oxybutynin, Colchicine; were 
detected as negative in AstraZeneca’s screen. Interestingly, on the FDA 
compound annotation (Table 9), only Oxybutynin was marked as a 
non-DILI concern compound. Clotrimazole and Colchicine presented 
less-DILI and ambiguous-DILI concerns respectively. Detection of 
Clotrimazole and Colchicine as hits could be explained due to a 
phenotype improvement. Changes in the AstraZeneca screen design 
could explain the reduced specificity. Our compound incubation was 
48h versus 72h from AstraZeneca. In addition, we limited DMSO 
concentration to 1% due to its toxicity. This limited our higher 
concentration to 200 μM, while several compounds displayed toxicity 
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at higher concentrations. Further work could be focused on increasing 
assay sensitivity.  
For the 384-well screen higher concentration was kept at 200 μM to 
maintain 1% DMSO concentration but compound incubation was 
extended to 72h. Following data analysis, 66 compounds were called a 
hit. See Table 11 for details. Despite the increase in sensitivity (79.7%) 
15 compounds annotated as negative were detected as a hit. FDA 
compound annotation showed 8 of the 15 compounds: Betaine, 
Diphenhydramine, epinephrine, folic acid, isoproterenol, Oxybutynin, 
Procyclidine, streptomycin were annotated as non-DILI related on the 
FDA. These results make 384-well plate more prone to false positives 
limiting its use as a drug exposure model.  
In summary, development of high-throughput generation of HLCs in 
96 and 384-well plate can be achieved by the implementation of 
automation. By using liquid handling systems and high content 
imaging standardisation and reproducibility from the differentiation to 
the analysis can be achieved. After comparing both multi-well systems, 
96-well plate format displayed a higher specificity. In addition, 96-well 
plate format allows sample acquisition for other downstream 
applications such as protein or gene expression analysis. We used this 
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4.1.1 Liver disease  
Liver disease is a major cause of death. It is increasing every year in 
the UK with a four-fold increase in mortality rates since 1970 (178). 
Drug-induced liver injury (DILI) is the most common cause of acute 
liver failure (ALF) (179). Drugs and their metabolites can expose the 
organ to adverse events such as endoplasmic reticulum and 
mitochondrial stress. This can alter cellular homeostasis, inducing the 
generation of reactive oxygen species (ROS) and the triggering of cell 
death (180–182). Paracetamol-induced injury is the most common 
cause of DILI (183). It is characterised by hepatocyte death and organ 
failure. Phase II enzymes are responsible for a non-toxic paracetamol 
metabolism. During an overdose, non-toxic metabolism is saturated 
and paracetamol is then metabolised by CYP P450 proteins generating 
a toxic intermediate metabolite N-acetyl-p-benzoquinone imine 
(NAPQI). NAPQI is a highly reactive toxic metabolite that will induce 
hepatocyte death. Following the first injury insult, spreading of 
hepatocyte senescence occurs via TGF-b activation reducing liver 
regeneration which can results in organ failure and possible death 
(57,58).  
N-Acetylcysteine (NAC) is the only current treatment for paracetamol 
overdose. Following treatment, NAC increases the production and 
availability of hepatic glutathione. This neutralises NAPQI reducing the 
hepatocyte death (58–60). To be an effective therapy, NAC has to be 
administrated within the first 8-10 h following paracetamol overdose 
consumption (58). Therefore, new treatments that can improve patient 
outcome or prolong the window of effective treatment are required.  
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4.1.2 Nrf2 stimulation as a tissue repair therapy 
Anti-inflammatory and antioxidant therapies have been proposed in 
the past as a powerful approach to reduce the severity of acute injury 
and enhance organ regeneration. The transcription factor ‘nuclear 
factor erythroid-derived 2-like 2’ (Nrf2) is a transcription factor involved 
in the defence mechanism against ROS. Therefore, the clinical 
activation of Nrf2 activation may provide a successful therapy for acute 
disorders (184,185).  
Nrf2 regulates multiple antioxidant genes involved in glutathione 
synthesis, ROS elimination, detoxification, drug excretion and NADPH 
synthesis that are activated following injury. In the absence of stress, 
Nrf2 is bound to its inhibitor ‘kelch-like ECH-associated protein 1’ 
(Keap1) promoting the ubiquitination and degradation of Nrf2. Keap1 
is a cysteine-rich protein. These cysteine residues are highly reactive 
and can act as stress sensor. Oxidative stress and electrophile 
compounds can interact and modify covalently cysteine residues 
reducing its binding capacity with Nrf2 (101,186). Among all the 
cysteine residues, Cys-151, Cys-226, Cys-273, Cys-288 and Cys-613 
are the most common modified residues with Cys-151 the preferable 
residue for electrophile compounds (101). Upon cell stress, Keap1 
losses its capacity to bind Nrf2; Nrf2 translocates into the nucleus, 
forms an heterodimer with MafG and binds to the Antioxidant 
Response Element (ARE) - a promoter motif of multiple genes. This 
initiates the antioxidant and anti-inflammatory gene response (Figure 
8) (94,117,187).  
Several studies suggest that the activation of the Nrf2 pathway can 
have cytoprotective and anti-inflammatory effects (188–190). 
Therefore, pharmacological activation of Nrf2 could represent a 
promising therapeutic option to limit acute tissue injury and inhibit 
detrimental loss of function and scarring (184). A recent study also 
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showed that the activation of Nrf2 suppresses the macrophage 
inflammatory response by blocking the transcription of pro-
inflammatory cytokines (IL6, IL1b, IL1a and Nos2) via an ARE non-
dependent mechanism (109). Consequently, the activation of Nrf2 as a 
therapy could provide a dual protective role by reducing organ injury 
inflammation and enhancing regeneration.  
4.1.3 Pharmacological activation of Nrf2 by dimethyl fumarate 
Dimethyl fumarate (DMF) is a drug approved by the food and drug 
administration (FDA) and the European Medicines Agency (EMA) for 
some forms of multiple sclerosis and psoriasis (191). The full 
mechanism of DMF is not completely understood. In vivo, DMF is 
metabolised by hydrolysis to monoethyl fumarate (MMF) by esterases 
(123). Both DMF and MMF can interact with the Cys-151 residue of 
Keap1 allowing the activation of Nrf2 and its anti-oxidative and anti-
inflammatory responses (Figure 45). Therefore pharmaceutical 
repurposing of the use of DMF could potentially lead to a successful 
treatment to reduce the severity of acute liver injury (192). By 
understanding the effects of DMF in the modulation of the Nrf2 
pathway in liver injury, this research may provide a platform for 
translation to patients with acute liver disease. 
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Figure 45. Schematic representation of the mechanism of action of dimethyl 
fumarate. DMF interacts with KEAP1 blocking the binding capacity to Nrf2. Nrf2 
can then undergo nuclear translocation and induce gene expression. Figure drawn 
by author. 
4.1.4 Cytoprotective effects of DMF in in vitro and in vivo models 
Both in vitro and in vivo systems were used to study the cytoprotective 
properties of DMF in the context of paracetamol injury. For the in vitro 
work, HLCs were used as a human, defined and reproducible model to 
recapitulate human hepatocyte drug metabolism (91). In combination 
with our semi-automated differentiation platform, HLCs are an 
excellent tool to study the cytoprotective effects of DMF. A zebrafish 
model of paracetamol injury was chosen as an in vivo model. The 
advantages of working with zebrafish are: rapid liver development, 72 
– 96 hours postfertilization, easy scalability, reduced costs, overlap 
with 82% of disease-associated targets and drug metabolism pathways 
and transparent embryos with transgenic reporter lines (193). This 
makes zebrafish an interesting in vivo model with translational 
potential to bring in vitro results into the clinic.  
Investigating the protective properties of dimethyl fumarate and 145 
Nrf2 signalling during drug-induced hepatotoxicity      





4.2.1 Dimethyl fumarate in HLCs 
4.2.1.1 Dimethyl fumarate safety 
Before investigating the cytoprotective effects of DMF, compound 
toxicity was assessed. HLCs at day 18 were treated with DMF 
(dissolved in DMSO) in a concentration range of 5 μM, 10 μM, 20 μM, 
50 μM, 150 μM; concentrations based on the literature (193). 
Compounds were incubated for 48 h with drug replenishing at 24 h. 
Following incubation, ATP depletion was quantified (CellTiter-Glo, 
Promega). After 48 h, no significant reduction of ATP was detected in 
any of the tested concentrations (Figure 46). Apoptosis induction 
following DMF 50 μM administration was tested for further validation. 
A caspase 3/7 induction assay (Caspase 3/7 - Glo, Promega) was 
performed at time 0, 30 min, 90 min and 6 hours post administration 
of DMF 50 μM. DMF 50 μM was selected as a starting concentration 
as no toxicity was observed in HLCs as well as being reported to induce 
cytoprotective effects via Nrf2 activation (123,131,195). No significant 
induction of apoptosis was detected between conditions from the same 
time point (Figure 47). Based on the literature, 50 μM and 10 μM were 
selected as working concentrations (196).  
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Figure 46. Assessment of DMF toxicity in HLCs. HLCs were incubated with DMF for 
48 h in a concentration range of 5 μM, 10 μM, 20 μM, 50 μM, 150 μM. Following 
incubation, total ATP was quantified. No significant changes were detected. A One-way 
ANOVA with Tukey's post-hoc statistical tests was employed. Box plot, whiskers 
represents Min-Max. n=8 replicates of one plate. 
 
Figure 47. Caspase 3/7 induction following DMF incubation. Time course 
experiment to assess potential apoptosis induction from DMF. There was no 
significant increase between conditions from within the same point. A One-way 
ANOVA with Tukey's post-hoc statistical tests was employed. Dot plot, with mean 
and SD. n=16 replicates of one plate.  
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4.2.1.2 High content imaging of Nrf2 nuclear translocation 
Antibody optimisation 
Next, DMF potential to induce Nrf2 nuclear translocation was 
assessed. Two Nrf2 antibodies commonly used in the literature were 
tested. First, a rabbit polyclonal anti-Nrf2 ab31163 (Abcam) (197) and 
a mouse monoclonal anti-Nrf2 sc-365949 (Santa Cruz Biotechnology) 
(198). From the antibodies used, Nrf2 staining was only detected with 
the Abcam antibody (Figure 48). For subsequent studies, the anti-Nrf2 
ab31163 antibody was used. 
 
Figure 48. Nrf2 antibody optimisation. Representative staining of HLCs at day 18 were 
stained with the anti-Nrf2 antibodies. Reactivity was only observed on the Abcam 
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Following this, a time course experiment was designed to determine 
the capacity of DMF to induce Nrf2 nuclear translocation. HLCs at day 
18 were administered with DMF 50 μM. Parallel plates were prepared 
and fixed at time 0, 0.5 h, 2 h, 6 h and 24 h. Plates were stained for 
Nrf2 on the red channel (568 nm), cytoplasm (CellMask green 488 nm) 
and nuclei (Hoechst 361 nm).  
 
Nrf2 nuclear translocation by high content imaging  
Following staining, plates were imaged using the Operetta high content 
microscope and cell segmentation was performed. Hoechst and 
Cellmask stain were used for cell identification. After the quality 
control step, Nrf2 intensity was calculated. 
Nuclei and cytoplasm intensity were quantified separately, this allowed 
Nrf2 localisation as well as nuclear/cytoplasmatic staining ratio to 
assess Nrf2 nuclear translocation. After image quantification, an 
intensity threshold was applied to separate nuclear Nrf2 positive cells 
(Nrf2+) from nuclear Nrf2 negative cells (Nrf2-) (Figure 49). The value 
obtained represents the percentage of Nrf2+ cells per well. At time 0, 
the majority of the HLCs displayed cytoplasmic staining of Nrf2 (Figure 
50), with only 31.2% Nrf2+ cells (Figure 51).  
At 0.5 h following DMF administration, most of the cells displayed a 
marked Nrf2 nuclear staining (Figure 50), this change was quantified 
with an increase of Nrf2+ cells up to 71.2% (Figure 51). This was 
maintained at two hours, with 74.1% of Nrf2+ cells, followed by a 
decrease down to 58.4% Nrf2+ cells at 6 h and acquiring basal levels 
of 35.2% after 24 h of DMF administration (Figure 51, Figure 50). This 
result highlights the sensitivity of the Nrf2 pathway. DMF treatment 
induced Nrf2 nuclear translocation as early as 30 minutes.  
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This pipeline allows an automatic quantification of Nrf2 nuclear 
translocation following stimuli. The only limitation of this approach is 
the manual thresholding for Nrf2+ quantification. 
 
Figure 49. Example of the thresholding for Nrf2+ selection. (A) HLCs treated with 
DMF 50 μM for 2 hours, HLCs were stained for Nrf2 in orange and nuclei in blue. (B) 
Cell segmentation for HLCs detection. (C) Selection of Nrf2 nuclear positive cells. (D) 
Threshold applied to select Nrf2 nuclear positive cells based on Nrf2 nuclear 
intensity. Scale bar = 100 μm.  
Further improvement on the quantification process was required to 
develop an unbiased quantification of Nrf2 dynamics. Previous data 
analysis was performed using well level data, as shown on Figure 49. 
Values obtained represented the average from all the cells within a well. 
This approach requires a manual thresholding to determine what a 
Nrf2+ cell is. This process is time consuming and it has to be adjusted 
for each plate due to batch-to-batch staining variations. To improve 
this, single cell level information was extracted.  
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This approach is referred to as image cytometry (166,199). Single cell 
level data allows an easy visualisation and quantification of protein 
localisation. For each cell, nuclear, cytoplasmic and the ratio of 
nuclear/ cytoplasmic Nrf2 staining were calculated. 
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Figure 50. Nrf2 nuclear translocation following DMF administration. HLCs at day 
18 were treated with 50 μM for 0, 0.5 ,2, 6 and 24 h. After treatment cells were stained 
for Nrf2. Representative images from each time point. Scale bar 100 μm. For each 
replicate, eight wells of a 96-well plate were imaged, n=3 biological replicates.  
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Figure 51. Time course quantification of Nrf2+ cells. Nrf2 positive cells 
were quantified using cell segmentation. Nrf2+ cells threshold was adjusted 
empirically to correct for staining variation. A One-way ANOVA with Tukey's 
post-hoc statistical tests was employed. Dot plot, where each dot represents a 
replicate with whiskers as SD, n=3 biological replicates. 
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By using single cell level data, the dataset size obtained was increased 
from one value per well to several thousand values per well. Data 
visualisation and normalisation was performed using Spotfire software 
as explained in Chapter 3. The advantage of using single cell data can 
be seen in Figure 52. In Figure 52A, data is plotted in a scatter plot, 
where each dot represents a cell, the X-axis represents the amount of 
Cytoplasmatic Nrf2 signal and the Y-axis represents the amount of 
Nuclear Nrf2 signal. Each scatter plot represents a time point in the 
time course. By using this method, it is possible to visualise Nrf2 
dynamics upon time. In addition, this method allows detection of 
subpopulations that would be missing by using well level data. 
Moreover, by calculating the ratio of nuclear/cytoplasmic Nrf2, data 
can be visualised in a histogram as shown in Figure 52B. The 
histogram can help in visualising the shifts of the Nrf2+ cell 
populations upon treatment and time. Finally, this can be quantified 
in a box plot. Figure 52C shows each time point represented in a box 
plot with a histogram to show the sample distribution. The white line 
represents the median of the sample, the white semi-dotted line 
represents the average and the black bar next to the box plot 
represents the 95% confidence interval.  
In addition, significance differences between time points can be seen 
in the comparison circles on the right, where alpha = 0.01 was applied 
(200). The centre of the circle is located at the same level as the average 
value of each time point. The size of the circle reflects the degree of the 
variability, the more variability of the sample the higher the circle. 
Circles that do not overlap indicate a significance difference.  
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This improved approach allows an unbiased image processing and data 
analysis to study Nrf2 dynamics. Comparison of Figure 51 and Figure 
52 showed a similar trend: there is a significant increase of nuclear 
Nrf2 as early as 30 minutes with a peak at 2 hours, with a decrease 
after 6 hours of treatment. 
In addition, vehicle and untreated groups were added as negative 
controls; H2O2 1 mM was used as a positive control. H2O2 is an Nrf2 
inducer via oxidative stress injury (52).  
Surprisingly, all conditions, positive and negative controls, showed 
similar patterns on Nrf2 dynamics. These results suggested that the 
increase of Nrf2 was not specific to the effects from DMF but to the 
medium change (Figure 53).  
This could be explained by medium sock change. Changes in 
temperature or incorrected medium buffering could affect oxygen 
levels, triggering oxidative stress and Nrf2 nuclear translocation (201). 
To reduce this, further improvements were incorporated and a new 
time course experiment was performed. Media change was performed 
using the Viaflow automatic pipette. To minimise heat shock, the plate 
holder and tips from the Viaflow were preincubated at 37 °C overnight. 
In addition, culture medium containing the different treatments were 
prepared in a 96-well deep-well plate and preincubated for at least 6 
hours in the same incubator as the HLCs. The same time points were 
chosen. Following compound incubation, staining and imaging, 
Figure 52. Single cell analysis of Nrf2 dynamics upon DMF 50 μM administration. 
(A) Scatter plot of single cell level data, where each dot represents a cell, the X-axis 
represents the amount of cytoplasmatic Nrf2 signal, Y-axis represents the amount of 
Nuclear Nrf2 signal. Each plot represents a time point (B) Histogram showing the ratio 
of nuclear/cytoplasmic Nrf2 intensity over time. (C) Box plot where each time point is 
represented in a box plot with a histogram to show the sample distribution. The white 
line represents the median of the sample, the black semi-dotted line represents the 
average and the black bar next to the box plot represents the 95% confidence interval. 
Comparison circles on the right show significant difference. Alpha = 0.01. n= 4 
replicates from one plate. 
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unbiased data analysis was performed as before. Both untreated and 
vehicle did not show major population shifts over time (Figure 54 A-
B). On the other hand, both DMF and H202 showed an increase of Nrf2 
at 2 hours. In the DMF group, Nrf2 stimuli decreased after 6 h, whereas 
in the H2O2 group, Nrf2 nuclear translocation was visible up to 24 
hours (Figure 54 C-E). By minimising the cell stress from medium 
change, it is possible to study accurately Nrf2 dynamics following 
compound administration. 
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Figure 53. Medium induced Nrf2 stimulation. Analysis from Nrf2 nuclear 
translocation time course using single cell data form (A) untreated, (B) vehicle and (C) 
H2O2 1 mM. Box plots show similar trends in all conditions, implying that the effect on 
Nrf2 nuclear translocation is unsepecific to DMF (Figure 52) or H2O2. n=4. Alpha = 0.01. 
n= 4 replicates from a plate. 
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Figure 54. Assay optimisation leads to a specific Nrf2 nuclear translocation 
quantification. Following assay optimisation, Nrf2 nuclear/cytoplasmic ratio was 
maintained on (A) untreated and (B) vehicle during the time course. (C) DMF 10 μM and 
(D) DMF 50 μM showed an increase in Nrf2 nuclear population at 2 h post administration 
followed by a decrease of Nrf2+ at 24 h. (E) H2O2 1 mM showed an increase of Nrf2+ at 2 
h which it was maintained at 6 and 24 h post administration. n=3. Alpha = 0.01. n= 4 
replicates from a plate. 
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4.2.1.3 DMF drives Nrf2 gene transcription 
After confirmation of Nrf2 nuclear translocation following DMF 
administration, the potential of DMF to induce Nrf2 target genes 
expression was tested. HLCs at day 18 were treated for 3 hours with 
dimethyl fumarate (50 μM), H2O2 (1 mM) and compared to controls. 3 
hours post compound administration was selected to study the initial 
gene response following Nrf2 nuclear translocation. 
Nrf2-driven gene expression was examined using three representative 
Nrf2 target genes (Figure 55): Glutathione-Disulfide Reductase (GSR), 
NADPH dehydrogenase quinone 1 (NQO1) and Heme oxygenase 1 
(HMOX1) (94).  
Both dimethyl fumarate and H2O2 induced expression of the three Nrf2 
target genes (Figure 55). To determine whether there is a distinct gene 
response from a pro-injury Nrf2 activation such as H2O2 versus a 
cytoprotection activation from DMF, a RT² Profiler Oxidative Stress 
Plus PCR Array (Qiagen) was used. This array measures 84 genes 
related to oxidative stress and Nrf2 (Figure 56A). Pathway enrichment 
analysis from the subset of genes differentially expressed from DMF 
versus H2O2 showed that DMF increases the detoxification of ROS, and 
increases cell response to stress, metabolism and glutathione 
synthesis recycling (Figure 56B). On the other hand, pathway 
enrichment analysis from the set of genes differentially expressed only 
in H2O2 group showed an increase in the TP53 Metabolic Genes and 
decrease in Glutathione metabolism and decrease in drug metabolism 
in cytochrome P450 proteins (Figure 56C).  
Investigating the protective properties of dimethyl fumarate and 159 
Nrf2 signalling during drug-induced hepatotoxicity      





Figure 55. Nrf2 target genes expression following DMF 50 μM or H2O2 1mM 
treatment for 3h. The three target genes tested, (A) HMOX1, (B) NQO1 and (C) GSR 
were upregulated following treatment of wither DMF 50 μM or H2O2 1mM. HMOX1= 
Heme Oxygenase 1, NQO1= NAD(P)H Quinone Dehydrogenase 1, GSR= Glutathione-
Disulfide Reductase. (n=6) * p < 0.05, n= 6 biological replicates. 
 
GSR NQO1 HMOX1 
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Figure 56. Human Oxidative Stress Plus RT² Profiler PCR Array was used to 
investigate differential expression of an injury stimulus (H2O2) or a 
cytoprotective stimulus (DMF). (A) Heatmap of the PCR array, a subset of genes 
differentially expressed from DMF versus H2O2. (B) List of genes up and down 
regulated in the DMF group versus H2O2. (C) List of genes up and down regulated in 
the H2O2 group versus DMF. (D) Pathway enrichment analysis of the genes up and 
down regulated in the DMF group. (E) Pathway enrichment analysis of the genes up 
and down regulated in the H2O2 group.  
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4.2.1.4 Role of Nrf2 in paracetamol-induced hepatotoxicity 
The cytoprotective properties of DMF were tested in HLCs in an 
established model of paracetamol-induced hepatotoxicity (91). First, a 
concentration response was employed to test the paracetamol toxicity 
and determine IC50. HLCs at day 18 were incubated with 10 mM, 20 
mM, 30 mM, 40 mM, 50 mM, 100 mM for 24 h. After treatment, total 
ATP was quantified (CellTiter-Glo – Promega). All the concentrations 
apart from 10 mM showed a significant decrease of ATP content when 
compared to vehicle (DMSO) (Figure 57A). Following quantification, 
IC50 was determined to be 35.58 mM (Figure 57B). Paracetamol 
30mM was selected to induce hepatotoxicity as it is close to the IC50 
concentration and it can be prepared with increased reproducibility 
than 35.58 mM.  
 
Figure 57. Paracetamol dose response toxicity following 24 h treatment. HLCs were 
treated with 10 mM, 20 mM, 30 mM, 40 mM, 50 mM, 100 mM for 24 h. Following treatment, 
(A) total ATP content was quantified and (B) IC50 was calculated. N=8 replicates from a plate, 
n.s.=non-significant, *=p < 0.05. Vehicle was kept at DMSO 1%, paracetamol concentrations 
from 40 to 100 mM contained > 1% DMSO.  
Next, the cytoprotective properties of dimethyl fumarate were tested in 
HLCs in an established paracetamol-induced hepatotoxicity (91). To 
counteract drug-induced hepatotoxicity two concentrations of DMF 
were used, 10 μM and 50 μM. The concentrations were chosen due to 
recent studies showing a dose dependent DMF efficacy (196). HLCs at 
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day 18 were treated with DMF or vehicle for 24 hours. Following pre-
incubation with DMF, HLCs were treated with paracetamol 30 mM for 
a further 24h. Total ATP and Caspase 3/7 induction were quantified. 
Pre-treatment with both DMF 10 μM and 50 μM significantly reduced 
ATP loss when compared to paracetamol 30 mM alone. Interestingly, 
DMF exhibited a concentration-dependent response. HLCs pre-treated 
with DMF 10 μM displayed a higher level of protection against 
paracetamol toxicity when compared with pre-treatment DMF at 50 μM 
(Figure 58A). Similar results were obtained after Caspase 3/7 
induction quantification. Pre-treatment with DMF 10 μM inhibited the 
induction of Caspase 3/7 more profoundly than pre-treatment with 
DMF 50 μM (Figure 58B).  
 
 
Figure 58. DMF exhibits protective effects upon paracetamol exposure in 
concentration dependent manner. Pre-treatment of either DMF 10 μM or 50 μM 24 
h before paracetamol 30mM treatment prevented a decrease of (A) ATP or (B) caspase 
3/7 induction. DMF 10 μM was more effective than in DMF 50 μM in both ATP and 
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Based on these results, DMF 10 μM exhibits increased cytoprotective 
properties than DMF 50 μM. Therefore DMF 10 μM was chosen for the 
subsequent experiments.  
To assess whether the cytoprotective properties of DMF were 
dependent of the Nrf2 pathway a combination of pharmacological 
inhibition of Nrf2 with DMF were tested in a paracetamol injury model. 
Brusatol was chosen as a Nrf2 inhibitor as it produces a rapid and 
transient inhibition of Nrf2 (202). Protein translation inhibition is the 
proposed mechanism of action of Brusatol (203). First, viability of the 
drug in HLCs was tested. HLCs at day 18 were treated with 150 nM, 
250 nM, 500 nM, 1 μM or vehicle for 24 h, concentrations chosen 
based on the literature (202). Following compound treatment, total ATP 
was quantified. No significant changes were detected in any of the 
concentrations used after 24 h (Figure 59). Therefore 1 μM was chosen 
as a working concentration to ensure efficacy.  
 
Figure 59. Brusatol showed no depletion of ATP synthesis in HLCs after 24h 
incubation. HLCs at day 18 were treated with 150 nM, 250 nM, 500 nM, 1 μM or 
vehicle for 24 h. Following compound treatment, total ATP was quantified. No 
significant changes were detected. n=8 replicates from a plate.  
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Next, inhibition of Nrf2 upon Brusatol administration was tested. HLCs 
were treated with Brusatol 1 μM. Total protein was collected at 0, 0.5, 
2, 6 and 24 h after treatment. Western blot shows a decrease in Nrf2 
at 2 h followed by a complete loss of Nrf2 at 6 and 24 h (Figure 60). 
 
Figure 60. Inhibition of Nrf2 upon Brusatol treatment. Total protein was collected 
from HLCs. (A) Western Blot shows a rapid inhibition of Nrf2 upon Brusatol 
administration. 2 h after treatment, there is a partial reduction in Nrf2. 6 h following 
brusatol administration no Nrf2 is detected, this is maintained 24 h after 
administration. Β-actin variability could be due to changes in protein concentrations 
as not the same amount of protein was loaded to perform the wester blot or by side 
effects of Brusatol treatment (B) Densitometry quantification of Nrf2, calculation was 
normalised by B-actin expression, quantification performed using ImageJ.  
Finally, to test whether Nrf2 is required for the cytoprotective 
properties of DMF, HLCs were pre-treated with a combination of DMF 
and Brusatol for 24h prior to paracetamol 30 mM incubation for 24 h. 
Following treatment, total ATP was quantified. The protective effect of 
the pre-treatment of DMF was lost when DMF was combined with 
Brusatol (Figure 61). These results demonstrate the requirement of 
Nrf2 in the cytoprotective properties of DMF.  
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Figure 61. Nrf2 is required for DMF to protect HLCs from paracetamol. HLCs at 
day 18 were pre-treated with DMF 10 μM, Brusatol 1 μM or a combination of the two 
for 24h, prior to paracetamol 30mM administration. Nrf2 is required for DMF to 
protect HLCs as the combination of DMF and Brusatol blocks the protective effects 
























































































































































 166 Jose Meseguer Ripollés 
4.2.1.5 Cytoprotective studies of DMF in a paracetamol-induced 
toxicity model 
The efficacy of DMF to protect hepatocytes from paracetamol-induced 
toxicity was compared with the current clinical treatment for 
paracetamol-induced injury, N-acetylcysteine 1 mM (60). In addition, 
a combination of DMF + NAC was performed to determine any potential 
synergic effects. First, a 24 h pre-treatment of dimethyl fumarate 10 
μM, NAC 1mM or combination followed by 24 h of paracetamol 30mM 
was performed (Figure 62A). Secondly a co-treatment of paracetamol 
30mM with DMF, NAC or in combination for 24 h was performed 
(Figure 62B). Lastly, HLCs were treated with paracetamol 30mM for 
24 h followed by 24 h of dimethyl fumarate 10 μM, NAC 1 mM or a 
combination of the two. (Figure 62C). Assessment of the cytoprotective 
effects were analysed by total ATP production.  
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In all cases, DMF showed a significant increase in ATP content when 
compared to paracetamol. NAC showed a significant ATP increase 
when compared to paracetamol in pre-treatment and co-treatment but 
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Figure 62. DMF 10 μM protects HLCs from paracetamol-induced 
hepatoxicity. (A) Pre-treatment of 10 μM DMF, NAC 1 mM or combination of the 
two for 24 h prior to the administration with 30mM of Paracetamol for 24 h shows 
a reduced loss of ATP in HLCs when compared to 30 mM paracetamol alone. (B) 
Co-treatment of DMF 10 μM, NAC 1 mM or combination of the two with 
paracetamol 30mM for 24 h shows a reduced loss in total ATP when compared to 
paracetamol 30 mM alone (C). Post-treatment of DMF 10 μM after a 24 h 
incubation with paracetamol 30mM shows a reduced loss of total ATP when 
compared to paracetamol 30 mM alone. * p < 0.05, ** p < 0.01, **** p < 0.0001 n=6 
replicates from a plate. 
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significant increase in ATP in the pre- and post- treatments groups but 
not in the co-treatment group (Figure 62).  
Cell painting assay was used for further validation of the cytoprotective 
effects of dimethyl fumarate. Pre-, co- and post- treatment were stained 
and imaged using the operetta microscope. Using cell segmentation, 
86 different image-based features were used to create a morphological 
profile (Figure 63), a python code was used for data normalisation and 
sample clustering. Un-biased clustering of the different treatments was 
done based on the morphological profiling (Figure 64A). Principal 
Component Analysis (PCA) was performed for data reduction (Figure 
64B). Both sample clustering graph and PCA plot paracetamol-treated 
group showed a distinct profile when compared with the dimethyl 
fumarate-treated groups or vehicle (Figure 64). 
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Figure 63. Correlation map of the DMF cytoprotection quantification by Cell 
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Figure 64. DMF cytoprotection quantification by Cell Paint profiling. (A) Cluster of the 
different populations based on similarities between the profiling of the different features. (B) 
PCA plot of all the different features comparing the different populations. n = 8 replicates from 
a plate. 
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4.2.2 Assessment of DMF effects in a Zebrafish paracetamol injury 
in vivo model 
4.2.2.1 Zebrafish lines 
Zebrafish larvae were used to validate the efficacy of DMF in an in vivo 
situation. Two different lines were used for these studies. First a wild-
type WIK line was used for concentration and assay optimisation. 
Following this, a zebrafish liver GFP reporter line (Tg(-2.8lfabp:GFP)) 
was used to quantify changes in GFP fluorescence due to liver injury 
(146,147). This is a GFP reporter line for the liver-type fatty acid-
binding protein (LFABP) which is only expressed in the hepatocytes. 
The zebrafish experiments were performed at 3 days post fertilisation 
(d.p.f) following zebrafish hatching. Experiments were stopped 5 d.p.f. 
in accordance with Home Office Regulations.  
4.2.2.2 Cytoprotection studies with DMF in a zebrafish model of 
paracetamol injury 
The cytoprotective properties of DMF were tested with the wild-type 
WIK line. Zebrafish embryos at 3 d.p.f. were pre-treated with DMF 2.5 
μM for 6 h prior to paracetamol treatment 10 mM for 42 h. After 
treatment, survival was determined by both mobility test and heartbeat 
of the larvae. An embryo was marked as dead if no mobility and lack 
of heartbeat were detected upon magnification lenses observation. 
Dimethyl fumarate 2.5 μM exhibited significant larvae survival when 
compared to Paracetamol 10 mM alone (Figure 65) 
 


























































Figure 65. Protective effects of DMF in a zebrafish model of liver injury. WiK-
larvae were treated with paracetamol 10mM (P 10 mM) for 42 hours or with a pre-
treatment of 2.5uM of dimethyl fumarate for 6 hours, vehicle and dimethyl fumarate 
(DMF) alone were used as controls. Each dot represents the survival percentage of a 
biological replicate containing 30-35 zebrafish. Following treatment, survival was 
determined calculating the number of alive fish versus the initial population. * =p < 
0.05. n>5. 
 
4.2.2.3 Development of quantitative analysis to liver injury 
Following this, a zebrafish liver GFP reporter line (Tg(-2.8lfabp:GFP)) 
was used to quantify changes in GFP fluorescence upon liver injury 
(146,147). Two different methods were developed for fluorescence 
acquisition, first a live imaging high throughput platform using the 
Operetta microscope; Secondly, a total larva fluorescence acquisition 
using a fluorescence plate reader.  
For the live imaging, after paracetamol exposure, single larvae were 
embedded in agarose 0.75% wt/vol in a 96-well plate. Following 
embedding, imaging was performed to assess system performance. 
Due to the high variability in terms of orientation and plane focusing 
(Figure 66), an orientation tool developed by Wittbrodt et al was 3D 
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printed by CNCvac 3D Printing (Figure 10) (148). Briefly, 0.75%, 
wt/vol agar was added into the 96-well plate following the positioning 
of the orientation tool (Figure 10). Once the agar solidified, removal of 
the orientation tool creating an agar ‘V’ shape where the larvae could 
be position, increasing reproducibility in terms of focus plane and 
orientation (Figure 66). 
Following zebrafish positioning standardisation, a supervised machine 
learning algorithm was developed for automatic zebrafish larva 
detection following automatic GFP+ liver segmentation and 
fluorescence quantification (Figure 67). A similar texture-based 
method as discussed in chapter 3 was used. First, manual annotation 
of both fish and background was uploaded into the algorithm. 
Following fish identification, selection of the fish ROI was performed 
based on shape and intensity features. After fish segmentation, liver 
detection was performed using a similar approach with and increase 
reproducibility. This system allows a fast and unbiased quantification 
of liver intensity. On the other hand, a plate reader was used to detect 
GFP fluorescence. Following paracetamol exposure, single embryos per 
well were placed into a black 96-well plate and green fluorescence was 
measured. Fluorescence quantification using both methods allows a 
detection of fluorescence loss upon paracetamol exposure for 48 h 
(Figure 68).  
 





Figure 66. Methods for larvae orientation for live imaging. Left, manual agarose 
embedding. Right, 3D scaffold orientation tool. 3D orientation allows a reproducible 
position in terms of focus plane and orientation.  
 
Figure 67. Automatic zebrafish segmentation for image analysis. Supervised 
machine learning for automatic zebrafish recognition using pixel texture was used to 
exclude background (red) from zebrafish (green) following zebrafish of region of interest 
refinement by size and shape. Next, supervised machine learning was used for GFP+ 
liver recognition. 
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Figure 68. Loss of GFP upon paracetamol 10 mM treatment for 48 h was detected in 
both platforms. Quantification of the GFP signal loss after paracetamol 10 mM was 
quantified using (A) high content imaging or (B) total fish fluorescence using the plate 
reader. Wild type lines were used to detect any potential fish autofluorescence. n > 6 
zebrafish embryo. ***=p < 0.001, ****=p < 0.0001. WT = wild type.  
 
4.2.2.4 Quantification of DMF cytoprotection upon paracetamol-
induced injury 
Larvae were pre-treated with dimethyl fumarate 2.5 μM for 6 h followed 
by paracetamol treatment for 42 h. This was compared to vehicle and 
DMF 2.5 μM and paracetamol alone. Wild-type larvae were used to 
subtract larvae autofluorescence. In both systems, GFP fluorescence 
was significantly increased in the DMF pre-treatment group when 
compared to a paracetamol group; In addition, DMF 2.5 μM treatment 
for 6 h did not affect GFP levels when compared to vehicle (Figure 69).  
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4.3 Discussion 
Despite advances in liver biology and human liver injury management, 
DILI is maintained as the leading cause of acute liver failure (178). 
Paracetamol-induced hepatotoxicity is one of the most common causes 
of DILI (179), and it is characterised by major hepatocyte death due to 
an excess in NAPQI production. Recent reports indicate that following 
the initial injury, the remaining hepatocytes enter into cellular 
senescence via TGB-b1 activation (57). This prevents the hepatocytes 
from restoring organ homeostasis leading to liver failure. Current 
treatments include supportive treatments such as activated charcoal 
or gastric emptying or therapeutic agents that detoxify the liver such 
as N-acetylcysteine (60). Despite its efficacy, NAC has to be 
administrated within the first 8-10 h following paracetamol overdose 
(183). In the absence of treatments that restore liver function, organ 
transplant is the only treatment to overcome liver failure. Despite its 
success, liver transplant is not a scalable alternative for acute 
 
Figure 69. Pre-treatment with DMF 2.5 μM protects zebrafish from paracetamol 
10 mM induced injury. Quantification of the GFP from (A) high content imaging or 
(B) total fish fluorescence using the plate reader shows a reduction on GFP loss on the 
DMF pre-treated group when compared to paracetamol 10 mM. n > 3 each dot 
represents a zebrafish embryo.  
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diseases. Therefore, novel approaches are needed to overcome acute 
liver failure. Nrf2 activation upon injury has been proposed as potential 
therapy to treat DILI and induce tissue repair.  
Nrf2 is a transcription factor which plays a key role in the regulation 
and modulation of key pathways involved in oxidative stress 
management, cell proliferation and inflammation modulation 
(117,187). Consequently, pharmacological activation of Nrf2 following 
DILI might represent a novel therapy to restore liver homeostasis. Nrf2 
has been shown to be essential for managing paracetamol overdose. 
Nrf2-knockout mice exhibited a higher degree of injury or even death 
when treated with non-lethal doses of paracetamol (106,110,111). 
Opposite effects were observed when hepatocyte Keap1-knockout mice 
exhibited increased resistance to toxic doses of paracetamol (112). 
Moreover, a different study showed Nrf2 nuclear translocation 
following paracetamol administration in a mouse model of paracetamol 
overdose, where Nrf2 nuclear translocation was observed in both toxic 
and non-toxic concentrations (113). Interestingly, upregulation of Nrf2 
target genes was not detected at the toxic concentration despite 
detection of Nrf2 nuclear translocation. More recently, the potential 
interaction of NAPQI and Nrf2 during paracetamol overdose was 
investigated (114). Authors report how NAPQI can activate Nrf2 nuclear 
translocation by either modifying cysteine residues of Keap1 or by 
depleting cellular glutathione. While NAPQI can activate Nrf2, during 
a paracetamol overdose Nrf2 gene upregulation is stopped (113,114). 
The absence of gene upregulation might be due to the level of injury 
developed by the paracetamol overdose, resulting in a disruption of 
cellular processes involved in gene transcription or cell metabolism.  
Therefore, pharmacological activation of Nrf2 might represent a 
promising approach to prevent liver failure following paracetamol 
overdose. Recent work has reported the beneficial effects of the 
pharmacological activation of Nrf2 in the context of liver disease 
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(189,190). Within the different Nrf2 inducers, fumaric acid esters have 
been proposed as potent Nrf2 inducers due to their electrophilic 
activity (204). Electrophilic compounds react with Cys-151 in Keap1 
activating Nrf2 (6,18). Dimethyl fumarate is a fumaric acid compound 
approved for the treatment of psoriasis and relapsing-remitting 
multiple sclerosis (121,192). DMF has been shown to induce gene 
expression of Nrf2 target genes such as glutathione transferases (GST), 
NQO1 or HMOX1 (194,205,206). 
In this chapter, the potential protective effects of DMF in a 
paracetamol-induced hepatotoxicity model were investigated. This was 
first tested in vitro using stem cell-derived hepatocyte-like cells. 
Findings from the in vitro work were validated in vivo using a zebrafish 
model of liver injury.  
In HLCs, Nrf2 nuclear translocation analysis following DMF 
administration was performed by using high content imaging. By 
implementing single cell imaging analysis, it was possible to perform 
an unbiased analysis of single cell dynamics. The use of single cell 
analysis allows for visualisation of cell population shifts upon time and 
treatment. This single cell imaging analysis pipeline could be applied 
to any protein upon pharmacological treatment or gene alteration, 
providing a powerful tool for biomedical research.  
Following analysis, it was possible to detect Nrf2 nuclear translocation 
upon time, detecting Nrf2 nuclear accumulation as early as 30 minutes 
upon administration, with a peak at 2 hours and returning to basal 
levels 24 h post administration. Surprisingly, negative controls showed 
a similar trend in Nrf2 nuclear translocation dynamics upon time 
(Figure 52, Figure 53). These results suggested that Nrf2 nuclear 
translocation upon time was not a specific effect of any of the 
treatments but from medium change. This highlights the sensitivity of 
the Nrf2 pathway as a master regulator of cell stress where minor 
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changes in the culture homeostasis can trigger Nrf2 nuclear 
translocation (207). Medium shock change could explain this 
phenomena, where culture medium not buffered properly can induce 
both heat shock effects and the Nrf2 pathway (207). By preincubating 
the medium, tips and plate holder prior to administration, Nrf2 
pathway activation from medium changes were minimised (Figure 54). 
A recent study by Bischoff et al showed similar results using HepG2 
cells (208). In this study Nrf2 was tagged with GFP and Nrf2 dynamics 
were investigated following xenobiotic exposure. Nuclear translocation 
reached its peak at 2 h following compound administration.  
Following assay optimisation, single cells analysis showed a transient 
Nrf2 nuclear translocation peaking at 2h post administration of DMF. 
In contrast, H2O2 1 mM displayed a marked increase on nuclear Nrf2 
positive cell population up to 24 hours post treatment (Figure 54). 
These results reflect changes of Nrf2 dynamics upon a cytoprotective 
Nrf2 activation by DMF versus a stress response Nrf2 activation by 
H2O2. It has been shown than DMF not only activates Nrf2 but it also 
inhibits Nf-kb activation (131,194); an injury stimulus such as H2O2 
would trigger multiple pathways for cell stress management such as 
NF-κB and Nrf2 (209). These differences could explain changes in Nrf2 
nuclear translocation dynamics from DMF and H2O2. 
Gene transactivation upon Nrf2 nuclear translocation was analysed 
following exposure to DMF and H2O2. Gene expression was analysed 3 
h post administration to detect the early gene response after Nrf2 
nuclear translocation. GSR, NQO1 and HMOX1 were selected as 
representative Nrf2 target genes. DMF and H2O2 induced the gene 
expression of the three target genes (Figure 55). GSR is a central 
enzyme of cellular antioxidant defence replenishing glutathione. NQO1 
reduces quinones to hydroquinones, accumulation of quinones results 
in the production of radical species. Finally, HMXO1 catabolises the 
free heme and produces carbon monoxide (CO) and up-regulates an 
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anti-inflammatory cytokine interleukin 10 (IL-10). To understand the 
differences in Nrf2 gene regulation between DMF and H2O2, an 
oxidative Stress PCR Array was used. This array measures 84 genes 
related to ROS metabolism, antioxidants, pathway activity signature 
genes involved in oxidative stress and oxygen transporters. Heatmap 
visualisation of the results (Figure 56), shows a subset of genes 
differentially expressed from DMF vs H2O2. Changes in the Nrf2 
nuclear translocation dynamics between DMS and H2O2 also translate 
in gene response. HLCs treated with DMF displayed an increase in 
metabolism and anti-oxidative stress-related functions (Figure 56B) 
(196). On the other hand, HLCs treated with H2O2 displayed an 
increase in TP53 and a decrease in drug metabolism (Figure 56C). 
These changes could be related to an increase in inflammation during 
the Nrf2 activation (59).  
In this study, paracetamol was solubilised in DMSO, this could 
increase cell toxicity as low concentrations of DMSO (>1%) can induce 
cell toxicity (171). In addition, DMSO is a direct substrate of CYP 2E1 
(210). This could potentially alter paracetamol metabolism in HLCs. 
Higher concentrations than 1 % of DMSO were used in the paracetamol 
IC50 assay (Figure 57). Here, the paracetamol concentrations from 40 
to 100 mM contained > 1% DMSO. As result, increased cell toxicity 
could have been observed in the higher paracetamol concentrations. 
Further work could be focused to investigate the relationship of DMSO-
induced toxicity in combination to paracetamol-induced toxicity. To do 
so, a comparison of paracetamol-induced toxicity resuspended in 
DMSO and H2O could be performed. Another possibility would be to 
use a CYP P450 inhibitor such as 1-aminobenzotriazole to test the 
toxicity of DMSO as a vehicle for paracetamol (211). To minimise 
DMSO-induced toxicity, the maximum DMSO concentration used in 
the rest of the studies was kept at 1 %. 
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Cytoprotective properties of DMF were tested in a paracetamol-induced 
toxicity model. First, HLCs were pre-treated with DMF for 24 h followed 
by paracetamol for 24 h. Both DMF concentrations showed an increase 
in HLCs survival. Interestingly, DMF showed a dose dependent efficacy 
where DMF 10 μM had higher cytoprotective effects than DMF 50 μM. 
These results coincide with a recent work published by Saidu et al 
(196) where they showed how DMF concentrations higher than 25 μM 
induced oxidative stress-reducing Nrf2 pathway activation and leading 
to a reduced cytoprotection. 
The role of Nrf2 in the cytoprotective properties of DMF was tested by 
inhibiting Nrf2 with Brusatol. Brusatol provokes a rapid inhibition of 
Nrf2 (202). Nrf2 inhibition could be achieved as a result of protein 
translation inhibition as Nrf2 is constantly produced in the cell. 
Potential off-target effects of protein inhibition should be investigated 
in the future. In HLCs, reduction of Nrf2 was detected as early as 2 h 
following Brusatol administration. There was no Nrf2 protein detection 
at 6 or 24 h post administration. Coadministration of DMF and 
Brusatol for 24 h prior to paracetamol injury obliterated the protective 
effects of DMF (Figure 61). This might indicate the requirement of Nrf2 
for the protective effects of DMF.  
Following DMF concentration optimisation, DMF efficacy was 
compared with the current clinical treatment for paracetamol-induced 
injury, N-acetylcysteine. The efficacy was tested in three different 
combinations: pre-treatment, co-treatment and post-treatment 
following paracetamol injury.  
In all cases, DMF showed a significant increase in ATP content when 
compared to paracetamol. NAC showed a significant ATP increase 
when compared to paracetamol in pre-treatment and co-treatment but 
not in the post-treatment group (Figure 62). Combination of DMF with 
NAC showed a significant increase in ATP in the pre and post 
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treatments but not in the co-treatment. Even though DMF treatment 
showed an increase in cell viability in both pre and co treatments, these 
scenarios have a reduced clinical relevance in the context of 
paracetamol overdose. The clinical scenario for a paracetamol overdose 
would require a post-treatment intervention. Notably, post-treatment 
with DMF after paracetamol treatment showed a significant increase 
in cell survival, which was not detected in the NAC treated group; with 
similar results in the combination of DMF+NAC. Current guidelines 
suggest administering NAC within the first 8-10 h following 
paracetamol overdose consumption (182). These results could open a 
new opportunity to treat paracetamol overdose patients by expanding 
the treatment window. On the other hand, pre and co treatment results 
could be applied in other clinical contexts as shown by Takasu et al 
where pre-treatment of DMF ameliorated liver ischemia reperfusion 
injury in mice (212).  
The relevance of the in vitro findings were tested in an in vivo zebrafish 
model of paracetamol injury. The zebrafish model was selected because 
it allows a rapid assessment of liver damage and has overlapping 
targets and drug metabolism pathways found in humans. In zebrafish, 
Nrf2a and Nrf2b are paralog genes to the human Nrf2 (213). Nrf2a 
seems to be regulated similarly to Nrf2 upon oxidative stress whereas 
Nrf2b might be a negative regulator during embryonic development 
(214). Expression of Nrf2 paralog genes make zebrafish a good model 
to study the protective effects of DMF during liver disease. By working 
with the Tg(-2.8lfabp:GFP) zebrafish line, it is possible to quantify 
hepatocyte damage due to GPF fluorescence changes (147). In a recent 
study, Vliegenthart et al, showed how GFP loss was linked with 
hepatocyte injury in a DILI model (147).  
In this study, I developed two different methods to detect GFP changes 
upon paracetamol injury. First, a high content imaging method was 
developed for single embryo live imaging and liver fluorescence 
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quantification. Secondly, total fluorescence was quantified in live 
single embryos using a fluorescence plate reader. DMF treatment for 6 
h did not affect normal liver development as no significant changes in 
fluorescence were detected (Figure 69). In addition, paracetamol 
treatment reduced zebrafish survival (Figure 65) and GFP fluorescence 
(Figure 68). Pre-treatment of DMF for 6 h prior to paracetamol 
administration showed an increase in GFP fluorescence (Figure 69). 
This was quantified using both plate reader fluorescence quantification 
and by high content imaging.  
By moving the in vitro findings into a more translational model, it was 
possible to test the protective effects of DMF in a whole organism where 
multiple cell types are involved in the generation and resolution of the 
injury. Further work is required to develop a post-treatment scenario 
to validate the in vitro findings, and NAC comparison would be 
necessary for efficacy comparison. 
In summary, this chapter showed the cytoprotective properties of DMF 
in the context of a paracetamol injury in both in vitro and in vivo 
models. These effects are Nrf2 dependent. The following chapter will 
describe RNA sequencing analysis performed in the different 
treatments of DMF and paracetamol to further understand the 
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5.1 Introduction 
Dimethyl fumarate exhibited cytoprotective effects in HLCs challenged 
with paracetamol. DMF was administered pre- paracetamol exposure, 
during paracetamol exposure and following paracetamol exposure. The 
in vitro findings were corroborated on a Zebrafish model of 
paracetamol-induced toxicity. In these studies, the fish were pre-
treated with DMF prior to paracetamol exposure, and displayed 
reduced liver damage. RNA sequencing (RNA-seq) analysis was 
performed to dissect the underlying mechanism of cell protection in 
each scenario.  
5.1.1 Transcriptomic analysis of DMF cytoprotection  
Recent advances in Next Generation Sequencing (NGS) allow the 
sequencing of the transcriptome in a high throughput manner at a 
reduced cost (215). Therefore RNA-seq has become a widely used tool 
to study biological changes. Following RNA acquisition, cDNA library 
preparation from the transcript is required prior to sequencing. The 
protocol used for library preparation (QuantSeq 3′ mRNA-Seq Library 
Prep Kit - Lexogen) generates Illumina-compatible libraries from 
polyadenylated RNA. This protocol generated only one fragment per 
mRNA transcript with sample-specific adapters to allow sample 
multiplexing. After sequencing, raw reads were mapped onto their 
transcripts using a genome of reference. As the library used only 
produced one fragment per transcript, gene expression counting can 
be more accurate. This pipeline generated a file containing gene counts 
for all the genes per sample.  
Following data preparation, differential expression genes (DEGs) 
identification between conditions was performed. DESeq2 was used for 
DEGs identification. DESeq2 is an easy-to-use tool for RNA-seq 
analysis (216). Finally, biological relevance from the identified DEGs 
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was evaluated. For this gene set enrichment analysis tools were used 
to identify the relevant biological process involved with the expression 
changes obtained from the analysis (217,218).  
5.1.2 Dimethyl fumarate in the context of liver disease 
To date, a few studies have been published on the cytoprotective effects 
of DMF in liver disease. Brennan et al, showed that DMF effects in mice 
are tissue specific (205). In the liver, several Nrf2 target genes: Cdkn1a, 
sqstm1, gclc, Nqo1, Srxn1, Akr1b8 were upregulated upon DMF (100 
mg/kg) administration. These effects were time dependent with peak 
stimulation from 6 to 12 hrs.  
In the pre-treatment context, Takasu et al showed that DMF pre-
treatment ameliorates liver ischemia/reperfusion injury in rats (212). 
In this study, DMF 25 mg/kg was orally administrated twice a day two 
days prior to ischemia/reperfusion injury. The DMF treated group 
showed a significant reduction of several liver injury markers such as 
aminotransferase (ALT) and malondialdehyde (MDA) as well as an 
increase of liver ATP. DMF treatment reduced Nf-kb expression as well 
as several inflammatory mediators such as IL-6, IL-10 or TNF-a. 
Finally, Sun et al, showed that DMF pre-treatment mitigated ethanol-
induced liver injury in mice. In this study, pre-treatment with 
25 mg/kg of DMF twice a day for five days prior to ethanol 
administration showed an increase in survival as well as an increase 
in blood glucose levels compared to vehicle. This was in part mediated 
by upregulation of several Nrf2 target genes: GCLC, NQO1 and HMOX1.  
In the post-treatment scenario, Giustina et al showed that post-
administration of DMF 15 mg/kg in rats reduced sepsis-induced 
inflammation and oxidative stress in the liver (219). Finally, a recent 
study from Abdelrahman et al, showed that post-administration of 
DMF 100 mg/kg protected mice from paracetamol-induced injury 
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markers when compared to a paracetamol-treated group. These 
markers include: serum glutamic oxaloacetic transaminase (SGOT), 
serum glutamic pyruvic transaminase (SGPT), gamma-glutamyl 
transferase (GGT) and alkaline phosphatase (ALP). These were linked 
with a reduction of hepatic Nf-kb activity and TNFa stimulation as well 
as an increase in HMOX-1 expression. This study was mainly 
descriptive rather than investigating the mechanism of protection.  
Finally, only two studies use DMF in zebrafish models. First, García-
Caballero et al showed that DMF inhibits angiogenesis in zebrafish 
(221). In this study, zebrafish embryos were used at 24 h 
postfertilization for a further 24 hrs using from 5 to 25 μM of DMF. In 
our work, we used DMF at a lower concentration (2,5 μM). In our 
model, no transcriptional changes involved in angiogenesis were 
detected (Table 18 and Table 19). The likely explanation for this is 
that the zebrafish were used at 72 h post postfertilization instead of 24 
h as reported by García-Caballero et al. In addition, effects observed in 
this study could be due to DMF concentration. This could differ in our 
model as DMF presents dose-dependent protective effects (196). In 
addition, Kulkarni et al developed a model of experimental 
autoimmune encephalomyelitis in adult zebrafish and used dimethyl 
fumarate validate the model (222) where DMF-treated zebrafish were 
able to reverse the clinical signs of the encephalomyelitis. Validation of 
the clinical recovery was focused in clinical assays such as mobility, 
survival and body weight rather than on mechanistic studies. 
This chapter will present the transcriptional changes that take place 
during hepatocyte exposure to paracetamol and how DMF mediates its 
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5.2 Results 
5.2.1 RNA extraction & Library preparation 
The objective was to understand the cytoprotective effects of DMF in 
the context of paracetamol injury in both HLCs and ZF. In HLCs, pre, 
co and post treatments were used to investigate any time dependent 
treatment mechanism. To do so, mRNA sequencing of these models 
was performed.  
DMF cytoprotection was assessed by ATP production. This method is 
an end-point assay which requires cell lysis hindering RNA collection. 
To solve this, mirror plates for each treatment were prepared. One plate 
was used for ATP quantification and the other one for RNA collection.  
For zebrafish, total GFP was quantified using the plate reader as shown 
in the previous chapter. As GFP quantification is not an end-point 
assay, single embryos were collected for RNA isolation following 
fluorescence quantification.  
Following treatment, mRNA from HLCs was extracted using the 
Dynabeads mRNA direct kit (ThermoFisher). This kit allows simple and 
fast isolation of intact polyadenylated mRNA. For zebrafish, RNA was 
isolated from single embryos using the MIRneasy micro kit (Qiagen). 
This kit permits the extraction of RNA from reduced starting cell 
population.  
RNA quality was measured by the RNA integrity number (RIN) using 
the TapeStation system. RIN is an algorithm used to assess RNA 
integrity by gel electrophoresis (Figure 70). Only samples that 
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Figure 70. Example from RIN score quantification. (A) Images from a RNA 
electrophoresis with RIN score calculations. (B). Example of a RNA spectrum with a 
high RIN score >9.  
Library preparation was performed using Lexogen’s QuantSeq kit FWD 
HT. This kit allows a high-throughput library preparation and sample 
multiplexing generating Illumina-compatible libraries. Library size 
generated from this kit should be between 200 and 350 base pairs (bp). 
After sample multiplexing, a final library was generated. Library size 
was measured by TapeStation DNA electrophoresis (Figure 71). 
Library size was within the recommended size with a mean of 262 bp. 
Sequencing was performed using Illumina NextSeq 500 System with 
NextSeq 500/550 high output kit of 75 cycles. Library preparation and 
sequencing was performed during a three weeks internship at Novo 
Nordisk Research Centre Oxford (NNRCO).  
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Figure 71. Assessment of library size quantification after multiplexing. Prior to 
sequencing, a combination of the different samples into a master library was performed 
and library size quantified.  
 
5.2.2 Differential expression analysis 
Following sequencing, mapping and gene counting was performed by 
our collaborators at NNRCO. Next, differential expression and pathway 
enrichment analysis were performed using R programming. DEseq2 
package was used for DEGs quantification and pathway viewer 
package for pathway enrichment (216). Analysis was performed 
comparing paracetamol + DMF versus paracetamol, p adjusted value 
> 0.05 was chosen as a threshold to detect DEGs. Then, only genes 
that displayed log2 Fold Change ± 0.58 were selected for downstream 
analysis; ±0.58 log2 Fold Change equals a 1.5 fold change gene 
expression (224). In addition, EnrichR, a web-based tool for gene list 
enrichment analysis was used (217). Gene expression analysis was 
focused on the DMF + paracetamol versus paracetamol in the different 
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Finally, Gene Set Enrichment Analysis (GSEA) from the analysed data 
after DEseq2 was performed. GSEA evaluates gene expression changes 
at the level of gene sets to identify the relevant biological process 
involved with the expression changes (218). In combination with GSEA, 
the molecular signatures database (MSigDB) hallmarks gene sets were 
used for the enrichment analysis (225). MSigDB hallmarks consist of 
50 refined gene sets involved in key biological processes involved in 
metabolism, proliferation, cell signalling, immune response, DNA 
damage, development, cell singling pathways and cellular components. 
By using MSigDB, RNA-seq results can be refined from gene lists into 
biological changes.  
 
5.2.2.1 HLCs pre-treatment transcriptomic analysis 
Before performing gene expression analysis, sample variability of the 
pre-treatment was examined and visualised by performing principal 
component analysis and heatmap visualisation of the top 200 genes. 
For the PCA plot, two factors were created using R and samples were 
clustered by treatment and shaped by replicates (Figure 72). 
Replicate-to-replicate variations were observed. Heatmap of the top 
200 most variable genes was performed for sample hierarchical 
clustering (Figure 73). Notably, paracetamol-treated versus vehicle 
clustered separately, facilitating analysis.  
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Figure 72. PCA plot of HLCs pre-treatment clusters the different treatments 
differently. PCA plot from HLCs pre-treatment, colours were used for the different 
conditions, shape for replicates. P_DMF = paracetamol + DMF. 
 
Following further analysis, differential gene expression analysis was 
performed using DESeq2 (216). Threshold applied for DEGs detection 
was p adjusted value > 0.05 and log2 Fold Change ± 0.58. From all the 
genes, 76% (14010) displayed a low count value and they were omitted 
from the detection analysis. DEseq2 analysis from DMF + paracetamol 
treated group versus paracetamol showed an upregulation of 22 genes 
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Figure 73. Replicate variability assessment using heatmap visualisation. 
Heatmap with the top 200 most variable genes clusters the replicates from the 
different conditions together.  
 
The top 5 upregulated DEGs from DMF treatment included enzymes 
involved in cell protection such as phase I drug metabolism enzymes: 
prostaglandin reductase 1 (PTGR1) and NQO1, as well as phase II 
proteins glutathione S-transferase alpha 1 (GSTA1) and glutathione S-
transferase alpha 2 (GSTA2) and the Electron Transfer Flavoprotein 
Subunit Beta (ETFB) (Table 12A).  
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On the other hand, downregulated DEGs included transcripts that are 
involved in cytoskeleton maintenance and cell-to-cell contact including 
claudin 6 (CLDN6), cell metabolism solute carrier family 2 member 3 
(SLC2A3), a member of the short chain dehydrogenases/reductases 
family Dehydrogenase/Reductase 7 (DHRS7), Tropomyosin 1 (TPM1) 
and Neurogranin (NRGN) (Table 12B).  
 
To help elucidate the protective mechanism of the DEGs in HLCs 
protection, DEG gene list was uploaded into EnrichR and 
Wikipathways (226) and pathway enrichment analysis was performed. 
Pathway enrichment analysis of the upregulated DEGs showed 
interaction in several pathways such as Nrf2 pathway wikipathway 
(WP) 2884, estrogen metabolism WP697, transcriptional activation by 
Nrf2 WP3, aryl hydrocarbon receptor pathway WP2873 and zinc 
homeostasis WP3529 (Table 13A).  
 
Table 12. Differential expressed genes in DMF + Paracetamol 
versus paracetamol in pre-treatment HLCs. (A) Top 25 upregulated 





Transcriptomic analysis of drug-induced hepatotoxicity with and 197  
without therapeutic intervention with dimethyl fumarate  
In the downregulated DEGs, pathway enrichment analysis showed an 
interaction with several pathways including Nrf2 pathway WP2884, IL-
1 signalling pathway WP37/WP195, striated muscle contraction 
WP383, RANKL/RANK signalling pathway WP2018 and glycolysis and 
gluconeogenesis WP534 (Table 13B).  
Finally, GSEA-MSigDB analysis shows a positive enrichment in 
multiple pathways including adipogenesis, xenobiotic metabolism, 
oxidative phosphorylation or fatty acid metabolism. It also shows a 
reduction in TNFA signalling via Nf-kb, epithelial mesenchymal 
transition, apical junction or apoptosis (Figure 74). 
Enrichment analysis from both wikipathways and GSEA-MSigDB 
suggests that DMF pre-treatment increased the metabolic capacity of 
the cell via Nrf2 activation prior to paracetamol administration. This 
prevented the development of pro-injury mechanisms such as Nf-kb 
activation or apoptosis.  
 
 




Table 13. Pre-treatment pathway enrichment analysis using Wikipathways. (A) 
pathways enrich from the upregulated DEGs. (B) Pathways enriched from the 
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Figure 74. GSEA-MSigDB enrichment analysis from HLCs pre-treatment RNA-
seq dataset. Graph represents the normalized enrichment score from the 50 
hallmarks, these hallmarks are representative of important biological processes. In 
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5.2.2.2 HLCs co-treatment transcriptomic analysis 
Prior to gene expression analysis, data exploration of the co-treatment 
was visualised by performing PCA and heatmap visualisation of the top 
200 genes with higher variability. For the PCA plot, two factors were 
created and samples were clustered by treatment and shaped by 
replicates (Figure 75). Replicate-to-replicate variations were observed 
but conditions were separated based on the two components. Heatmap 
visualisation of the top 200 most variable genes showed a clear 
difference between vehicle treated HLCs and the other two treatments, 
paracetamol or DMF + paracetamol (Figure 76).  
 
 
Figure 75. PCA plot of HLCs co-treatment clusters the different treatments 
differently. PCA plot from HLCs co-treatment, colours were used for the different 
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Figure 76. Replicate variability assessment using heatmap visualisation. 
Heatmap with the top 200 most variable genes clusters the replicates from the 
different conditions together. 
Following data exploration, differential expression analysis was 
performed using DESeq2 as explained before. The detection threshold 
applied was p adjusted value > 0.05 and log2 Fold Change ± 0.58. From 
all the genes, 79% (16444 genes) displayed a low count value and they 
were omitted from the detection analysis. DEseq2 analysis from DMF 
+ Paracetamol treated group versus paracetamol showed an 
upregulation of 9 genes (Table 14A) and a downregulation of 37 genes 
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Table 14. Differential expressed genes in DMF + Paracetamol versus paracetamol in 
co-treatment HLCs. (A) Upregulated genes (B) Top 25 downregulated genes. lfcSE = 
standard error value. 
DEGs upregulated by the co-treatment of DMF + paracetamol versus 
paracetamol include: ATP Binding Cassette Subfamily A Member 1 
(ABCA1), a cholesterol transporter, Ubiquitin Protein Ligase E3 
Component N-Recognin 4 (UBR4) and UBR5 which form part of the N-
end rule pathway, Nidogen 1 (NID1), dual oxidase 2 (DUOX2) and 
Tetratricopeptide Repeat Domain 37 (TTC37) (Table 14A).  
Downregulated DEGs include Tissue Factor Pathway Inhibitor 2 
(TFPI2), Tumor Associated Calcium Signal Transducer 2 (TACSTD2), 
Serpin Family B Member 8 (SERPINB8), Natriuretic Peptide B (NPPB) 
and Spermine Oxidase (SMOX) (Table 14B).  
Pathway enrichment analysis of the upregulated DEGs include SREBF 
and miR33 in cholesterol and lipid homeostasis WP2011, Nuclear 
Receptors in Lipid Metabolism and Toxicity WP299, Tryptophan 
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WP465. On the other hand, pathway enrichment from the 
downregulated DEGs include Cytoplasmic Ribosomal Proteins WP477, 
Pathogenic Escherichia coli infection WP2272, EGFR1 Signaling 
Pathway WP572, Quercetin and Nf-kb/ AP-1 Induced Cell Apoptosis 
WP2435 and TP53 Network WP1742 (Table 15).  
Finally, GSEA-MSigDB analysis shows a positive enrichment in 
multiple pathways including mitotic spindle, protein secretion, G2M 
checkpoint and fatty acid metabolism. In addition, there was a 
reduction in several hallmark pathways including TNFA signalling via 
Nf-kb, P53 pathway, UV response, KRAS signalling, inflammatory 
response and apoptosis (Figure 77).  
Enrichment analysis from both pathway enrichment analyses suggests 
that in the co-treatment scenario, DMF cytoprotection was driven by a 
dual mechanism. This was mainly due to an increase in the metabolic 
capacity of the HLCs as well as by stopping the progression of pro-
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Table 15. Co-treatment pathway enrichment analysis using Wikipathways. (A) 
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Figure 77. GSEA-MSigDB enrichment analysis from HLCs co-treatment RNA-seq 
dataset. Graph represents the normalized enrichment score from the 50 hallmarks, 
these hallmarks are representative of important biological processes. In blue are labelled 
the hallmarks with an adjusted p value < 0.05. 
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5.2.2.3 HLCs post-treatment transcriptomic analysis 
 
For the post treatment group, only two biological replicates were 
sequenced due to time limitations, an extra replicate will be performed 
in the future. Despite the reduced replicate number, it is still possible 
to perform quantitative analysis from two replicates with reduced 
biological variability. By using a lower number of replicates, only genes 
with the largest effect size will be detected (227). In addition, 
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Data exploration was performed as explained before, and a PCA plot 
was created to visualise condition variation. All three conditions 
showed a clear separation in the PCA plot (Figure 78). In addition, a 
heatmap of the top 200 genes with higher variation was created.  
Similar clustering was observed, where vehicle-treated HLCs cluster 
separately from the post-treated groups and the replicates cluster 
together (Figure 79). These results highlight a reduced variability 
between replicates permitting subsequent analysis.  
Following data exploration, differential expression analysis was 
performed using DESeq2 as explained before. The detection threshold 
applied was p adjusted value > 0.05 and log2 Fold Change ± 0.58. 
During the analysis, 13380 genes displayed low counts and it was not 
 
Figure 78. PCA plot of HLCs post-treatment clusters the different treatments 
differently. PCA plot from HLCs post-treatment, colours were used for the different 
conditions, shape for replicates. P_DMF = paracetamol + DMF. 
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possible to include them into the analysis. Only 21% of the total counts 
passed the quality control required for DEseq2 analysis. From the 
DEGs obtained from the analysis from DMF + Paracetamol treated 
group versus paracetamol, 5 genes were upregulated (Table 16A) and 
32 were downregulated (Table 16B shows top 25 genes, for full list see 
supplementary information).  
DEGs upregulated by the post-treatment of DMF+paracetamol versus 
paracetamol included DUOX2, Sodium Channel Epithelial 1 Alpha 
Subunit (SCNN1A), Tripartite Motif Containing 71 (TRIM71) or Nuclear 
Enriched Abundant Transcript 1 (NEAT1) and Nuclear Protein 1 
(NUPR1) (Table 16A).  
Downregulated DEGs include: C-C Motif Chemokine Ligand 3 Like 1 
(CCL3L1), CD44, Cytoskeleton Regulator RNA (CYTOR), MIR4435-2GH 
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Figure 79. Replicate variability assessment using heatmap visualisation. 
Heatmap with the top 200 most variable genes clusters the replicates from the 
different conditions together. 
Following DEGs acquisition, pathway enrichment of the upregulated 
DEGs showed an increase in several pathways including NOD pathway 
WP1433, endochondral ossification WP474 and spinal cord injury 
WP2431. Pathway enrichment analysis from the downregulated DEGs 
showed interactions with several pathways including: focal adhesion-
PI3K-Akt-mTOR-signaling pathway WP2841, TGF-beta signalling 
pathway WP366 and Nrf2 pathway WP2884 (Table 17). 
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Finally, GSEA-MSigDB analysis shows a positive enrichment in 
multiple pathways, including interferon alpha response, bile acid and 
fatty acid metabolism and xenobiotic metabolism. In addition, there 
was a reduction in several hallmark pathways including TNFA 
signalling via Nf-kb, MYC targets, TGF-b signalling pathway, P53 
pathway, inflammatory response and apoptosis (Figure 80). 
In the post-treatment scenario, enrichment analysis from both 
wikipathways and GSEA-MSigDB suggests that DMF protection was 
achieved from the downregulation of genes involved in multiple pro-
injury pathways. In addition, DMF increased the xenobiotic 




Table 16. Differential expressed genes in DMF + Paracetamol versus 
paracetamol in post-treatment HLCs. (A) Upregulated genes (B) Top 25 
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Table 17. Post-treatment pathway enrichment analysis using Wikipathways. (A) 
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Figure 80. GSEA-MSigDB enrichment analysis from HLCs post-treatment RNA-
seq dataset. Graph represents the normalized enrichment score from the 50 
hallmarks, these hallmarks are representative from important biological processes. In 
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5.2.2.4 Zebrafish transcriptomic analysis 
Data variability from the zebrafish data was assessed using PCA. Total 
gene counts from the sequencing was transformed into two 
components. The PCA plot on Figure 81 shows conditions by colours 
and replicates by shape. Different conditions are separated in the PCA 
plot but there is variability between replicates. Heatmap of the top 200 
most variable genes was performed for sample hierarchical clustering. 
Heatmap shows some variability between clustering replicates of the 
same condition together: one of the replicates from the paracetamol 
treated group was clustered with the vehicle group and one of the DMF 
+ paracetamol group was clustered alone (Figure 82). This variability 
reduces the power of the DEseq2 analysis. 
 
Figure 81. PCA plot zebrafish clusters the different treatments differently. PCA 
plot from zebrafish, colours were used for the different conditions, shape for replicates. 
D_P = paracetamol + DMF. 
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Following data exploration, differential expression analysis was 
performed using DESeq2 as explained before. The detection threshold 
applied was p adjusted value > 0.05 and log2 Fold Change ± 0.58. 
During the analysis, 9395 genes displayed low counts and it was not 
possible to include them into the analysis. Only 53% of the total counts 
passed the quality control required for DEseq2 analysis. From the 
DEGs obtained from the analysis from DMF + Paracetamol treated 
group versus Paracetamol, 30 genes were upregulated and 10 were 
downregulated (Table 18) 
 
Figure 82. Replicate variability assessment using heatmap visualisation. 
Heatmap with the top 200 most variable genes clusters the replicates from the 
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From the upregulated DEGs, the top 5 include: transcobalamin beta a 
(tcnba), several members of the crystallin family (crygm), structural 
protein of eye lens and the cornea and the sequencing conting, 
CABZ01080568.1. Nucleoporin 160 (nup160) is expressed within the 
CABZ01080568 conting (Table 18A). 
Downregulated DEGs included 3-hydroxyanthranilate 3, 4- 
dioxygenase (haao), the LOC100149563 which is homologous to the 
human gene HtrA serine peptidase 2 (HTRA2), F-Box Protein 32 
(fbxo32) and apolipoprotein Da, duplicate 1 (apoda.1), Retinoid 
Isomerohydrolase (rpe65a) (Table 18B)  
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Pathway enrichment of the upregulated DEGs showed an increase in 
several pathways including IL-3 Signaling Pathway WP373, 6 signaling 
Pathway WP387, IL-7 Signaling Pathway WP205 and p38 MAPK 
Signaling Pathway WP350. Pathway enrichment analysis from the 
downregulated DEGs showed interactions with several pathways 
including NAD biosynthesis II WP2485, tryptophan metabolism WP79 
and monoamine transport WP727 (Table 19).  
 
Table 18. Differential expressed genes in DMF + Paracetamol versus paracetamol 
in zebrafish. (A) Top 25 upregulated genes and (B) Downregulated genes. lfcSE = 
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Table 19. Zebrafish pathway enrichment analysis using Wikipathways. (A) 
pathways enriched by the upregulated DEGs. (B) pathways enriched by the 
downregulated DEGs. 
 
Finally, zebrafish gene names were converted into human homologues 
and GSEA-MSigDB analysis was performed. There was a positive 
enrichment in multiple pathways including MYC targets, oxidative 
phosphorylation, reactive oxygen species pathway, DNA repair, 
apoptosis and G2M checkpoint. There were no significant hallmark 
decreases (Figure 83). 
In zebrafish, enrichment analysis from both Eikipathways and GSEA-
MSigDB highlights an increase in several cellular stress mechanisms 
as well as a reduction in the zebrafish metabolic capacity.  
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Figure 83. GSEA-MSigDB enrichment analysis from the zebrafish RNA-seq dataset. 
Graph represents the normalized enrichment score from the 50 hallmarks, these 
hallmarks are representative of important biological processes. In blue are labelled the 
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5.3 Discussion 
In the previous chapter we investigated the cytoprotective effects of 
DMF in the context of paracetamol hepatotoxicity. To try to elucidate 
the mechanism of action of DMF, mRNA sequencing was performed in 
both HLCs and zebrafish. RNA-seq analysis was focused in the 
differences between paracetamol + DMF versus paracetamol alone. In 
HLCs, gene regulation changes following DMF treatment were assessed 
in the three different scenarios pre, co and post treatment. This 
approach would elucidate any potential time-dependent effect of the 
DMF treatment. Finally, translation of these findings to a zebrafish in 
vivo model was performed. Gene function of the DEGs in the context 
of liver disease was investigated.  
5.3.1 HLCs pre-treatment gene expression 
HLCs pre-treated with DMF displayed an increase in antioxidant 
capacity as shown by the upregulation of several enzymes from phase 
I drug metabolism such as NQO1 or prostaglandin reductase 1 
(PTGR1). The function of NQO1 is to reduce quinones to 
hydroquinones. This prevents the production of radical species by 
preventing the one electron reduction of quinones (228). Whereas 
PTGR1 encodes an oxidoreductase involved in the inactivation of the 
chemotactic factor, leukotriene B4 by converting leukotriene B4 to 12-
oxo-leukotriene B4. PTGR1 is regulated by Nrf2 promoting cell 
proliferation and resistance to oxidative stress (229). In addition, there 
was an increase in glutathione metabolism as shown by the 
upregulation of glutathione S-transferase alpha 2 (GSTA2) and 
glutathione S-transferase alpha 1 (GSTA1). GSTA1 and GSTA2 are 
detoxification enzymes, part of the glutathione S-transferase (GST) 
alpha families, highly expressed in the liver (230). Cytoprotective 
effects of GSTs are based on the conjugation of reduced glutathione to 
xenobiotics (231,232). Expression of GSTs is regulated in part by Nrf2 
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(94). Upregulation of these enzymes prior to paracetamol-induced 
hepatotoxicity could explain the protective effects of DMF.  
Moreover, there was an upregulation of several genes responsible for 
cell metabolism and lipid metabolism. Genes involved in cell 
metabolism include homogentisate 1,2-dioxygenase (HGD) and 
electron transfer flavoprotein subunit beta (ETFB) (233,234). In 
contrast, Dual specificity phosphatase 9 (DUSP9) and apolipoprotein 
C3 (APOC3) are involved lipid metabolism (235,236). These results 
indicate that DMF pre-treatment induced cell metabolism, which could 
improve cell health following paracetamol administration.  
However, HLCs treated without DMF exhibited an upregulation of 
genes involved in several injury pathways including apoptosis, 
tumourgenesis, TGF-b activation or inducing inflammation. 
CLDN6 is a tight junction membrane protein. Upregulation of CLDN6 
has been shown to induce apoptosis and stop cell growth (237,238). In 
addition, changes in claudins expression can affect hepatocyte polarity 
leading to tumour formation (239–241). In addition, several genes that 
were identified in this dataset are involved in hepatocellular carcinoma 
development. These genes include SLC2A3, DHRS7, NRGN and KRT19.  
First, SLC2A3 forms part of the glucose transporter family, 
upregulation of glucose transporters are linked to some cases of 
hepatocellular carcinoma (242). Interestingly, DHRS7 expression has 
been reported to be upregulated during rat liver regeneration process 
as well as downregulated in advanced HCC (243,244). Next, TPM1 is 
considered a tumour suppressor gene, TPM1 aberrant regulation is 
controlled by TGF-b induced epithelial–mesenchymal transition (EMT) 
(245). TPM1 downregulation has been linked with poor cancer 
prognosis (246). Despite NRGN being a neuron specific gene, Daust et 
all showed an upregulation of NRGN in liver progenitor cells from rats 
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promoting compounds (247). In this work NRGN was only reported not 
investigated. Further work would be required to fully understand the 
effect of NRGN expression in liver biology. To conclude, KRT19 is a 
member of the keratin family. KRT19 is expressed in hepatic progenitor 
cells (HPCs) (248) as well as a marker of hepatocellular carcinoma 
(249).  
Finally, SQSTM1 or p62/SQSTM1 is a stress-inducible scaffold protein 
that regulates autophagy. p62/SQSTM1 is involved in multifunctional 
processes including apoptosis, inflammation, regulation of endosomal 
trafficking as well as activating Nrf2 via KEAP1 degradation (250,251). 
These results suggest that the gene response triggered by the DMF pre-
treatment stopped the development of a pro-injury gene response.  
These findings were further validated by GSEA analysis. DMF-treated 
group showed an increase in several hallmarks involved in protein 
secretion, G2M checkpoint or fatty acid metabolism. In addition, there 
was a reduction in several pro-injury hallmarks such as TNFA 
signalling via Nf-kb, apoptosis or epithelial mesenchymal transition 
(Figure 74).  
From these results, I hypothesise that pre-treatment of DMF drove an 
upregulation of the drug metabolism and antioxidative stress 
machinery in HLCs prior to paracetamol administration. This led to an 
improved ROS management resulting in an increased cell survival and 
higher metabolic activity of the cell. This would be achieved by stopping 
the excessive generation of NAPQI due to the upregulation of Phase I 
and Phase II enzymes. By doing this, the development of a pro-injury 
environment was stopped as evidenced by the decrease in the different 
pro-inflammatory hallmarks shown in the GSEA analysis (Figure 84).  
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Figure 84. Proposed mechanism of action of DMF cytoprotection in the pre-
treatment. During DMF pre-treatment, Nrf2 activation upregulates phase I and 
phase II genes. This leads to a better stress management after paracetamol 
administration and NAPQI generation. Figure drawn by author.  
 
5.3.2 HLCs co-treatment gene expression 
In the co-treatment scenario, DMF treatment upregulated genes 
involved in lipid metabolism (ABCA1), cell survival (UBR4 and UBR5) 
or NADPH metabolism (DUOX2). In hepatocytes, ABCA1 depletion 
impairs lipogenesis and insulin signalling (252) and is regulated by 
Nrf2 (253). UBR4 it has been found to be essential for membrane 
morphogenesis and cell survival. Loss of UBR4 induces cells to 
undergo apoptosis by cell detachment (254). UBR5 is involved in 
multiple processes such as progesterone-regulated cell proliferation, 
DNA repair and tumorigenesis (255,256). NID1 is a basement 
membrane glycoprotein involved in cell interactions with the 
extracellular matrix. NID1 methylation has been shown in 
gastrointestinal cancer (257). Finally, DUOX2 has been shown to be 
upregulated during alcohol hepatitis and as a marker of hepatocellular 
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Moreover, TTC37 was upregulated. Whilst little is known about the 
function of TTC37, its function might be involved in mediating protein-
to-protein interactions or chaperone activity. TTC37 mutations are the 
cause of trichohepatoenteric syndrome, an untreatable disorder with 
multiple organ defects such as life-threatening diarrhoea during 
infancy, immunodeficiency or liver disease among other symptoms 
(260). TTC37 mutations might cause changes in transporter proteins. 
Further research would be necessary to understand the TTC37 
function during paracetamol injury.  
But the main effect detected from DMF co-treatment was not an 
upregulation of a battery of xenobiotic metabolic enzymes as shown in 
the pre-treatment scenario but to block the development of a pro-injury 
pathway activation. HLCs treated with paracetamol only exhibited an 
upregulation of genes involved in TGF-b activation, inflammation or 
tumour progression.  
Indications of TGF-b activation were observed by the detection of 
SERPINB8 and SEMA7A. SERPINB8 is a member of the serine 
proteases family and is mainly expressed in platelets (261). SERPIN 
proteins inhibit target proteins by conformational changes. SERPINB8 
inhibits furin, a serine protease involved in platelet activity. SERPINB8 
upregulation has been detected during a TGF-b/TNFa induction of 
EMT in lung cancer cells (262). In addition, SERPINB8 upregulation 
was included in a molecular fibrosis signature dataset from a non-
alcoholic steatohepatitis (NASH) mouse model (263). Next, 
Semaphorin7A (SEMA7A) expression indicates an induction of a pro-
fibrotic environment. SEMA7A is a membrane protein involved in 
inflammatory responses and fibrosis and its expression can be induced 
via TGF-b (264). In mice, SEMA7A overexpression induced a profibrotic 
response in liver. These findings were corroborated in human liver 
samples where SEMA7A expression was increased in patients with 
liver fibrosis (265). 
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Development of a pro-inflammatory response was observed by SMOX 
expression. SMOX upregulation is induced during cell stress and 
inflammation (266). SMOX catalyses the oxidation of spermine to 
spermadine and hydrogen peroxide as a secondary product. 
Finally, HLCs treated with paracetamol only expressed genes involved 
in tumour development. These genes include TACSTD2, NPPB and 
TFPI2. TACSTD2 is a carcinoma-associated antigen. TACSTD2 
expression has been detected in KRT19-positive HCC (267). NPPB is a 
cardiac hormone secreted by cardiomyocytes. Upregulation of NPPB in 
non-cardiomyocyte cell types has been linked with an aggressive 
osteosarcoma and it is also expressed in cancer-associated fibroblasts 
in ovarian tumours (268,269). Interestingly, TFPI2 has tumour 
repressor activities by inhibiting plasmin- and trypsin-matrix 
metalloproteinases, and this leads to reduced tumour progression and 
metastasis. TFPI2 methylation has been found in some forms of HCC 
(270,271).  
Results from the GSEA analysis from the co-treatment show a similar 
trend as the one described from the DEGs. DMF-treated cells displayed 
hallmarks involved in cell homeostasis such as mitotic spindle or G2M 
checkpoint and hallmarks involved in cell metabolism like fatty acid 
metabolism or protein secretion. Most of the changes detected from the 
GSEA analysis were from downregulation of pro-injury hallmarks. 
These hallmarks include TNFA signalling via Nf-kb activation, 
apoptosis, P53 pathway, IL2 STAT5 signalling or reactive oxygen 
species response.  
From these results, I hypothesise that DMF co-treatment protection is 
due to a dual mechanism of action. On the one hand, DMF induced 
the expression of several Nrf2 target genes involved in cell metabolism 
and survival (ABCA1, UBR4, UBR5 and DUOX2). On the other hand, 
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Dimethyl fumarate has been shown to block Nf-kb activation by a 
covalent modification of p65, a subunit of Nf-kb transcription complex. 
DMF inhibits the nuclear translocation blocking the DNA binding 
activity of phosphorylated p65 (130,131). In addition, DMF mediated 
Nrf2 activation has been shown to block TGF-b1 activation by 
interacting and blocking Smad3 protein activity in a model of renal 
fibrosis (206). Similar results have been shown in hepatocytes. Oh et 
al showed a TGF-b 1 inhibition in hepatocytes via a reduction of Smad3 
phosphorylation following exposure to sulforaphane which is a Nrf2 
inducer (272). In addition, Nrf2 activation reduced hepatic stellate cell 
activation into myofibroblasts via Smad3 inhibition (273) .  
 
Figure 85. Proposed mechanism of action of DMF cytoprotection in the co-
treatment. During DMF co-treatment, Nrf2 activation induces cell metabolism as 
well as blocking phase I and phase II genes. This leads to a better stress management 
after paracetamol administration and NAPQI generation. Moreover, DMF inhibited 
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5.3.3  HLCs post-treatment gene expression 
DMF post-treatment induced the expression of genes involved in cell 
proliferation and xenobiotic metabolism. Genes involved in cell 
proliferation include NEAT1, TRIM71 and NUPR1. Firstly, NEAT1 
upregulation promotes cell proliferation by reducing apoptosis in 
hepatocellular carcinomas (274,275). Next, TRIM71 has been shown to 
target p53 to stop cell death and promote differentiation (276). Lastly, 
NUPR1 is a stress inducible protein and it has been shown to be 
essential for cell survival and proliferation of HCC (277,278).  
Moreover, an increase in xenobiotic metabolism was observed by the 
upregulation of GSR. GSR is an antioxidant enzyme that reduces 
GSSG replenishing GSH and is regulated by Nrf2 (279). Therefore, 
NAPQI damage can be reduced by replenishing GSH (183). Finally, 
upregulation of SCNN1A was detected. SCNN1A is a sodium channel 
and its inhibition has been shown to reduce hepatitis B infection (280). 
Similar to co-treatment, the main effect observed from the post-
treatment was not from the gene upregulation but from a 
downregulation of genes involved in multiple pro-injury pathways. 
HLCs treated with paracetamol only exhibited an upregulation of genes 
involved in Nf-kb and TGF-b activation, inflammation or tumour 
progression. From these genes, CD44 is a cell surface glycoprotein 
involved in cell-to-cell interactions. CD44 has been seen shown to be 
increased in paracetamol-induced hepatotoxicity and is regulated 
through Nf-kb activation (281).  
Following this, TGF-b activation was observed by the detection of 
MIR4435-2GH, TAGLN and ITGA2. High expression of MIR4435-2GH 
has been linked with poor prognosis in several cancers by inducing cell 
proliferation via b-catenin activation (282,283). Moreover, a positive 
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squamous cell carcinoma (284). In addition, transgelin (TAGLN) and 
integrin a2 (ITGA2) are regulated by the TGF-b pathway (285,286).  
In addition, CYTOR and EST1 upregulation has been found in some 
cases of hepatocellular carcinoma. CYTOR is a long noncoding RNA, 
that has been shown to be upregulated in hepatocellular carcinoma 
(287,288). Finally EST1 is a transcription factor involved in many cell 
processes such as cell proliferation and angiogenesis (289). EST1 
overexpression has been found in HCC (290). Interestingly, ETS1 has 
been reported to play a role in hepatic stellate cell activation during 
Non-alcoholic steatohepatitis (NASH) development (291). Lastly, 
CCL3L1 upregulation has been linked to an increased susceptibility to 
acute rejection following liver transplantation (292). GSEA analysis 
from the post-treatment data showed similar results. Analysis showed 
an enrichment in hallmarks involved in xenobiotic metabolism or bile 
acid and fatty acid metabolism. This was accompanied by a decrease 
in pro-injury hallmarks such as TNF-a signalling via Nf-kb, TGF beta 
signalling, apoptosis or epithelial mesenchymal transition (Figure 80).  
In the post-treatment scenario, DMF was administrated after 
paracetamol and NAPQI-induced cell damage. Similar to the co-
treatment, I hypothesise that DMF protection in the post-treatment 
scenario is due to a dual mechanism. This entails an induction of cell 
proliferation and oxidative stress management, whilst inhibiting the 
progression of Nf-kb and TGF-b activation.  
In the previous chapter we observed that in the post-treatment 
scenario only DMF was able to recover cell viability. Cell recovery was 
not observed with NAC post-treatment (Figure 62). The combination 
of the proposed hypothesis obtained from the RNA-seq data with the 
cytoprotective effects observed in the previous chapter highlight a 
potential clinical therapy for acute liver diseases. DMF cytoprotection 
was achieved by a multi-factor response including Nrf2 activation and 
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the inhibition of Nf-kb and TGF-b response. The protective mechanism 
could be similar to a recent study by Bird et al (57) where they showed 
that TGF-b inhibition following paracetamol injury induces liver 
regeneration by blocking injury-induced senescence. Similar processes 
occur in our case where HLCs treated with DMF show an upregulation 
of proliferative markers and a reduction of senescence markers such 
as p53 or KRAS (293). Further work is required to validate the role of 
senescence inhibition in the cytoprotective properties of DMF (Figure 
86). 
 
Figure 86. Proposed mechanism of action of DMF cytoprotection in the post-
treatment. In the post-treatment scenario, DMF was administrated after paracetamol 
and NAPQI-induced cell damage. DMF cytoprotection was due to multiple-factors. First 
DMF increased the glutathione replenishing capacity of the HLCs. Moreover, DMF 
inhibited Nf-kb and TGF-b activation reducing necrosis and inflammation. Figure 
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5.3.4  Zebrafish cytoprotective gene regulation.  
In the zebrafish scenario, DMF pre-treatment showed an increase in 
several genes including tcnba, nup160 and members of the crystallin 
family. In zebrafish, tcnba is expressed in the intestinal bulb and it 
plays a role in vitamin B12 transport (294). nup160 is expressed in the 
kidney, where nup160 knockdown in mice induced apoptosis and cell 
migration as well as inhibiting cell proliferation in podocytes, a member 
of the kidney glomerulus (295). In addition, abnormal development 
following paracetamol administration could explain the changes found 
in the crystallin family overexpression in the DMF-treated group. Pinto 
et al showed that liver X Receptors (LXRs) are responsible for crystallin 
expression during zebrafish development (296). In addition, Saini et al 
reported that LXR activation increases paracetamol clearance in mice 
(297). This could indicate that in the paracetamol-treated group the 
reduction of crystallin might be related to a reduction of LXR activity 
which might impair paracetamol clearance, inducing liver damage and 
reduction of GFP in our model. Yan et al showed how curcumin 
reduced steatosis in a NAFLD mice model via the activation of Nrf2 and 
LXRs pathways (298). Further validation is required to confirm this 
proposed mechanism.  
In contrast, zebrafish treated with paracetamol only showed an 
increase in expression in several genes including haao, HTRA2, fbxo32, 
apoda.1 and rpe65a. Firstly, haao is an enzyme that catalyzes 
quinolinic acid (QUIN) synthesis from 3-hydroxyanthranilic acid 
Excessive production of QUIN can lead to oxidative stress and it has 
been shown to cause neurologic damage (299). Downregulation of haao 
is correlated with poor HCC prognosis due to alterations in 
nicotinamide adenine dinucleotide (NAD+) metabolism (300).  
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Next, HTRA2 is a pro-apoptotic mitochondrial protein via caspase 
activation (301,302). fbxo32 is a novel TGF-beta/SMAD4 target gene 
and it is involved in phosphorylation-dependent ubiquitination (303). 
fbxo32 methylation silencing was observed in ovarian cancer and it 
was associated with poor prognosis (303).  
In addition, apoda.1 encodes an apolipoprotein with lipid transport 
activity. apolipoprotein D (APOD) is its human homologue. APOD has 
been shown to be linked with several neurological disorders where ROS 
induced APOD expression (304). In addition, APOD expression has 
been shown to inhibit cell proliferation as well as being a direct target 
of p53 family members (305,306). Finally, rpe65a is a oxygenase 
member of the visual cycle of the retina (307).  
Interestingly, GSEA analysis showed an increase in several pro-injury 
markers of apoptosis and reactive oxygen species pathways, as well as 
an enrichment of genes involved in cell proliferation and DNA repair. 
One limitation of the GSEA analysis in this scenario is due to analysing 
zebrafish data in a dataset designed to analyse human data (225).  
From these results, we propose that the cytoprotective effects of DMF 
pre-treatment in zebrafish are due to the modulation of multiple 
pathways. Firstly, DMF-treated zebrafish showed an increase in 
metabolism and cell proliferation and this could be due to Nrf2 
activation. Even though no Nrf2 target genes were detected, the 
possible induction of LXR pathway involved in the crystallin expression 
might involve Nrf2 activation (298). On the other hand, DMF pre-
treatment reduced the development of cell apoptosis by the reduction 
of HTRA2, a pro-apoptotic mitochondrial protein. This mechanism 
could be mediated in part by p53 and TGF-b inhibition as shown by 
the reduction of fbxo32 and APOD expression (308,309). The lack of 
detection of Nrf2 target genes might be a result of the experimental 
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was performed 42 h post-administration of DMF. Further work is 
required to validate the mechanism proposed.  
5.3.5 Conclusion 
Findings from the RNA-seq highlight the protective mechanism of DMF 
shown in the previous chapter. DMF treatment not only activates Nrf2 
target genes but is also able to stop the development of a pro-injury 
response by inhibiting Nf-kb and TGF-b activation. These findings are 
novel in the context of paracetamol-induced hepatotoxicity. Moreover, 
these results have translational relevance from HLCs to zebrafish as 
TGF-b inhibition was also observed in the zebrafish RNA-seq. Finally, 
results showing cytoprotection in the post-treatment scenario where 
NAC efficacy was lost have interesting clinical relevance. These results 
suggest that DMF could represent a novel therapy to treat patients with 
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Drug-induced liver injury represents a major cause of acute liver 
failure, so to improve patient outcome it is necessary to develop new 
therapies (310). Nrf2 stimulation has been proposed as a potential 
therapy to reduce DILI severity. Nrf2 is a major regulator of 
cytoprotective genes involved in multiple processes such as oxidative 
stress management, glutathione synthesis, detoxification, drug 
excretion and NADPH synthesis (94). Dimethyl fumarate is a drug 
approved to treat relapsing multiple sclerosis and psoriasis; DMF 
beneficial effects are due in part to Nrf2 activation (191). The objective 
of this thesis was to investigate cytoprotective properties of dimethyl 
fumarate via Nrf2 stimulation during drug-induced hepatotoxicity. 
This was tested in both hepatocyte-like cells (HLCs) and in zebrafish.  
During my project, I developed a semi-automated platform to produce 
HLCs in 96-well plate format to study liver biology and disease 
modelling (67,89). Following platform optimisation, the effects of DMF 
in HLCs were investigated. DMF induced Nrf2 nuclear translocation 
and upregulated Nrf2 target genes. In addition, DMF displayed 
cytoprotective properties in the context of paracetamol-induced injury. 
This protection was Nrf2 dependent. Interestingly, DMF showed an 
increase in cell viability where NAC treatment was not effective. These 
findings were translated into a zebrafish model of paracetamol injury 
where pre-treatment with DMF protected zebrafish from paracetamol-
induced injury.  
To understand the cytoprotective mechanisms, RNA-sequencing was 
performed in both systems. In HLCs, DMF exhibited a time-dependent 
mechanism. From these results, the proposed mechanism during the 
pre-treatment scenario is that DMF cytoprotection is due to an 
upregulation of the drug metabolism and reduced oxidative stress. 
Meanwhile in the co- and post-treatment scenarios cytoprotection was 
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due to a reduction of spreading senescence and inflammation as well 
as by the induction of Nrf2 target genes. In zebrafish, we hypothesised 
that the protection could be due to Nrf2 activation as well as TGF-b 
inhibition. Further validation is required to confirm the mechanism 
proposed.  
Findings of this study are novel in the context of paracetamol-induced 
hepatotoxicity and could have clinical relevance providing a new 
therapy to treat patients with acute liver disease.  
6.2 Future perspectives 
Evidence from this project provides proof-of-concept for using DMF to 
reduce the severity of acute liver injuries. Further work is required to 
improve current in vitro models to better recapitulate human liver 
biology and this would allow a better understanding of DMF in the 
context of liver injury and provide better tools for regenerative medicine 
research. Going forward, further in vivo characterisation of these 
datasets is required to validate the proposed mechanisms of action of 
DMF. In addition, a mouse model of paracetamol induced liver injury 
could be used to study the effects on a mammal system. This would 
allow to study the immunomodulation effect of DMF in the immune 
system following the initial hepatocyte death caused by paracetamol 
overdose. 
6.2.1 Improved HLCs disease modelling 
Although the semi-automated differentiation platform allows a rapid 
and reproducible production of HLCs, further improvements could be 
implemented to better recapitulate situations in the clinic. This could 
be achieved by using panels of iPSC-derived lines that recapitulate 
genetic polymorphisms, CYP450 genotypes and sex differences. This 
work was performed using the female hESC line H9, by adding multiple 
lines from different donors, a better representation of human 
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variability could be achieved. By using iPSC derived HLCs, it might be 
possible to reduce significant sources of interindividual variability. In 
this regard, Takayama et al. generated 12 individual HLC lines that 
exhibited interindividual differences in drug metabolism that are 
similar to the ones found in the originating primary human 
hepatocytes (311). Drug-induced liver damage often occurs within pre-
existing hepatic illnesses such as NAFLD (312). These could be easily 
modelled in HLCs by combining current NAFLD models in the context 
of paracetamol injury (67).  
Nrf2 studies could also be improved by using an Nrf2 reporter line or 
an Nrf2 target gene reporter line. This would allow a real time 
quantification of Nrf2 dynamics upon treatment and time. Genome 
editing in hPSC could be performed using CRISPR/CAS technology 
(313,314). The potential of this approach can be seen by the recent 
work from Bischoff et al, (208), where HepG2 Nrf2 were tagged with 
GFP allowing a real time study of Nrf2 dynamics upon xenobiotic 
exposure. Finally, efficacy of DMF could be compared with recent 
compounds with slow and sustained release of MMF that would 
improve MMF bioavailability (96). These compounds include diroximel 
fumarate, currently in phase III clinical trial for MS (NCT03093324) or 
tepilamide fumarate, currently in phase II for psoriasis (NCT02173301) 
(96). Overall, the technology developed in this study provides an 
excellent tool to test the improvements suggested above.  
6.2.2 Nf-kb and TGF-b regulation by DMF treatment 
Here, we proposed that part of the cytoprotective properties of DMF 
was through the inhibition of both Nf-kb and TGF-b signalling 
pathways. Several studies have provided insights that DMF treatment 
inhibits Nf-kb activation via covalent modification of p65. DMF 
treatment blocks the nuclear translocation and DNA binding activity 
of p65 (130,131). In addition, TGF-b1 inhibition from DMF-mediated 
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Nrf2 activation has been reported in a model of renal fibrosis, where 
inhibition was due to an interaction between Nrf2 and Smad3 leading 
to a Smad3 inhibition (206).  
Further work would be focused on investigating the interactions 
between DMF, p65 and Smad3 in HLCs. This could be performed using 
the high content analysis pipeline developed in this study to quantify 
p65 nuclear translocation dynamics upon DMF treatment. In addition, 
TGF-b inhibition following paracetamol injury could promote liver 
regeneration by blocking senescence (57). This could be validated by 
staining for both senescence (p21, p16 or p53) and cell proliferation 
(Ki67) markers in the post-treatment scenario (57,293,315).  
Finally, the capacity of DMF to reduce the TGF-b induced fibrosis could 
be tested in an in vitro model of fibrosis by using stem cell-derived 
stellate cells (316). Recent work from Coll et al, developed a novel 
protocol to differentiate hepatic stellate cells from human pluripotent 
cells. These cells exhibit a quiescent phenotype but can develop a 
fibrogenic response secreting collagen and a-SMA expression in 
response to TGF-b (316). By using these cells, inhibition of TGF-b 
following DMF treatment in HLCs could be tested by culturing the 
stellate cells with the supernatant from the post-treatment.  
6.2.3 Three-dimensional (3D) cellular aggregates  
To date most of the work has been focused on monolayer differentiation 
of HLCs. Despite its advantages, monolayer HLCs do face some 
limitations including different cell-to-cell interactions, mixture of foetal 
and adult hepatocyte traits, lack of blood flow, and limited tissue 
organisation and as a consequence cannot recapitulate in vivo 
situations (78,90). To overcome these limitations, organoid and 3D 
aggregates have been developed showing promising results. Despite 
requiring more complex differentiation protocols, organoids and 3D 
systems better recapitulate human tissue structure and display a more 
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mature and functional phenotype such as improved cytochrome P450 
3A4 activity, higher expression of Phase II and III enzymes, reduction 
of foetal gene expression and longer lifespan (317,318). Recent work 
from Takebe et al reported a protocol to generate 3D ‘liver buds’ formed 
by hepatic endoderm, endothelial and mesenchymal progenitor cells 
generated from the same iPSC line (319). In addition, a recent study 
from Rashidi et al developed a stem cell-derived self-aggregation 
protocol to produce 3D liver tissue under defined conditions. These 3D 
liver tissues displayed a stable phenotype for over one year in culture, 
providing an attractive tool for long-term in vitro studies. In addition, 
the liver tissue generated provided liver support in immune-competent 
or -deficient mice (Fah−/− , Rag2 −/− and IL2rg−/− mice) with 
compromised liver function (320).  
Future work could be focused to study the cytoprotection of DMF in a 
3D system that better mimics liver injury. Although stem cell-derived 
3D liver models are promising, further work is required to determine 
the potential use of these systems for drug-induced liver injury 
prediction, repeated dosing or modelling human disease.  
6.2.4 In vivo translational work 
In this study, a zebrafish liver-GFP reporter line was used to validate 
the in vitro findings. Pre-treatment of DMF prevented GFP fluorescent 
loss. For the RNA sequencing, single embryos were used for total RNA 
preparation. To study the effect of DMF treatment in hepatocytes, 
hepatocyte sorting based on GFP intensity could be done in future 
experiments (321). One of the disadvantages of this approach could be 
the isolation of healthy hepatocytes expressing GFP, following injury, 
GFP expression could be altered leading into a hepatocyte 
underrepresentation. To solve this, whole embryo cell sorting could be 
performed. Further studies characterising the level of GFP loss upon 
injury at single cell level should be considered. In addition, 
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development of a post-treatment scenario in zebrafish would provide a 
more clinically relevant model to study DILI. Finally, these findings 
could be tested in a mouse model of paracetamol-induced 
hepatotoxicity. Mouse models are commonly used to study DILI. Their 
advantages are a better recapitulation of the human immune response 
following injury. In mouse models, paracetamol toxicity is 
characterised by the overproduction of NAPQI by CYP P450 proteins 
mimicking human physiology (322). With this, my studies might 
provide the foundation for a new clinical application of DMF to reduce 
acute liver injury.  
6.2.5 Potential risks of DMF induced Nrf2 stimulation in the 
clinic 
The safety of a potential DMF treatment for acute liver failure should 
be investigated prior drug repurposing into the clinic. DMF was 
approved by the FDA on 2013 as a treatment for multiple sclerosis 
and it has been used for more than 30 years for psoriasis treatment 
(121,122). Golf et al performed a long-term study called ENDROSE as 
a follow up study of the phase III clinical trial for DMF. ENDORSE 
focused on DMF treatment in patients with relapsing–remitting 
multiple sclerosis investigated the potential efficacy and safety (323). 
This study focused in a 14 years follow-up of patients treated with 
DMF. The main adverse events observed in patients were flushing 
and gastrointestinal alterations. These adverse events are common 
and tend to occur during within the first months after starting the 
treatment. The other main adverse event presented following long 
term DMF treatment is a reduction of neutrophils and lymphocytes 
counts. The clinical implications of the lymphopenia following DMF 
treatment are not completely understood. The immune response 
plays a key role during the initiation and resolution of acute liver 
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injury. Therefore, the interaction of DMF and the immune response 
during acute liver failure should be investigated to ensure safety. 
Another potential risk from Nrf2 stimulation could be an increase risk 
in cancer development. Maintained expression of cytoprotective genes 
via Nrf2 stimulation can lead into increased cell growth in cancer cells 
as well as chemoresistance (324,325). Nrf2-induced tumorigenesis has 
been observed in mutations in both Nrf2 and Keap1. Nrf2 mutations 
that lead to overactivation of Nrf2 have been observed in primary lung 
cancers and neck tumours (326). In addition, Keap1 mutations that 
reduce the Keap1 repressor activity have been reported in lung cancer 
(327). Therefore, DMF patients with those mutations could be at risk 
of developing more aggressive cancers. The potential correlation of 
DMF patients and cancer development was investigated in the 
ENDORSE study. Increased risk of malignancy was not observed in 
DMF-treated patients compared with general multiple sclerosis 
patients; Results from the ENDORSE study suggest that the mutations 
in Nrf2 have more carcinogenesis potential than Nrf2 stimulation as 
long term stimulation of Nrf2 via DMF treatment did not increase 
carcinogenesis. A new clinical application of DMF to reduce acute liver 
injury should investigate any potential adverse effects involved in liver 
disease.
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baseMean log2FoldChange lfcSE pvalue padj symbol 
ENSG00000154146 176.1492 -0.87921 0.235473 7.00E-06 0.000988 NRGN 
ENSG00000184697 430.7649 -0.76242 0.166474 2.00E-07 8.21E-05 CLDN6 
ENSG00000059804 799.089 -0.74165 0.171346 5.72E-07 0.000152 SLC2A3 
ENSG00000140416 1273.229 -0.69862 0.163399 7.42E-07 0.000186 TPM1 
ENSG00000100612 220.7108 -0.69833 0.248381 0.00017 0.013692 DHRS7 
ENSG00000171345 2596.852 -0.68819 0.114423 8.41E-11 7.60E-08 KRT19 
ENSG00000159674 721.8794 -0.65178 0.14468 3.01E-07 0.000105 SPON2 
ENSG00000023902 462.8413 -0.63449 0.15318 1.63E-06 0.000306 PLEKHO1 
ENSG00000120885 1067.668 -0.60927 0.154848 3.50E-06 0.000565 CLU 
ENSG00000135414 155.5532 -0.596 0.241361 0.000487 0.030177 GDF11 
ENSG00000153140 956.237 -0.59296 0.147858 2.66E-06 0.000463 CETN3 
ENSG00000161011 4552.491 -0.58536 0.124209 1.17E-07 5.87E-05 SQSTM1 
ENSG00000198730 870.5006 -0.56766 0.137643 1.76E-06 0.000319 CTR9 
ENSG00000148677 14628.68 -0.54212 0.129276 1.25E-06 0.000248 ANKRD1 
ENSG00000221890 849.8509 -0.51825 0.142292 1.27E-05 0.001553 NPTXR 
ENSG00000121060 220.4191 -0.48466 0.217785 0.000941 0.048888 TRIM25 
ENSG00000170456 425.2846 -0.47743 0.162212 0.000145 0.011888 DENND5B 
ENSG00000137070 235.1593 -0.47656 0.214939 0.00097 0.049805 IL11RA 
ENSG00000176014 2418.556 -0.46366 0.126835 1.27E-05 0.001553 TUBB6 
ENSG00000167772 463.9657 -0.46094 0.160644 0.000187 0.014789 ANGPTL4 
ENSG00000153048 1004.467 -0.4321 0.12796 3.77E-05 0.004017 CARHSP1 
ENSG00000175137 343.4006 -0.42641 0.179639 0.000754 0.041032 SH3BP5L 
ENSG00000182985 947.9779 -0.41071 0.134181 0.000114 0.009928 CADM1 
ENSG00000151233 1475.528 -0.38601 0.119227 6.18E-05 0.00582 GXYLT1 
ENSG00000117298 778.273 -0.37681 0.137566 0.000316 0.022227 ECE1 
ENSG00000125266 1400.448 -0.37581 0.151253 0.000583 0.035109 EFNB2 
ENSG00000142089 1254.776 -0.37356 0.136804 0.000318 0.022227 IFITM3 
ENSG00000225663 980.8937 -0.36671 0.133531 0.000325 0.022227 MCRIP1 
ENSG00000164465 1988.957 -0.36392 0.114886 8.90E-05 0.00804 DCBLD1 
ENSG00000160310 832.5637 -0.34943 0.138207 0.0006 0.035682 PRMT2 
ENSG00000162734 3369.087 -0.34521 0.112813 0.000132 0.011068 PEA15 
ENSG00000105993 1149.809 -0.34066 0.126914 0.000389 0.025835 DNAJB6 
ENSG00000187514 3068.093 -0.33719 0.117952 0.000239 0.018341 PTMA 
ENSG00000169976 2016.428 -0.30686 0.119964 0.00064 0.036364 SF3B5 
ENSG00000166441 15370.79 -0.27885 0.110802 0.000792 0.042105 RPL27A        
Upregulated 
genes 
baseMean log2FoldChange lfcSE pvalue padj symbol 
ENSG00000106853 911.0608 1.272486 0.127419 8.40E-25 3.80E-21 PTGR1 
ENSG00000244067 811.2315 1.26809 0.136508 5.53E-22 1.25E-18 GSTA2 
ENSG00000243955 530.7982 1.086071 0.15379 7.35E-14 1.11E-10 GSTA1 
ENSG00000105379 351.7488 0.933055 0.161774 3.87E-10 2.91E-07 ETFB 
ENSG00000181019 548.9379 0.928922 0.152759 5.37E-11 6.07E-08 NQO1 
ENSG00000110245 269.9286 0.872558 0.197433 4.03E-07 0.000122 APOC3 
ENSG00000113924 254.488 0.825786 0.197871 1.26E-06 0.000248 HGD 
ENSG00000205358 237.9697 0.793595 0.261699 7.33E-05 0.006756 MT1H 
ENSG00000130829 379.3415 0.77465 0.160505 6.54E-08 3.70E-05 DUSP9 
ENSG00000155657 162.2048 0.747947 0.29652 0.000381 0.025681 TTN 
ENSG00000128965 636.4172 0.734153 0.158965 1.64E-07 7.43E-05 CHAC1 
ENSG00000179094 466.6753 0.71376 0.157606 2.64E-07 9.94E-05 PER1 
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ENSG00000162433 357.9543 0.697369 0.164386 1.02E-06 0.000231 AK4 
ENSG00000198417 521.524 0.666587 0.177103 6.72E-06 0.00098 MT1F 
       
ENSG00000213190 134.2237 0.665018 0.254615 0.000324 0.022227 MLLT11 
ENSG00000184640 460.1329 0.641653 0.170593 7.22E-06 0.000989 Sep-09 
ENSG00000204128 244.4756 0.635055 0.198485 5.60E-05 0.005477 C2orf72 
ENSG00000188643 1336.004 0.629924 0.122695 1.42E-08 9.15E-06 S100A16 
ENSG00000176046 907.2515 0.617522 0.147267 1.24E-06 0.000248 NUPR1 
ENSG00000163993 1045.176 0.616031 0.166832 9.00E-06 0.001197 S100P 
ENSG00000244187 512.8864 0.601183 0.150211 2.94E-06 0.000493 TMEM141 
ENSG00000165283 292.7543 0.599431 0.179309 3.63E-05 0.003998 STOML2 
ENSG00000074800 3251.871 0.562303 0.128658 5.62E-07 0.000152 ENO1 
ENSG00000051108 627.8994 0.550683 0.155298 1.77E-05 0.001998 HERPUD1 
ENSG00000166136 400.125 0.548642 0.16445 3.82E-05 0.004017 NDUFB8 
ENSG00000068615 233.4204 0.548451 0.206217 0.000309 0.022227 REEP1 
ENSG00000008394 716.1526 0.539736 0.150493 1.57E-05 0.00187 MGST1 
ENSG00000138207 2336.284 0.53767 0.12029 3.94E-07 0.000122 RBP4 
ENSG00000143575 211.1934 0.508738 0.224584 0.000846 0.044433 HAX1 
ENSG00000076770 330.4757 0.501908 0.214283 0.000678 0.03734 MBNL3 
ENSG00000004779 352.2827 0.500239 0.187213 0.000313 0.022227 NDUFAB1 
ENSG00000144136 1575.529 0.483909 0.129729 9.58E-06 0.001237 SLC20A1 
ENSG00000105327 321.4598 0.48045 0.193017 0.000528 0.032229 BBC3 
ENSG00000130208 1593.716 0.461142 0.120039 6.39E-06 0.000963 APOC1 
ENSG00000125148 15127.21 0.457588 0.118531 5.74E-06 0.000894 MT2A 
ENSG00000250479 441.49 0.449027 0.161142 0.000244 0.018407 CHCHD10 
ENSG00000158874 6172.306 0.444126 0.103393 9.76E-07 0.000231 APOA2 
ENSG00000177733 544.2009 0.440403 0.154288 0.000199 0.015506 HNRNPA0 
ENSG00000178741 876.8116 0.437595 0.134039 5.70E-05 0.005477 COX5A 
ENSG00000177156 713.1106 0.430635 0.170282 0.000483 0.030177 TALDO1 
ENSG00000130522 1611.075 0.430228 0.119238 1.65E-05 0.001909 JUND 
ENSG00000125144 3217.309 0.425566 0.128123 4.66E-05 0.004678 MT1G 
ENSG00000169635 745.0314 0.417749 0.137551 0.000121 0.010322 HIC2 
ENSG00000154277 977.675 0.399299 0.151444 0.000396 0.025913 UCHL1 
ENSG00000169715 3521.445 0.394455 0.159491 0.000638 0.036364 MT1E 
ENSG00000189334 1678.432 0.393898 0.159928 0.000611 0.035884 S100A14 
ENSG00000127184 1868.739 0.357801 0.114745 0.000101 0.008993 COX7C 
ENSG00000103363 675.9637 0.356096 0.147308 0.000773 0.041571 ELOB 
ENSG00000087086 20918.04 0.343291 0.101014 4.61E-05 0.004678 FTL 
ENSG00000112695 840.871 0.339853 0.135263 0.000652 0.036364 COX7A2 
ENSG00000166165 1962.221 0.328942 0.124718 0.000445 0.02872 CKB 
ENSG00000121274 1799.263 0.322542 0.122129 0.000484 0.030177 TENT4B 
ENSG00000182774 4013.075 0.276809 0.108003 0.000645 0.036364 RPS17 
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Downregulated genes baseMean log2FoldChange lfcSE pvalue padj symbol 
ENSG00000105825 261.6677 -1.08036 0.261259 1.23E-06 0.001502 TFPI2 
ENSG00000184292 267.5707 -1.06425 0.259239 1.42E-06 0.001502 TACSTD2 
ENSG00000166401 270.9469 -0.9036 0.287292 4.97E-05 0.013178 SERPINB8 
ENSG00000124302 258.919 -0.85907 0.318414 0.000183 0.021526 CHST8 
ENSG00000120937 1027.292 -0.83766 0.215754 3.81E-06 0.002692 NPPB 
ENSG00000088826 452.0769 -0.77327 0.253153 7.59E-05 0.015604 SMOX 
ENSG00000269893 1058.67 -0.76366 0.178234 8.42E-07 0.001502 SNHG8 
ENSG00000160888 1668.114 -0.75288 0.234789 4.39E-05 0.012405 IER2 
ENSG00000244405 621.8365 -0.73807 0.255455 0.000124 0.017016 ETV5 
ENSG00000064300 259.1061 -0.73396 0.248353 0.000121 0.017016 NGFR 
ENSG00000138623 240.5932 -0.72986 0.271044 0.000247 0.023015 SEMA7A 
ENSG00000234741 1267.109 -0.70516 0.165374 9.67E-07 0.001502 GAS5 
ENSG00000144485 431.8835 -0.70293 0.263752 0.00025 0.023015 HES6 
ENSG00000163132 281.4012 -0.67829 0.292548 0.000621 0.034224 MSX1 
ENSG00000167081 900.9591 -0.65693 0.212706 7.98E-05 0.015604 PBX3 
ENSG00000188229 645.6846 -0.65502 0.226651 0.000145 0.018808 TUBB4B 
ENSG00000245910 1337.182 -0.65297 0.16323 3.14E-06 0.002669 SNHG6 
ENSG00000115271 429.9702 -0.64972 0.234696 0.00022 0.022459 GCA 
ENSG00000105640 612.7302 -0.63968 0.206739 8.47E-05 0.015604 RPL18A 
ENSG00000109089 788.3575 -0.6307 0.207182 9.44E-05 0.015604 CDR2L 
ENSG00000141682 501.639 -0.62729 0.27813 0.000713 0.037328 PMAIP1 
ENSG00000112306 43780.08 -0.62663 0.168181 9.18E-06 0.003899 RPS12 
ENSG00000162783 1671.919 -0.62492 0.228937 0.000225 0.022459 IER5 
ENSG00000085063 4042.655 -0.62105 0.188671 4.20E-05 0.012405 CD59 
ENSG00000161091 1473.693 -0.61992 0.235708 0.000289 0.025546 MFSD12 
ENSG00000111057 4893.181 -0.61917 0.188944 5.43E-05 0.013548 KRT18 
ENSG00000173334 738.5834 -0.61271 0.234589 0.000334 0.025797 TRIB1 
ENSG00000198804 3510.582 -0.61132 0.158626 6.48E-06 0.003437 COX1 
ENSG00000115756 1076.253 -0.60522 0.202452 0.000118 0.017016 HPCAL1 
ENSG00000253368 1671.67 -0.60053 0.233393 0.000353 0.025797 TRNP1 
ENSG00000178585 486.7062 -0.60029 0.226562 0.000328 0.025797 CTNNBIP1 
ENSG00000142541 7360.029 -0.59807 0.159899 9.19E-06 0.003899 RPL13A 
ENSG00000148677 21957.93 -0.59056 0.191931 8.32E-05 0.015604 ANKRD1 
ENSG00000109321 555.7752 -0.58772 0.207573 0.000197 0.021746 AREG 
ENSG00000170421 1704.135 -0.58702 0.191104 9.56E-05 0.015604 KRT8 
ENSG00000108107 2337.985 -0.58077 0.165222 2.30E-05 0.008138 RPL28 
ENSG00000224032 1013.183 -0.58006 0.185657 8.36E-05 0.015604 EPB41L4A-AS1 
ENSG00000249992 352.3268 -0.57148 0.236596 0.000614 0.034224 TMEM158 
ENSG00000143947 50720.52 -0.57048 0.190975 0.000121 0.017016 RPS27A 
ENSG00000184515 541.2307 -0.56652 0.245746 0.000695 0.036836 BEX5 
ENSG00000266402 3268.263 -0.56416 0.206962 0.000245 0.023015 SNHG25 
ENSG00000182580 1113.056 -0.56403 0.255468 0.000888 0.04364 EPHB3 
ENSG00000177410 3541.361 -0.56219 0.168534 4.38E-05 0.012405 ZFAS1 
ENSG00000088986 2003.421 -0.5571 0.214841 0.000372 0.025881 DYNLL1 
ENSG00000197989 434.1653 -0.55707 0.259874 0.001103 0.048576 SNHG12 
ENSG00000255198 518.7972 -0.55698 0.265768 0.001206 0.04927 SNHG9 
ENSG00000277075 274.1023 -0.55281 0.256334 0.001131 0.048972 HIST1H2AE 
ENSG00000197756 29857.5 -0.55087 0.188845 0.000155 0.018855 RPL37A 
ENSG00000197019 1255.63 -0.5462 0.246071 0.000895 0.04364 SERTAD1 
ENSG00000185022 663.8621 -0.54502 0.214462 0.000465 0.030858 MAFF 
ENSG00000130255 8212.797 -0.54309 0.175012 9.17E-05 0.015604 RPL36 
ENSG00000102096 966.752 -0.53908 0.213212 0.000473 0.030858 PIM2 
ENSG00000128311 1047.822 -0.53578 0.238874 0.000847 0.042805 TST 
ENSG00000233016 607.7003 -0.53228 0.209082 0.000492 0.031154 SNHG7 
 
 
Supplementary information 277 
Supplementary table 2. Differential expressed genes on the HLCs co-treatment. 
Differential expressed genes with padj >0.05.  
 
       
ENSG00000211459 28720.17 -0.52542 0.18348 0.000192 0.021746 MT-RNR1 
ENSG00000132002 6732.186 -0.52392 0.20942 0.000556 0.033898 DNAJB1 
ENSG00000189325 639.7264 -0.52162 0.215078 0.000653 0.035506 C6orf222 
ENSG00000189077 512.094 -0.51901 0.208257 0.000565 0.033898 TMEM120A 
ENSG00000171858 6377.68 -0.50788 0.180065 0.000224 0.022459 RPS21 
ENSG00000171863 2543.412 -0.50784 0.165163 0.000111 0.017016 RPS7 
ENSG00000189143 1806.707 -0.50511 0.202659 0.000548 0.033898 CLDN4 
ENSG00000143933 1741.947 -0.4931 0.176206 0.000259 0.02336 CALM2 
ENSG00000133818 558.8907 -0.49032 0.195514 0.000578 0.034034 RRAS2 
ENSG00000231500 6648.419 -0.4896 0.159365 0.000156 0.018855 RPS18 
ENSG00000169567 4322.211 -0.48547 0.185603 0.000434 0.02925 HINT1 
ENSG00000145592 6911.284 -0.48348 0.175963 0.000297 0.025689 RPL37 
ENSG00000196937 898.6864 -0.47676 0.190701 0.000599 0.034224 FAM3C 
ENSG00000099804 1643.701 -0.47655 0.218678 0.001188 0.04927 CDC34 
ENSG00000075618 2575.555 -0.47396 0.17859 0.000404 0.027641 FSCN1 
ENSG00000168002 1232.994 -0.45868 0.203267 0.00111 0.048576 POLR2G 
ENSG00000105193 5919.662 -0.45541 0.182555 0.000617 0.034224 RPS16 
ENSG00000110700 5111.901 -0.45351 0.196515 0.000952 0.044371 RPS13 
ENSG00000105372 18430.03 -0.43627 0.188252 0.000947 0.044371 RPS19 
ENSG00000163682 4325.1 -0.43249 0.1879 0.001037 0.046554 RPL9 
ENSG00000089157 15728.21 -0.43233 0.174032 0.000694 0.036836 RPLP0 
ENSG00000117410 2517.668 -0.42902 0.190001 0.001202 0.04927 ATP6V0B 
ENSG00000136942 3530.71 -0.42245 0.177208 0.000906 0.043673 RPL35 
ENSG00000213741 21920.03 -0.42093 0.186449 0.00119 0.04927 RPS29 
ENSG00000133639 4443.254 -0.41166 0.176117 0.001042 0.046554 BTG1 
ENSG00000167526 4896.005 -0.4059 0.172152 0.001001 0.045901 RPL13 
ENSG00000210082 179937.4 -0.39343 0.165492 0.001006 0.045901 MT-RNR2 
ENSG00000198886 10165.78 -0.3772 0.16083 0.001208 0.04927 ND4        
Upregulated genes baseMean log2FoldChange lfcSE pvalue padj symbol 
ENSG00000104517 517.4942 0.741003 0.190105 4.70E-06 0.002846 UBR5 
ENSG00000116962 382.7241 0.730912 0.235122 7.33E-05 0.015604 NID1 
ENSG00000140279 892.983 0.662857 0.187177 1.85E-05 0.007126 DUOX2 
ENSG00000165029 321.0358 0.655037 0.267391 0.000482 0.030968 ABCA1 
ENSG00000198677 395.8516 0.626011 0.242216 0.000368 0.025881 TTC37 
ENSG00000127481 1058.952 0.613457 0.233124 0.000306 0.025797 UBR4 
ENSG00000100354 356.816 0.610498 0.214936 0.0002 0.021746 TNRC6B 
ENSG00000206557 353.4599 0.602846 0.274969 0.000926 0.044168 TRIM71 
ENSG00000100815 441.0969 0.581967 0.218913 0.00034 0.025797 TRIP11 
ENSG00000122299 374.0185 0.575035 0.215921 0.000343 0.025797 ZC3H7A 
ENSG00000171316 467.9534 0.568548 0.215603 0.000359 0.0258 CHD7 
ENSG00000054118 792.9844 0.567535 0.192042 0.000146 0.018808 THRAP3 
ENSG00000038427 1125.683 0.566572 0.215176 0.00034 0.025797 VCAN 
ENSG00000187498 1118.726 0.542228 0.192925 0.000228 0.022459 COL4A1 
ENSG00000186951 577.2873 0.522842 0.221617 0.000764 0.039548 PPARA 
ENSG00000011114 498.0748 0.510569 0.215697 0.000787 0.040207 BTBD7 
ENSG00000084674 5348.217 0.498255 0.186529 0.000349 0.025797 APOB 
ENSG00000102024 1312.153 0.496447 0.198403 0.000567 0.033898 PLS3 
ENSG00000244067 1248.57 0.491888 0.197842 0.000594 0.034224 GSTA2 
ENSG00000141252 367.8466 0.482994 0.216176 0.001171 0.04927 VPS53 
ENSG00000108861 818.7747 0.462999 0.193906 0.000878 0.04364 DUSP3 
ENSG00000171560 25873.67 0.46225 0.169575 0.00034 0.025797 FGA 
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Downregulated baseMean log2FoldChange lfcSE pvalue padj symbol 
ENSG00000241794 51.01052 -2.12689 0.603346 1.31E-05 NA SPRR2A 
ENSG00000122641 78.932 -1.97629 0.500934 2.26E-06 NA INHBA 
ENSG00000276085 214.0358 -1.90757 0.298406 7.39E-12 1.28E-08 CCL3L1 
ENSG00000274012 58.20267 -1.69323 0.535591 5.55E-05 NA RN7SL2 
ENSG00000026508 320.7262 -1.48105 0.273237 2.33E-09 1.61E-06 CD44 
ENSG00000226380 58.65134 -1.46174 0.557825 0.000258 NA 
LINC-
PINT 
ENSG00000222041 1491.51 -1.39564 0.560638 0.000291 0.030453 CYTOR 
ENSG00000172965 5036.48 -1.33168 0.199259 8.15E-13 2.82E-09 
MIR4435-
2HG 
ENSG00000149564 99.45685 -1.32098 0.453763 0.000102 NA ESAM 
ENSG00000134954 294.5387 -1.27715 0.2681 8.03E-08 3.47E-05 ETS1 
ENSG00000164171 2152.881 -1.12809 0.184412 4.18E-11 4.82E-08 ITGA2 
ENSG00000205420 432.2669 -1.11016 0.266388 1.10E-06 0.000346 KRT6A 
ENSG00000185022 230.5556 -1.10327 0.294964 7.17E-06 0.001684 MAFF 
ENSG00000149591 292.1205 -1.07995 0.32768 2.77E-05 0.005024 TAGLN 
ENSG00000131016 3599.472 -1.06989 0.180657 1.49E-10 1.28E-07 AKAP12 
ENSG00000138166 971.9109 -1.05339 0.202684 9.03E-09 4.45E-06 DUSP5 
ENSG00000058085 321.8058 -1.0221 0.27468 7.69E-06 0.001684 LAMC2 
ENSG00000109321 773.8499 -0.96762 0.230979 1.05E-06 0.000346 AREG 
ENSG00000050405 539.4222 -0.94899 0.234615 2.11E-06 0.000607 LIMA1 
ENSG00000103187 523.6473 -0.94247 0.242423 3.82E-06 0.001013 COTL1 
ENSG00000059804 1759.993 -0.924 0.196697 1.11E-07 4.25E-05 SLC2A3 
ENSG00000163584 209.9762 -0.87975 0.361753 0.000404 0.03985 RPL22L1 
ENSG00000132432 325.8817 -0.81446 0.305091 0.00023 0.024824 SEC61G 
ENSG00000163191 481.9524 -0.80986 0.286971 0.000142 0.018186 S100A11 
ENSG00000143322 474.3977 -0.79826 0.243811 4.34E-05 0.006584 ABL2 
ENSG00000148834 1469.689 -0.79782 0.2238 1.29E-05 0.002627 GSTO1 
ENSG00000175793 215.3717 -0.77658 0.330192 0.000558 0.04546 SFN 
ENSG00000026025 1393.804 -0.74408 0.198897 7.80E-06 0.001684 VIM 
ENSG00000141682 371.2127 -0.72725 0.266189 0.000218 0.024824 PMAIP1 
ENSG00000115641 454.6041 -0.71283 0.263053 0.00023 0.024824 FHL2 
ENSG00000136167 1898.231 -0.68956 0.192989 1.45E-05 0.002774 LCP1 
ENSG00000102317 396.1198 -0.68513 0.299396 0.000631 0.046427 RBM3 
ENSG00000181649 365.2326 -0.67825 0.287802 0.000566 0.04546 PHLDA2 
ENSG00000136810 1038.034 -0.61834 0.265885 0.000581 0.045589 TXN 
ENSG00000253368 1537.668 -0.60463 0.201769 0.000123 0.016872 TRNP1 
ENSG00000111057 6457.431 -0.59548 0.181213 4.20E-05 0.006584 KRT18 
ENSG00000142871 1666.391 -0.5927 0.249433 0.000516 0.04347 CYR61 
ENSG00000172115 810.391 -0.58592 0.234298 0.000425 0.040731 CYCS 
ENSG00000147065 847.0252 -0.56989 0.24169 0.000605 0.046427 MSN 
ENSG00000067082 2720.955 -0.56289 0.194969 0.000152 0.018714 KLF6 
ENSG00000072110 1845.467 -0.54918 0.207807 0.000304 0.030853 ACTN1 
ENSG00000184009 15273.92 -0.54727 0.184734 0.000125 0.016872 ACTG1 
ENSG00000132341 1763.957 -0.51188 0.204768 0.000487 0.043433 RAN 
ENSG00000176014 4625.958 -0.46554 0.192705 0.000491 0.043433 TUBB6        
Upregulated genes baseMean log2FoldChange lfcSE pvalue padj symbol 
ENSG00000162981 152.1544 1.02568 0.354092 0.000129 NA FAM84A 
ENSG00000245532 12920.73 0.946268 0.173667 3.88E-09 2.23E-06 NEAT1 
ENSG00000111319 543.1801 0.809522 0.281977 0.000127 0.016872 SCNN1A 
ENSG00000206557 522.3106 0.772307 0.237238 4.39E-05 0.006584 TRIM71 
ENSG00000140279 771.5025 0.740942 0.219261 2.91E-05 0.005024 DUOX2 
ENSG00000176046 453.7334 0.736752 0.271945 0.000225 0.024824 NUPR1 
ENSG00000106780 428.9418 0.664578 0.270105 0.000456 0.042512 MEGF9 
       
ENSG00000139219 544.9756 0.607067 0.260094 0.000632 0.046427 COL2A1 
ENSG00000104687 1124.282 0.542446 0.220829 0.000503 0.043433 GSR 
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baseMean log2FoldChange lfcSE pvalue padj symbol 
ENSDARG00000076487 29.05509 -6.35336 1.584918 7.52E-07 0.000625 haao 
ENSDARG00000069909 28.46049 -5.44275 1.2896 4.94E-07 0.000485 LOC100149563 
ENSDARG00000007480 100.2075 -2.81829 0.649972 2.02E-07 0.000242 rpe65a 
ENSDARG00000040277 352.1749 -1.85764 0.371364 2.12E-08 4.58E-05 fbxo32 
ENSDARG00000060345 112.819 -1.8496 0.682785 9.38E-05 0.02978 apoda.1 
ENSDARG00000056511 2120.804 -1.6904 0.445434 1.70E-06 0.001139 arr3a 
ENSDARG00000016391 210.4044 -1.48855 0.534133 0.000102 0.03057 calcoco1b 
ENSDARG00000056248 1247.315 -1.37855 0.485747 6.22E-05 0.022371 si:dkey-183i3.5 
ENSDARG00000045835 1749.698 -1.25324 0.443516 7.05E-05 0.024551 si:dkey-14d8.6 
ENSDARG00000103543 1871.383 -0.98687 0.372678 0.000195 0.049073 gngt2b 
ENSDARG00000002593 104.2687 -0.00494 0.030043 0.000134 0.03613 slc45a2 
ENSDARG00000077652 51.83696 -0.00327 0.029709 3.60E-05 0.014733 lratb.2 
ENSDARG00000070057 115.6232 -0.0031 0.029677 7.31E-05 0.024666 si:dkey-69o16.5        
Upregulated genes baseMean log2FoldChange lfcSE pvalue padj symbol 
ENSDARG00000068088 516.4075 2.442286 0.455423 8.14E-10 8.78E-06 tcnba 
ENSDARG00000051762 142.5607 2.280092 0.724905 7.95E-06 0.004169 CABZ01080568.1 
ENSDARG00000069826 869.9748 1.969861 0.37134 2.66E-09 1.40E-05 crygm2d15 
ENSDARG00000069792 1462.791 1.96209 0.475719 2.67E-07 0.000288 crygm2d5 
ENSDARG00000069817 1101.928 1.880228 0.411323 7.15E-08 0.000129 crygm2d17 
ENSDARG00000087301 1126.493 1.850981 0.366916 1.05E-08 2.84E-05 crygm2d14 
ENSDARG00000076572 1460.899 1.829098 0.411178 1.30E-07 0.000176 crygm2d7 
ENSDARG00000036140 252.9114 1.817982 0.703129 9.93E-05 0.03057 crybgx 
ENSDARG00000069827 861.6477 1.778383 0.394003 1.25E-07 0.000176 crygm2d11 
ENSDARG00000087164 1330.222 1.701993 0.320238 3.89E-09 1.40E-05 crygm2d4 
ENSDARG00000026871 109.6245 1.658356 0.588584 0.000109 0.031699 uchl1 
ENSDARG00000041065 2123.578 1.643173 0.49371 8.11E-06 0.004169 hspb1 
ENSDARG00000073750 949.22 1.584292 0.372289 5.51E-07 0.000496 crygm2d18 
ENSDARG00000076790 1300.437 1.507166 0.424185 6.65E-06 0.003986 crygm2d16 
ENSDARG00000086658 922.5474 1.502262 0.550307 5.65E-05 0.021028 crygm2d21 
ENSDARG00000073874 145.094 1.466385 0.509446 0.000128 0.035543 crygm2d6 
ENSDARG00000091148 1448.156 1.439415 0.433016 1.50E-05 0.00704 crygm2d20 
ENSDARG00000030411 1623.658 1.420965 0.489586 4.86E-05 0.018755 crygn2 
ENSDARG00000086917 2608.659 1.418607 0.356581 1.79E-06 0.001139 crygm2d2 
ENSDARG00000087324 1594.418 1.402341 0.431299 1.94E-05 0.00874 crygm2d1 
ENSDARG00000115701 1055.253 1.38857 0.341225 1.55E-06 0.001117 crygm2d9 
ENSDARG00000088823 3607.863 1.374161 0.326547 8.12E-07 0.000626 crygm2d3 
ENSDARG00000109861 1794.111 1.353566 0.396182 1.40E-05 0.006864 crygm2d19 
ENSDARG00000057460 2232.34 1.343253 0.372181 7.47E-06 0.004169 crygm2d13 
ENSDARG00000032929 872.6952 1.286035 0.469858 0.000119 0.033919 cryba1l1 
ENSDARG00000024746 4206.144 1.222288 0.435766 8.49E-05 0.027761 hsp90aa1.2 
ENSDARG00000018060 878.645 1.180174 0.466394 0.000191 0.049015 pik3r2 
ENSDARG00000116164 2501.711 1.141518 0.351502 3.15E-05 0.0136 crygm2d8 
ENSDARG00000016793 1456.38 1.108596 0.340958 3.68E-05 0.014733 crybb1l2 
ENSDARG00000102004 3696.718 0.945817 0.340642 0.000155 0.040767 apoea 
 
Supplementary table 4 Differential expressed genes on the zebrafish group. 
Differential expressed genes with padj >0.05. 
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